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ABSTRACT 
Excess body fat, diabetes, and metabolic syndrome are associated with certain 
types of cancers. Although obesity is strongly associated with metabolic 
dysfunction (MetDys), some overweight individuals do not develop MetDys, 
although certain lean individuals do. The objective of this dissertation was to 
determine whether MetDys modifies the effect of excess body fat on cancer risk. 
The independent and combined effects of body mass index (BMI), waist 
circumference (WC), and MetDys on obesity-related cancer (ObCa) risk was 
examined among 3,818 45–69 year-olds in the Framingham Offspring Study 
using Cox proportional hazard’s analysis. Primary ObCa types included 
postmenopausal breast, endometrial, and colon cancer. Markers of MetDys 
included fasting glucose, triglycerides, high density lipoprotein-cholesterol, and 
hypertension. Subjects with ≥2 metabolic abnormalities were considered to have 
prevalent MetDys. Obesity alone (BMI≥30) in both men and women led to about 
  v 
a two-fold increased risk of ObCa. WC and waist-to-height ratio (WHtR) were 
somewhat stronger risk predictors in men than in women. There was little 
evidence of effect modification of WC or WHtR by MetDys in either men or 
women. In obese men, however, prevalent MetDys was associated with a 2.5-fold 
increased risk (95% CI: 1.36–1.46) of ObCa while obese men without MetDys had 
only a non-statistically significant 1.5-fold increased risk (0.70–3.03). There was 
no effect modification in women. To separate the effects of overall body fat from 
fat distribution, hip circumference was added to the multivariable models. Here, 
the effect of a WC >40 inches in men was strengthened (HR=2.59; 95% CI: 1.53–
4.36) by controlling for HC. Conversely, when controlling for WC, the smallest 
HC in men conveyed a higher cancer risk (HR=2.68; 95%CI: 1.46–4.89). Subjects 
gaining ≥1 lb/year over approximately 14 years and who developed MetDys 
during that period had a 77% (95%CI: 1.21–2.59) increased ObCa risk while 
weight gainers not developing MetDys had a 31% (95%CI: 1.00–1.71) increased 
risk. Finally, weight gainers who became overweight/obese had a higher cancer 
risk than those with long-term overweight/obesity. This study suggests that 
those with excess body fat and long-term weight gain have higher ObCa risk, 
with little evidence that metabolic abnormalities modified the effect of obesity. 
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Chapter 1 
Introduction 
 
1.1 Obesity and Metabolic Health  
Obesity is recognized as public health problem since it contributes to 
chronic diseases. According to the 2007–2008 National Health and Nutrition 
Examination Survey (NHANES), the adult prevalence of obesity (BMI≥30 kg/m2) 
is approximately 33.9% and combined prevalence of obesity and overweight 
(BMI≥25 kg/m2) is 68.3%.44 A clustering of metabolic abnormalities that are 
known risk factors for cardiovascular disease and type 2 diabetes (T2D) often 
accompany obesity.9;60   
Not all individuals who are overweight or obese develop metabolic 
dysfunction. Some have called this phenomenon “metabolically healthy obesity” 
(MHO).164 Prevalence estimates of MHO depend on the criteria used.164 Some 
studies have categorized individuals as having metabolic dysfunction if they 
have even one characteristic of “metabolic syndrome“-- low high density 
lipoprotein (HDL) levels, high triglyceride (TG) levels, high fasting glucose levels 
(FG), hypertension (HTN), or insulin resistance (IR), while others require at least 
two of these characteristics. Prevalence data from 1999–2004 NHANES indicate 
that 29.2% of obese men and 35.4% obese women were considered “metabolically 
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healthy” (i.e., having no more than one of the following findings: HTN, high FG, 
low HDL, high TG, high hsCRP, and IR), while about 30% of normal-weight men 
and 21% of normal-weight women had prevalent metabolically abnormalities; 
these findings were similar across racial/ethnic groups.169 Therefore, normal 
weight individuals may also be “metabolically unhealthy”. 121 
One question for this dissertation is whether the MHO have the same 
excess risk of cancer as individuals with obesity and metabolic abnormalities. The 
overall goal for this thesis is to determine whether the obese without metabolic 
abnormalities have different risks of cancer than the obese or lean who do.  
1.1.1 Visceral Fat and Its Influence on Metabolic Dysfunction 
Overweight and obesity, as defined by BMI, have consistently shown 
positive associations with cardiovascular disease risk, insulin resistance, and 
certain cancers. 17;83;134;161;163 However, intra-abdominal obesity comprises about 
15% of total fat in both lean and obese indivdiduals105 and  is highly correlated 
with insulin resistance and related inflammatory pathways.149;161 Therefore, since 
BMI does not directly measure intra-abdominal obesity, it may not precisely 
capture the relevant exposure associated with cancer risk. 
The distribution of fat is believed to influence the development of 
metabolic dysfunction. Since a favorable metabolic profile defines MHO, one 
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could argue that the absence of metabolic abnormalities in obese individuals may 
be due to a more favorable fat distribution (i.e. away from the intra-abdominal 
compartment). Conversely, possibly by an unfavorable body fat distribution, the 
“metabolically unhealthy normal weight” phenotype is also increasingly 
recognized. 121 This suggests that among overweight and obese subjects without 
metabolic syndrome, those with a body fat distributed away from the abdomen 
may have a lower obesity-related cancer risk.  
Two simple anthropometric measures of visceral fat are waist 
circumference (WC) and the waist-to-height ratio (WHtR). Both measures have 
shown strong correlations with computed axial tomography of visceral fat.12;153  
Higher WHtR and WC have been associated with increasing cardiovascular 
disease risk.55 WC and especially WHtR have been shown to be better 
discriminators of cardiometabolic risk factors than BMI.13;26;99 Central adiposity 
may especially be relevant in identifying those who have a normal BMI but who 
have some cardiometabolic risk factors. 
At least as strong as the evidence for the detrimental effects of abdominal 
adiposity is that for the protective effects of gluteofemoral adiposity.104;131   
Recently, hip circumference (HC), a surrogate for the level of protective 
gluteofemoral depots, has been used in studies investigating the role of body fat 
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distribution and type 2 diabetes, CVD, and CHD.128;151;175 
In this dissertation I plan to use these anthropometric measures of body fat and body fat 
distribution to study their independent and combined effects with metabolic variables on 
obesity-related cancer risk.  
1.2 Proposed General Mechanism in the Association of Obesity and Cancer 
Obesity is a risk factor for some cancers. Both excess adiposity and insulin 
signaling initiate the chronic inflammation responsible for mitogenic and anti-
apoptotic pathways underlying obesity-related cancer risk. A dominant 
hypothesis for this association is that excess adipose tissue causes chronic low-
grade inflammation.  Adipose tissue is an active endocrine organ, secreting 
various hormones and other proteins collectively known as “adipokines”. 
Adipokines function to maintain a healthy adipose tissue microenvironment.174 
However, a greater volume of adipose tissue could upset the balance of 
inflammation of normal tissue maintenance toward a chronic pro-inflammatory 
state.174 This could lead to the development of greater circulating insulin, which 
promotes factors involved in cancer proliferation and inhibits apoptosis.142  
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1.3  Metabolic Variables and Cancer Risk 
1.3.1 Diabetes and Cancer Risk 
Extensive evidence suggests that T2D is a risk factor for several types of 
cancer. Diabetes is characterized by chronic inflammation, hyperglycemia, and 
hyperinsulinemia, and all three phenomena are thought to induce cancerous 
mechanisms. Biological studies demonstrate that hyperinsulinemia increases 
growth factors and steroid hormones that promote cell proliferation and inhibit 
apoptosis.142 While there is no epidemiologic evidence linking hyperinsulinemia 
directly with cancer risk, epidemiologic studies have shown an association 
between type 2 diabetes (T2D) and increased cancer risk. Epidemiologic data also 
demonstrate that some of the risk of breast and endometrial cancer is associated 
with relatively higher endogenous estrogen levels, which are also influenced by 
enhanced insulin activity.28  
Strength of the association between diabetes and cancer depends on 
cancer site. Fifty percent to up to two-fold risk estimates have been found in 
liver39;39;168, pancreatic73, and endometrial47;58 cancers; moderately elevated risk has 
been found for bladder94, non-Hodgkin’s lymphoma112, colorectal68;74;93,  
kidney98;166, and post-menopausal breast97 cancers. 58;78  
Some large-scale epidemiologic studies support the hypothesis that 
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elevated blood glucose is a risk factor for total cancers and some obesity-related 
cancers. A prospective cohort of 1,298,385 men and women in the Korean Cancer 
Prevention Study during a 10 year follow up showed  a trend toward increasing 
risk of total cancers from the lowest fasting glucose level (<90 mg/dL) to the 
highest (≥140 mg/dL). For both men and women fasting glucose levels (including 
within the non-diabetic range) were associated with increased risk of pancreatic 
cancer and, for men alone, an increased risk of kidney and liver cancer.77 
A similar analysis was done in 249,944 subjects in the Metabolic Syndrome 
and Cancer Project, comprised of six prospective cohorts with 11.3 and 9.6 years 
of follow-up in men and women, respectively.158 In that study, elevated blood 
glucose tended to be associated with higher risks of liver, gallbladder, and 
bladder cancer in men, and pancreatic, bladder, endometrial, and uterine cancer 
in women.  
Duration of impaired fasting glucose (IFG >110 mg/dL) was considered in 
a recent study in the Framingham Offspring Cohort by Parekh et al.127 They 
investigated markers of glucose metabolism (fasting glucose concentration, 
HOMA-IR, percentage hemoglobin A1c, insulin concentration) and obesity-
related cancers. They defined obesity-related cancers as those of the 
gastrointestinal tract, blood, bone, spleen, female reproductive tract, 
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genitourinary organs, and thyroid gland. When not accounting for duration of 
IFG, they found a 27% increased risk of obesity-related cancers among those with 
fasting glucose >110 mg/dL compared with those with fasting glucose <110 
mg/dL. However, in a separate analysis using the same comparison group, they 
found higher estimates for those who had IFG for 10–20 years and more than 20 
years (35% and 64% increased risks, respectively). They also found increasing RR 
estimates of 1.80 (95%CI: 1.15, 2.80), 2.50 (95%CI: 1.65, 3.78), and 3.47 (95%CI: 
1.92, 6.26) for colon cancer with increasing duration of IFG of 5–10, 10–20, and 
more than 20 years, respectively. This demonstrates that accumulating exposure 
to IFG produces a dose-response effect on obesity-related cancer risk.  
The association between T2D and pancreatic cancer is complex, because 
often it is difficult to distinguish which disease first induced the other in the 
pancreatic cancer patient with T2D.   The higher prevalence of T2D among those 
diagnosed with pancreatic cancer and by the short temporal relationship 
between new-onset T2D and diagnosed pancreatic cancer demonstrates that 
pancreatic cancer may cause T2D.125 Because methods varied on identifying and 
diagnosing DM, early literature has reported a wide range of T2D prevalence (4–
64%) in pancreatic cancer.125;126  The most recent study on the prevalence and 
temporality association between T2D and pancreatic cancer by Pannala et al.125 
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suggests the possibility that a pancreatic tumor could be the cause of T2D in 
patients with pancreatic cancer.125  Although, T2D has been demonstrated to 
develop as a consequence of pancreatic tumor, it does not preclude the 
possibility  that the formation of pre-diabetes beginning years prior to diabetes 
diagnosis120 promoted pancreatic cancer.  In this way, hyperglycemia or 
hyperinsulinemia could gradually promote mytogenic processes in pancreatic 
tissue several years prior to late detection of pancreatic cancer.  Therefore, this 
dissertation will include pancreatic cancer in the list of obesity-related cancer and 
analyze from sensitivity analyses whether in can be included.   
The complex association between the diabetes and cancer lies not only in 
the incomplete biological understanding of the association but also in the shared 
risk factors for the two diseases, including overweight and obesity, dietary 
patterns, aging, alcohol consumption, smoking, and physical activity.58 This 
complexity presents a strong methodological challenge for any study examining 
the relationship between diabetes and cancer.  
1.3.2 HDL and Cancer 
HDL has been studied as a risk factor for cancer. Some epidemiologic 
studies have shown an inverse association between HDL cholesterol levels and 
cancer risk. This includes evidence of a dose response association and of the 
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absence of reverse causality (i.e., of cancer leading to lower HDL cholesterol 
levels). A study of 29,093 male smokers in the Alpha-Tocopherol, Beta-carotene 
Cancer Prevention study found after 18 years follow-up and 7,545 incident 
cancer cases that those in the highest quintile of serum HDL-C (>55.3 mg/dl) had 
an 11% decreased risk of cancer compared with those in the lowest quintile (36.2 
mg/dl).7 This association remained after excluding cases in the first 12 years of 
follow-up. Spline regression analysis showed a mild dose-response relation, with 
a 5% lower cancer incidence for every 10 mg/dl increase of HDL-C.7;143 The 
inverse association across HDL-C quintiles over 18-years of follow-up was most 
evident in prostate, lung, and liver cancers; the association remained for lung 
and liver cancers, after excluding cases occurring during the first 9 years of 
follow-up.  
In the Framingham Offspring Cohort with 203 cancer cases, a non-
statistically significant 18–22 % increased risk of incident cancer was observed for 
those with HDL levels of 41–<53 and <41 mg/ compared with those with HDL 
levels ≥ 53 mg/dL.102     
The most comprehensive study on the association of HDL cholesterol and 
cancer risk is a meta-analysis by Jafri et al. of 24 randomized controlled trials of 
lipid-lowering interventions.75 There were 76,265 subjects in the intervention 
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arms, 69,478 subjects in the control arms, and 8,185 cases of incident cancer 
during a median follow-up time of 5 yrs. There was a 36% reduction in cancer 
incidence for every 10 mg/dl increase in baseline HDL-C (p=0.02); and this 
association was the same for those on treatment; LDL-C levels were inversely 
associated with incident cancer (p=0.007).  
Some studies have investigated HDL as an independent risk factor for 
breast cancer and, and earlier studies especially have shown mixed results. The 
earliest study, in 5,207 Danish women, with follow up time between 4 and 26 
years, found an 30% decreased risk of breast cancer among women in the highest 
quartile of serum HDL cholesterol levels (compared to the lowest quartile).67  A 
nested-case control study of 200 cases with matched controls in the Kaiser 
Permanente Medical Care Program, found a marginally statistically significant 
2% increased risk of breast cancer for every 1 mg/dl increase in HDL-C levels in 
postmenopausal women. Also, a non-statistically significant 68–70% increased 
risk was found in postmenopausal women with 31.5 to 37 mg/dl and >37 mg/dl 
compared to the women having <26 mg/dl.115  
A later study50 of 38,823 Norwegian women with 708 breast cancer cases 
found that those with serum HDL-C levels >1.64 mmol/L (63.3mg/dL) [compared 
with women having HDL-C <1.20 mmol/dL (46.3 mg/dL)] had a 25% decreased 
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risk of postmenopausal breast cancer. There was evidence for an interaction 
between overweight and HDL-C. Overweight women (BMI ≥25 kg/m2) with 
HDL-C levels in the top quartile (>1.64 mmol/L) had a 57% decreased risk of 
postmenopausal breast cancer. The trend across increasing HDL-C categories 
demonstrated an increased protective effect of breast cancer (p<0.001). 
The cumulative evidence demonstrates that HDL-C is inversely associated 
with total cancer incidence. Possible cancer protective roles for HDL-C involve 
multiple mechanisms with anti-inflammatory and anti-oxidant effects, including 
the protection of LDL from trace mineral peroxidation, regulating cell cycle entry 
and apoptosis.143  One study showed that low HDL-C is associated with 
increasing estrogens which is in turn associated with an increased risk of breast 
cancer in overweight women.51  HDL-C may be a marker of hormonal status 
(insulin and estrogen, and androgens) since hormones regulate hepatic lipase.30 
An alternate explanation is that low HDL-C levels may simply be an attribute of 
poor metabolic health and that HDL-C level is a marker of the state of metabolic 
regulation, which may contribute to a cancer-promoting environment.  
1.3.3 Blood Pressure and Triglycerides and Cancer Risk 
High blood pressure is a strong risk factor for total mortality18;59, but its 
association with obesity-related cancer incidence has not been examined. Early 
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studies have found that hypertension was positively associated with the 
incidence of kidney cancer.33;101;167 A study with a  cohort of more than 360,000 
Swedish men found that those with a DBP ≥90 mmHg (vs.<70mmHg) and SBP 
≥150 mmHg (vs. <120mmHg) had two-fold and 60% increased risks, respectively, 
for kidney cancer.33 The European Prospective Investigation in Cancer and 
Nutrition (EPIC) found that men and women with DBP ≥100 mmHg (vs. 
<80mmHg) and SBP ≥160 mmHg (vs. <120mmHg) had more than double the risk 
of kidney cancer; hypertensive medication use did not alter this association.167 
The most current study on blood pressure and risk of incident cancers is in the 
Metabolic Syndrome and Cancer Project, which included seven European 
cohorts. In more than 577,000 subjects followed for 12 years, there was a 7% 
increased risk of total cancer for every 10 mmHg increase in mid-BP, 
(SBP+DBP)/2, in men but not in women; 9–39% increased risks for every 10 
mmHg increase in mid-BP was also found for cancers of the esophagus, colon, 
rectum, liver, pancreas, kidney, and bladder in men and for cancers of the 
esophagus, liver, pancreas, bladder, cervix, and uterus in women.159   
 The association of serum triglyceride levels and obesity-related cancer risk 
is unknown. As part of the metabolic syndrome, high triglycerides may be 
associated with obesity-related cancer. The Metabolic Syndrome and Cancer 
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Project found that triglyceride levels in the fifth (vs. first) quintile had about a 
15% increased the risk of total cancer, with particular increased risks found in 
men for colon, kidney and thyroid cancer and melanoma and, in women, for 
cervical and non-melanoma skin cancer.24 
1.3.4 Metabolic Syndrome and Obesity-Related Cancer 
There has recently been a growing interest in the hypothesis that 
metabolic syndrome is the cause of cancers that are associated with overweight 
and obesity. Given that obesity is associated with the metabolic syndrome, the 
metabolic syndrome may have an etiologic role in the obesity-cancer link. The 
biological aspects of metabolic syndrome may mediate the association between 
overweight or obesity and cancer development. An interaction effect or 
interdependency of obesity and metabolic syndrome on cancer risk may also 
exist.  
The metabolic syndrome is a cluster of variables that has been shown to 
double the risk of cardiovascular disease and to increase the risk of type 2 
diabetes by 5-fold.9 According to AHA/NHLBI criteria, metabolic syndrome is 
defined as having at least 3 of the following: fasting glucose (FG) ≥100 mg/dL (or 
drug treatment for FG); triglycerides (TG) ≥150 mg/dL (or drug treatment for 
elevated for TG); HDL<40 mg/dL in men or <50 mg/dL in women; a systolic 
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blood pressure of ≥130 and/or diastolic≥80 mm Hg; and a larger waist 
circumference (for Caucasians,  ≥94 in men ≥80 cm in women).9  For cancer 
outcomes, the most frequently studied risk factor within the metabolic syndrome 
is impaired fasting glucose and diabetes. By the time diabetes is evident, other 
characteristics of metabolic syndrome generally are as well9, and whether there is 
an interdependent interaction between high fasting glucose levels and abnormal 
blood lipids and hypertension on cancer risk has not been effectively answered 
by current studies.  
In an meta-analysis of 43 studies using 116 data sets, with 38,940 cases, 
metabolic syndrome was associated with the following cancers: liver (RR: 1.43 
(95% CI: 1.23,1.65), colorectal (RR: 1.25; 95% CI: 1.19,1.32), and bladder (RR: 1.10; 
95% CI: 1.02,1.18) cancer in men and with endometrial (RR: 1.61; 95% CI: 1.20, 
2.15), pancreatic (RR: 1.58; 95% CI: 1.35,1.84), postmenopausal breast (RR: 1.56; 
95% CI: 1.03,2.24), rectal (RR: 1.52; 95% CI: 1.13, 2.05), and colorectal (RR: 1.34; 
95% CI: 1.09,1.64) cancers in women.41 In a nested case-control study of 
postmenopausal breast cancer among women ages 35–75 years, 30% of cases and 
19% of controls had metabolic syndrome. Those who met three of the metabolic 
criteria had about a 30% increased risk and those who met more than three 
criteria had a 69% increased risk.  
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One question is whether the associations seen for metabolic syndrome are 
separate from those seen with obesity. Aspects of the metabolic syndrome may 
be a marker of obesity, particularly visceral obesity, which has been shown to be 
linked with chronic low grade inflammation that encourages tumor formation.  
Metabolic syndrome could also be a marker for lifestyle-type cancer risk factors 
such as poor dietary choices and low physical activity.  
1.4 Obesity, Body Fat Distribution Measures, and Obesity-Related Cancer 
1.4.1 Obesity-Related Cancer 
Overweight is an established risk factor for some cancers. The American 
Cancer Society estimates that 14% of cancer deaths in men and 20% in women 
are attributable to overweight and obesity.28;72 The most consistent evidence has 
been shown for the following cancers: postmenopausal breast, endometrial, 
esophageal adenocarcinoma, pancreatic, kidney, leukemia, and gallbladder in 
women, and thyroid and liver in men.16;136;138  
For a given tumor site, the effect of body fat on cancer risk differs in men 
and women. A recent systematic review and meta-analysis concluded that a 5 
kg/m2 increase in BMI is associated with several common and less common 
cancers in men and women.138 In men, the strongest effects of a 5 kg/m2 increase 
in BMI were for esophageal adenocarcinomas, thyroid cancer, colon cancer, and 
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renal cancers. In women, the strongest effects of the same 5 kg/m2 increase in 
BMI were for endometrial, gallbladder, esophageal adenocarcinoma, and renal 
cancers.  
The Million Women Study of 1.2 million women living in the United 
Kingdom studied the effects of increasing BMI on the same cancer types.136 The 
referent group was women with 22.5≤BMI≤24.9 kg/m2. After a 5.4 year follow-up 
period, they found a strong increasing trend of risk with increasing BMI 
(BMI≥30, 27.5≤BMI≤29.5 kg/m2, and 25≤BMI≤27.4 kg/m2) for esophageal 
adenocarcinoma and endometrial cancer.  Lower relative risks were seen for 
postmenopausal breast cancer, pancreatic cancer, kidney cancer, Non-Hodgkin’s 
lymphoma, leukemia, multiple myeloma, and ovarian cancer. There were no 
associations found for colorectal, stomach, cervix, or bladder cancer incidence.   
1.4.2 BMI and Waist-Related Measures of Body Fat and Breast Cancer Risk 
There is evidence that higher BMI is inversely associated with pre-
menopausal breast cancers but directly associated with post-menopausal breast 
cancers.64 Several meta-analyses have concluded that obesity is not associated 
with pre-menopausal breast cancer,19;31 with the possible exception of a higher 
risk of triple negative breast cancer.130  
Studies of the association between waist-to-hip ratio (WHR) and 
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premenopausal and postmenopausal breast cancers have had mixed 
results.35;65;70;110;123;152  Post-menopausal non-hormone users have had the most 
consistent findings, with a higher WHR being linked with a higher risk of breast 
cancer.66 A systemic review by Harvie et al.65 of 5 cohort studies estimated that 
there were about a 40% and 24% risk reductions in post-menopausal breast 
cancer for women with smaller waist sizes and a smaller WHR, respectively. A 
meta-analysis of 19 studies by Connolly et.35 concluded that women with higher 
WHR had 50% and 79% increased risks for postmenopausal and premenopausal 
breast cancer, respectively. Ahn et al. 6 found associations of higher WC, hip 
circumference, and WHR categories and postmenopausal breast cancer among 
menopausal non-hormone users (highest quintiles with 55%, 49%, and 88% 
increased risk, respectively); but no association among menopausal hormone 
users.  
1.4.3 BMI, Body Fat Distribution, and Colon Cancer Risk  
Epidemiologic studies have found a higher BMI to be directly associated with 
colon cancer incidence, although this effect is generally stronger in men than in 
women.15;132 The large prospective EPIC study of more than 350,000 subjects  
found no BMI-related excess colon cancer incidence in women but a 55% 
increased risk in men with BMI ≥ 29.4 kg/m2 compared to men with BMI <23.6 
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kg/m2. A higher waist circumference [≥103 cm (40.5 inches)] was associated with 
39% and 48% greater colon cancer risks in men and women, respectively, 
compared with those with waist size <86 cm (34 inches). No association was 
found for BMI or waist size and rectal cancer.  
A 2009 meta-analysis61 found a 50–100% increased risks of colorectal 
cancer in overweight and obese men, with slighter weaker effects in overweight 
and obese women. In a larger meta-analysis of 30 prospective studies by Larsson 
et al.,95 a 5 kg/m2 increase in BMI increased colon cancer risk by 30% in men and 
12% in women. Similar effects were seen for waist size. In this study, BMI was 
only weakly associated with rectal cancer risk in both men and women, but 
stronger adverse effects were associated with waist circumference WHR.95  
In the Framingham Heart Study, compared with normal weight subjects 
(BMI 18.5–<25 kg/m2), obese (≥30 kg/m2) middle-aged (30–54years) men had a 
50% increase risk of colon cancer while older men had at least double the risk. 
These effects were weaker in women. However, a larger waist size in both men 
and women was associated with more than double the risk of colon cancer.113 
These effects were not attenuated when controlling for BMI. This suggests that 
body fat distribution may be as relevant a risk factor as is the overall measure of 
body mass, which also has been associated with the risk of cancer.  Therefore, 
  
19 
along with BMI, body fat distribution and the risk of obesity-related cancer is 
addressed in this dissertation. 
1.4.4 BMI Change or Weight Change and Obesity-Related Cancer Risk 
Few studies have examined the effect of weight loss or gain and obesity-related 
cancer. Such studies would help to quantify the effects of the amount of weight 
gain (or loss) as well as the duration of obesity. Weight loss or gain could impact 
cancer risk through effects on inflammatory and hormonal markers that 
accompany weight change. Inflammatory markers are hypothesized to be part of 
the mechanism linking adiposity-induced inflammation and risk of obesity-
related cancers.27;43 Some RCT studies on weight loss have also shown reductions 
in estradiol and increases in sex hormone binding globulin with weight loss; and 
since circulating estrogens are positively associated with endometrial and post-
menopausal breast cancer27, weight loss could thereby reduce risk of these 
particular obesity-related cancers.  
A recent analysis in the Health Professional’s follow-up study of 39,909 
men ages 40–75 years, followed for about 22 years examined the effect of BMI at 
21 years of age and the weight change since age 21 years on obesity-related 
cancers (colorectal, pancreatic, and esophageal).37  They found that, compared 
with men who had a BMI of 18.5–22.9 kg/m2 at age 21 years, those who had a 
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BMI ≥23 kg/m2 or higher at 21 years of age had 15–90% increasing risks with 
higher BMI categories. Compared with have a stable weight, a 10–14.9 kg and 
≥15 kg weight gain were respectively associated with increased risks of 16% 
(marginally statistically significant) and a 46% for obesity-related cancers.37  
Earlier studies on adult weight gain and cancer risk focused on 
postmenopausal breast cancer. A prospective study of 99,039 postmenopausal 
women in the National Institutes of Health–AARP Diet and Health Study 
examined the effect of weight gain during three life periods, during age 18–35, 
35–50, and 50 to present on postmenopausal breast cancer.6  Beginning from age 
18 to current weight and also from age 50 years to current age, they found that 
with every 10 kg gain there was trend of increasing risk of postmenopausal 
breast cancer in those not on menopausal hormone therapy. Throughout this 
study there were no associations found in menopausal hormone therapy users. 
These results in the National Institutes of Health –AARP Diet and Health 
Study were very consistent with the results in the Nurses’ Health Study (NHS) 
by Eliassen et al.40 of at least 87,000 women ages 30–55 years. Women never using 
postmenopausal hormone (PMH) and who since age 18 years gained 10–19.9 kg, 
20–24.9 kg, and 25 kg had 34%, 55% and 98% increased risks, respectively, of 
postmenopausal breast cancer compared to those who were weight stable. A 
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study in the Women’s Health Initiative (WHI) of 85,900 women ages 50–79 
years116 found that compared to those with no BMI change, BMI increases since 
age 18 and since age 50 years trended increased risk for non-hormone 
replacement therapy users, reaching 92% and 45 % increased risks for the highest 
quintiles, respectively.  
1.5 Dissertation Aims 
Obesity as measured by BMI and larger central adiposity as measured by 
waist circumference have consistently been associated with increased risks of 
particular cancers.  However, only a few studies so far have examined the 
association of these body fat measures and a composite outcome of obesity-
related cancers.  Biologically, except for endocrine-related mechanisms, obesity 
associated inflammatory mechanisms that deregulate metabolic and immune 
response that may contribute to cancer risk have not been definitively identified 
(Calle 2004, Nat Rev). Epidemiologic studies limiting cancer outcomes to a subset 
that have been shown to be obesity-related could inspire focused attention on 
shared mechanisms across these particular cancers.   In addition, less attention 
has been given to hip circumference, which could possibly clarify the role of 
body fat distribution as a risk factor for obesity-related cancers as a whole. Since 
women tend to have larger hips relative to waist size compared to men, HC may 
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inform the understanding of sex-specific cancer risk attributable to the location of 
excess body fat. The first aim of this dissertation is to estimate the effects of 
various anthropometric measures of body fat as well as hip circumference on 
obesity-related cancer.  
T2D and the metabolic syndrome are also associated with risk of 
individual cancers.  However, the association between different markers of 
metabolic dysfunction and cancer risk are less consistent. The second aim of this 
dissertation is to examine whether anthropometric measures of body fat are 
modified by metabolic dysfunction.  
Studies of weight change have also shown an increased risk of cancer 
associated with weight gain. Since hormonal and inflammatory profiles have 
been shown to be adversely affected by weight gain, I hypothesize that weight 
gain will increase the risk of obesity-related cancer. The third aim of this 
dissertation is to examine the effect of weight change on obesity related cancer 
and to examine whether this effect is modified by metabolic dysfunction.  
The overall goal of this dissertation was to separate the effects of excess 
body fat from the potential effect of metabolic disturbances on obesity-related 
cancers.  I address three specific aims using data from the Framingham Offspring 
cohort. 
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1. To estimate the effect of anthropometric measures (BMI, WHtR, WC, 
and HC) on obesity-related cancer risk.  
2. To determine if the effect of higher anthropometric measures of central 
body fat (WC, WHtR, HC) are modified by metabolic abnormalities.  
3. To estimate the effect of weight gain and whether its effect is modified 
by glucose dysregulation or metabolic dysfunction. 
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Chapter 2  
Methods 
 
2.1 Study Population 
The Framingham Offspring Study is a second-generation prospective 
cohort of the offspring of subjects originally participating in the Framingham 
Heart Study. The Offspring Study began in 1971 with the enrollment of 5,135 
subjects,85  5124 of whom attended the first exam. Exams 1 through 8 were 
conducted during the following respective date ranges: 1971–1975, 1979–
1983,1983–1987,1987–1991,1991–1995,1995–1998, 1998–2001, 2005–2008. At each 
examination visit (with eight years between exams 1 and 2 and approximately 
four years for all subsequent exams), the following data were collected: 
anthropometric variables, urinalysis, blood chemistries, blood pressure, medical 
history, and lifestyle habits. Subjects were also asked to report any diseases or 
conditions that had occurred since their last visit. Subjects who were unable to 
attend the visit were contacted by telephone or mail to complete questionnaires 
and interviews and to provide an updated medical history. All self-reported 
cardiovascular, cancer, and diabetes outcomes were confirmed by outside 
medical and pathological records.  
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2.1.1. Subject Selection  
The baseline visit for the different specific aims for this dissertation was 
variable and depended on the availability of data for each analytic goal. For 
analyses of BMI and metabolic dysfunction, the “baseline exam visit” for most 
subjects was Offspring visit 3. Exam visit 3 was used as it was the first exam at 
which reliable measures of HDL-C and fasting triglycerides and glucose were 
available. Since waist and hip girth were not measured until exam 4, analyses 
using waist girth, waist-to-height ratio (WHtR), and hip girth had their baseline 
at exam 4. Therefore analyses for BMI and central body fat were conducted in 
slightly different data sets. 
Subjects were included in these analyses who were 45–<70 years of age at 
baseline. Thus, for the BMI analyses, subjects who were too young at exam visit 3 
were included in the BMI analysis with baseline at a later exam visit if they met 
the criteria at that exam. For example, a subject who was 43 years of age at exam 
3 was ineligible at that exam but eligible at exam 4. Therefore, the baseline exam 
for the BMI analyses ranged from exam 3 to 5, with the vast majority of subjects 
having their baseline at exam visit 3.  
For the current analyses, subjects with prevalent cancer (except non-
melanoma skin cancer) at their “baseline visit” for these analyses were excluded. 
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Subjects with type 1 diabetes at baseline were also excluded. Subjects who were 
missing data for any of the exposure variables of interest (BMI, waist girth, blood 
glucose, triglycerides, HDL-C, and blood pressure) or covariates that were found 
to confound any of the main effect estimates (age, height, alcohol intake, physical 
activity, and education level) were excluded.  
Table 2.1 shows the number of subjects excluded for both the BMI and 
waist datasets. After exclusions, the final BMI data set comprised 3818 subjects 
(1816 men and 2002 women) while the waist data for analyses of central 
adiposity estimated by WHtR and WC had 3723 subjects (1772 men and 1951 
women). Table 2.2 shows the number of cases included in the BMI analysis by 
obesity-related cancer type. 
Table 2.1. Final sample sizes in BMI and waist dataset after exclusions 
BMI Dataset Waist Dataset 
Exclusion Criteria N Exclusion Criteria N 
Number subjects at exam 1  5124 Number subjects at exam 1 5124 
Exclusions  Exclusions  
Did not attend exams 3–7 645 Did not attend exams 4–7 799 
<45 or >69 years old at exam 3–7 315 <45 or >69 years old at exam 4–7 345 
Prevalent cancer at baseline 124 Prevalent cancer at baseline 140 
Missing BMI  26 Missing WC  47 
Missing metabolic variables 63 Missing metabolic variables 42 
No follow up after baseline 7 No follow up after baseline 8 
Missing WC  123 BMI missing or <18.5 18 
Missing HC 3 Missing HC 2 
Total sample for BMI-related 
analyses 
3818 Total sample for waist-related 
analyses 
3723 
(Number of subjects at exam 1 - exclusions)  
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Table 2.2. Number of incident obesity-related cancer cases for BMI and waist-
related analyses 
  BMI Data Set   Waist Data Set 
Incident First Obesity-Related Cancers Men Women Men Women 
Colon  25 20 22 17 
Rectal  13 5 11 5 
Liver  6 1 5 1 
Gallbladder  2 0 1 0 
Pancreatic  7 4 6 4 
Kidney  12 5 11 5 
Thyroid  2 6 2 6 
Stomach  7 2 7 2 
Esophageal Cancer, not basal or 
squamous 
1 0 1 0 
Multiple myeloma, malignant 0 1 0 1 
Malignant melanoma 21 12 19 11 
Leukemia 3 5 3 4 
Non-Hodgkin Lymphoma 17 16 16 15 
Ovarian 0 10 0 9 
Endometrial  0 22 0 20 
Post-menopausal Breast  0 74 0 63 
Subjects with an obesity-related cancer 116 183 104 163 
 
2.2 Exposure Variables 
2.2.1. Body Fat Measures  
Height measurements were rounded to the next lowest ¼ inch and weight 
to the nearest pound. Measurements were taken at each visit using a standard 
beam balance.54 To reduce random error around height measurement and to 
minimize effects of height loss with age, mean height from all measures prior to 
age 60 was used in combination with exam-specific weights calculate each visit-
specific BMI. Standard cutoff values for defining overweight (BMI: 25–<30 kg/m2) 
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and obesity (BMI: ≥30 kg/m2) were used. Abdominal skinfolds as well as left and 
right triceps and subscapular skinfolds were measured once, to the nearest 
millimeter.54 Waist circumference (WC) and hip circumference (HC) were 
measured starting at exam visit 4 and rounded to the next lowest ¼ inch; the 
waist-to-height ratio (WHtR) and WC were used as a simple anthropometric 
measure of central/abdominal obesity.  
2.2.2. Weight Change and Change in BMI Status  
Weight change for up to 20 years of follow up was calculated using a 
linear regression model to estimate subject-specific weight slopes (in pounds per 
year). Those with fewer than 10 years of measured weights were excluded from 
the weight change analysis. The average weight change period was 15 years. 
Subjects were then categorized according to whether they gained ≥ 1lb/year, 
remained weight stable (neither gained nor lost one pound or more per year), or 
lost ≥ 1lb/year. Those who were weight stable were the referent group.  
For the final analyses of weight change, we looked at change in the 
subjects’ obesity status during up to 20 years of follow up. Based on a series of 
sensitivity analyses, we chose to look at change in overweight status for women 
(BMI ≥25 vs. <25 kg/m2) while in men we looked at change in obesity status (BMI 
≥30 vs. <30 kg/m2). This will be further described in Chapter 5. Subjects were 
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classified into one of the following categories: (a) those who became overweight 
(women) or obese (men) during the follow-up period, (b) those who started out 
overweight or obese and remained that way, and (c) those who were never 
overweight or obese during the follow-up period. The latter category included 
the small number of subjects who started out overweight or obese and became 
non-overweight/obese during follow up.  
2.2.3. Blood Lipid Measurements  
Prior to each visit, subjects were asked to fast overnight (at least 12 hours). 
For lipid and glucose measurements blood was drawn into tubes containing 
EDTA centrifuged to separate plasma HDL-C, TG, and total cholesterol. Detailed 
methods of determining lipoprotein and glucose concentrations have been 
described in previous studies 108;109;141;146 LDL-C and VLDL were precipitated with 
dextran sulfate-magnesium precipitation procedure described by Warnick et 
al.165 Plasma HDL-C concentration was determined by subtracting the 
precipitating portions of LDL and VLDL. LDL cholesterol after exam 3 was 
calculated from fasting triglycerides and HDL using the Friedwald equation.48 
Triglycerides and total cholesterol were measured through enzymatic methods 
previously described 108;146 
Subjects were classified as having dyslipidemia when they took lipid-
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lowering medication, had an HDL-C<40 (men), <50 mg/dL (women); or had a 
triglyceride level ≥150 mg/dL. By this definition 1680 subjects (45.2%) had 
dyslipidemia at baseline. High TG and low HDL-C levels are considered 
dyslipidemia by the Third Report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (ATPIII).2 
2.2.4. Fasting Glucose and Impaired Fasting Glucose (IFG)  
Fasting glucose was measured at all exams, but hours of fasting at exams 1 
and 2 in Framingham were not recorded. Therefore, all glucose measures at 
exams 1 and 2 were considered to be non-fasting. Thus IFG was at exams 1 and 2 
was defined as a non-fasting glucose blood glucose ≥ 126 mg/dl while for 
subsequent exams IFG was defined as a fasting glucose of 100 to 125 mg/dL. 
Therefore, there is likely to be some underestimation of IFG at exams 1 and 2.  
The Framingham definition of type 2 diabetes mellitus (T2DM) is a fasting 
(≥10 hrs) glucose ≥126 mg/dL or non-fasting glucose ≥200 mg/dL or the use of 
diabetes medications (oral hypoglycemic medication or insulin). Subjects were 
also considered to have T2DM if they reported a medical history of diabetes and 
had a glucose level of 126–199 mg/dL, even if fasting status was unknown. For 
exams 1 and 2 (to account for unknown fasting status), subjects were diagnosed 
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with diabetes if their glucose level was ≥ 126 mg/dL and they had a <7% weight 
gain (according to the Framingham Heart Study coding manual) between the 
exam and the subsequent exam.   
2.2.5. Blood Pressure  
Blood pressure was measured twice by a nurse and then by an attending 
physician on the left arm while the subject was seated.54  High blood pressure 
(HBP) was defined using criteria modified from the seventh Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC7) 32.as follows: (a) SBP ≥160 and/or DBP ≥95 mmHg at any single 
exam; (b) SBP ≥140 or DBP ≥90 at one exam with SBP ≥130 or DBP ≥85 at one of 
the two previous exams; and (c) taking anti-hypertensive medication (for the 
purpose of lowering BP).  
2.2.6. Medications used for diagnosing HBP, Dyslipidemia, and Diabetes 
Self-reported medical and prescription drug history was completed by a 
physician.54 
During all exams subjects were asked whether they took anti-cholesterol 
or anti-hypertensive medications, oral hypoglycemic agents, or insulin currently 
or in the past. At exams 5–7, subjects were queried about the following types of 
lipid-lowering drugs: resins (Questran, Colestid), niacin, fibrates (gemfibrozil), 
  
32 
statins (lovastatin, pravastatin), and other agents, to be otherwise specified. 
However, which type of lipid-lowering medication taken by each subject was not 
indicated in the data set.    
Subjects were also asked whether they took diuretics (thiazides, Lasix, 
Aldactone, triamterene), ganglionic blockers, renin-angiotensin blockers 
(captopril), peripheral vasodilators (hydralazine, Minipress, minoxidil), 
methyldopa (Aldomet), clonidine (Catapres), Wytensin, alpha-2 blockers 
(prazosin, terazosin, doxazosin), potassium supplements, or any other anti-
hypertensive medication. 
 2.3. Potential Confounding Variables 
2.3.1. Alcohol Intake 
Subjects at each exam visit to report the number of drinks (beer, wine, and 
cocktail) consumed per day or per week and the number of days per week on 
which they consumed each. They were also asked to report the maximum 
number of drinks consumed at one time.  Ounce equivalents of alcohol intake per 
day were derived from amount of intake and grams of alcohol for each beverage 
type: (0.57*number of cocktails) + (0.444*number of beers) + (0.400*wine). This 
number was rounded and converted into grams. Baseline grams of alcohol per 
week constituted the primary alcohol intake variable used in the analysis. In 
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addition, these self-reported data were combined with other information from 
study and medical records to classify subjects at each exam according to alcohol 
drinking status (current, past drinker, abstainer, or abuser), drinking frequency 
(lifetime abstainer, past drinker, occasional drinker, regular drinker), and 
drinking amount (light, moderate, heavy).  
2.3.2. Cigarette Smoking 
Smoking was evaluated at the first exam by asking the subjects whether 
they smoked and, if so, how many cigarettes they smoked per day and when 
they started smoking. Current non-smokers were asked whether they had 
smoked previously and, if so, when they had started and stopped. At each 
subsequent exam, smoking status was updated by asking each subject to report 
whether they smoked cigarettes regularly during the interval since the previous 
exam, how many cigarettes they smoked per day. If they no longer smoked, they 
were asked to report when they had quit and how much they smoked prior to 
quitting.  
Cumulative pack-years of smoking at each exam was calculated. Exam 1 
pack-years were calculated by multiplying total number of years smoked by the 
usual number of cigarettes smoked per day divided by 20 (since there are 20 
cigarettes per pack). Number of years smoked was updated at each subsequent 
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exam. Cumulative pack-years was similarly updated at exams 2 to 7 by summing 
pack-years from the prior exam and pack-years derived from the period between 
the current exam and the previous non-missing exam.  
2.3.3. Physical Activity 
Physical activity was assessed at exams 2 and 4–7. Subjects were asked to 
report hours or minutes spent in sports or recreational activities during the past 
week and number of weeks engaged in the activity during the last year. Subjects 
were also asked to report number of hours per week that they spent doing 
activities of differing intensities (vigorous, moderate, and light activity). In 
addition, subjects were asked to compare their activity level with others their 
age; to report the amount of time spent walking, jogging, or running; the number 
of flights of stairs climbed each day, number of city blocks walked each day; and, 
lastly, to record hours the typical number of hours spent sitting and sleeping. 
Moderate activities were considered to be house work, climbing stairs, or light 
sports (bowling, golf). Vigorous activities were considered to be heavier 
household work (yard work) or intensive exercise (jogging, swimming). 
Estimated oxygen consumption for each activity was used to create a numeric 
weight for that activity, which was then multiplied by the length of time spent 
doing the corresponding activity. From this, using moderate and vigorous 
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physical activities only, each subject was assigned a physical activity index. 
2.3.4. Education  
Each participant’s education level was assessed at exams 2 and 8 and 
classified as follows: less than high school, high school, some college or college 
graduate or higher. Education category at exam 2 was to classify baseline 
education level for the current analyses. If at exam 2 information on education 
was missing, education level from exam 8 was substituted.   
2.3.5. Diet 
Diet was assessed at exams 3 and 5 using three-day dietary records 
(completed on 3 consecutive days, including at least one weekend day); 70% of 
those attending exam 3 and exam 5 completed the records. A trained nutritionist 
instructed the subjects in the completion of the diet records following a 
standardized protocol, and two-dimensional food models were used to help 
estimate food portions.  
For all dietary variables, mean values from exams 3 and 5 were used. 
Food intakes were derived (e.g., cup and ounce equivalents) according to the My 
Pyramid Equivalents Database 2.0 for USDA Survey foods (2003–2004).25  Dietary 
variables included were percentage of energy from fat, carbohydrates, and 
protein; iron (mg) and dietary fiber (g); mean ounce-equivalents of meat, franks, 
  
36 
and organ meats; poultry and fish; soy, nuts, seeds, and legumes; mean cup-
equivalents of total fruit and vegetables and dairy products. The variables 
examined as potential confounders were selected on the basis of their previously-
reported associations with cancer risk and obesity. 
2.3.6. Data Substitutions for Missing Covariates 
For a small number of subjects who were missing covariate data at a given exam, 
data from an adjacent exam was substituted. For example, six subjects were 
missing alcohol data at exam 3 but available data at exams 2 and 4 led us to 
substitute from the mean of the adjacent exams. Similar substitutions were used 
for cigarette smoking to estimate cigarettes per day and to update pack-years of 
smoking. When data on physical activity were missing, we substituted mean 
physical activity level from all subjects having the same occupation or, when 
occupation was not available, the mean activity for all individuals of the same 
age, sex, and education level.  
2.4. Outcome Variables 
Possible cancer cases were identified at the annual examination visits.90 
Diagnoses were confirmed from pathology, laboratory, and clinical records.90 The 
cancer diagnosis date was taken from other reports when pathology reports were 
unavailable or when diagnosis occurred before the pathological test.102 Cancer 
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cases were coded using the International Classification of Diseases for Oncology 
(ICD-O).  
For these analyses, we will include the following cancer types that have 
been previously-reported to be associated with obesity: female reproductive 
(breast, uterine, ovarian, and endometrial), colon, rectal, stomach, liver, 
gallbladder, pancreatic, kidney, thyroid, esophageal adenocarcinoma, leukemia, 
non-Hodgkin’s lymphoma, and multiple myeloma. 107;138 
For colorectal cancer, tumors in the proximal colon, distal colon, and 
rectum will be included. Proximal colon cancer includes cancer in the cecum, 
ascending colon, hepatic flexure, transverse colon, and splenic flexure. Distal 
colon cancer includes cancer in the descending and sigmoid colon as well as 
rectal carcinoma. Appendiceal carcinomas will be excluded. Female breast cancer 
excludes tumors in the skin of the breast, and pre-menopausal cancers. Cancer 
diagnosis date was taken from available pathology reports. 
Table 2.2 shows total obesity-related incidences for cancer types 
considered to be obesity-related for the analyses using BMI cases (116 in men, 
183 in women) and the analyses using WC and WHtR (104 in men, 163 in 
women).  Only the first cancer type experienced is tabulated for participants with 
multiple cancer types.  
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2.5. Statistical Analysis 
The first objective of these analyses was to estimate the independent 
effects of three measures of body fat (BMI, WHtR, and WC) and HC on the risk 
of obesity-related cancers.  BMI was measured at the baseline visit as previously 
described and all subjects with prevalent cancer (except non-melanoma skin 
cancer) at that visit were excluded. For the main analyses, follow-up for the 
occurrence of obesity-related cancers started at the end of the baseline visit and 
continued until the first of the following events: incident obesity-related cancer; 
incident non-obesity-related cancer; loss to follow-up; death; or date of last 
follow up. Incidence rates for obesity-related cancers were calculated as the 
number of incident cases occurring during follow up divided by the amount of 
person-time in each of the exposure categories. Multivariable modeling were 
carried out using Cox Proportional Hazards Models to estimate the adjusted 
relative risks (hazards ratios) for obesity-related cancer and 95% confidence 
intervals (CI) associated with BMI.  
BMI was categorized using sensitivity analyses, starting with sex-specific 
quintiles. The range of BMI values within the quintiles were used to inform the 
cutoff values for separate BMI exposure categories. Standard cutoff values for 
overweight (BMI, 25 kg/m2) and obesity (BMI, 30 kg/m2) were also explored. In 
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all analyses, there was a consistent J-shaped relation between BMI and obesity-
related cancer risk, with subjects in the lowest BMI category having a higher 
obesity-related cancer risk than those of normal, but slightly higher, body 
weight. A variety of analyses were carried out to evaluate the possible cause for 
the J-shaped relation, such as excluding various categories of subjects who might 
have related illnesses explaining low weight status and excluding current and 
past heavy smokers.  
Analyses with WC, WHtR and HC were performed similarly, starting 
with sex-specific quintile values and moving on to fewer categories for the 
analysis of effect modification. For example, WHtR was dichotomized into WHtR 
<0.58 and WHtR ≥0.58 for both men and women.  Analyses with waist simply 
used two categories: subjects were categorized with waist circumferences ≤40 
inches or >40 inches in men and ≤34 inches or >34 inches in women. 
The second objective was to estimate potential effect modification of each 
anthropometric measure of body fat by the presence of metabolic abnormalities. 
Analyses evaluating the combined effect body fat and each metabolic 
abnormality combined categories of BMI, WHtR, WC, or HC with previously 
described categories of IFG, TG, HDL, dyslipidemia, or metabolic dysfunction. 
The existence of effect measure modification was evaluated by determining 
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whether the combined effect of two exposures (subtracting the baseline HR of 1.0 
of the doubly non-exposed) is not equal to the sum of the individual effects of 
two single exposures (subtracting the baseline HR of 1.0): 
[HR (Jointly Exposed) -1] > [HR (Exposure 1)-1] + [HR(Exposure 2) -1] 
 
Alternatively, the incidence rate (IR) can be used to assess effect measure 
modification.  In this case the baseline rate of the doubly non-exposed would be 
subtracted from the rate of the doubly and singly exposed groups.   
[IR (Jointly Exposed) –IR(Jointly Unexposed)]≠ [IR (Exposure 1)  –IR(Jointly Unexposed)] + [IR(Exposure 2) -
IR(Jointly Unexposed)]  
 
If the sum of the risks of the two independent effects is the same as the 
effect of the doubly exposed then there is no evidence of effect measure 
modification. If the sum of the effects is lesser than the effect of those doubly 
exposed, then this would be consistent with the existence of an interaction effect 
between both exposures.   
The excess risk from the interaction may be quantified by subtracting from 
the doubly exposed group each of the incidence rate differences of the singly 
exposed groups and of the baseline doubly non-exposed group.  
 
[IR (Jointly Exposed) –IR (Jointly Unexposed)]- [IR (Exposure 1)  –IR(Jointly Unexposed)] - [IR(Exposure 2) -
IR(Jointly Unexposed)] -  IR(Jointly Unexposed) 
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The interpretation of this would be that the excess risk of subjects with 
exposure 1 who also have exposure 2 would be a certain number of cases per 
person-year more than if there were no interaction between the two exposures. 
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Chapter 3 
The Effect of Anthropometric Measures and Obesity-Related Cancer 
3.1 Introduction 
Obesity and overweight are strong risk factors for certain types of 
cancers.170  The publication of a 2004 article by Calle and Kaaks,28 addressing both 
the epidemiologic evidence of overweight and cancer risk and the potential 
biological mechanisms of excess adiposity in tumorigenesis, popularized the 
emerging concept that there exists a cluster of particular cancers strongly 
associated with overweight and obesity. A systematic review and meta-analysis 
of prospective studies by Renehan et al.138 concluded that a 5 kg/m2 increase in 
body mass index (BMI) in men led to moderately strong increased risks (24–52% 
increased risk) for esophageal adenocarcinoma, thyroid cancer, colon, and renal 
cancers; weaker effects were found for rectal cancer and malignant melanoma. In 
women, the effects (34–59% increased risk) of a 5 kg/m2 increase in BMI were 
strongest for endometrial, gallbladder, esophageal adenocarcinoma, and renal 
cancers; weaker effects in women were found for colon, pancreatic, thyroid, and 
postmenopausal breast cancers.138    
Although epidemiologic studies have shown that overweight and obesity 
are associated with individual and total cancer incidence, studies on the 
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association of body fat measures other than BMI and obesity-related cancers 
considered as a whole are not as common. Better estimates of sex-specific 
obesity-related cancer risk could depend on better measures of body 
composition, such as measures of central body fat rather than BMI. For example, 
while BMI has a weaker association with colon cancer in women than in men113, 
this could simply indicate that body composition is a stronger predictor of cancer 
risk in women than is overall body fat.29  Supporting this, the European 
prospective investigation into cancer and nutrition found that higher BMI was a 
predictor of colon cancer risk in men but not in women, while higher waist 
circumference (WC) and waist-to-hip ratio were strong predictors in both men 
and women.132 Overall evidence suggests that waist circumference may be more 
strongly associated than BMI with colorectal, postmenopausal breast, 
endometrial, and pancreatic cancers.170 Long-term, well-controlled studies that 
directly compare the impact of both BMI and simple anthropometric measures of 
central adiposity on obesity-related cancers are needed. 
The objective of this study is to estimate and compare the independent 
effects of three measures of body fat (BMI, WC, and waist-to-height ratio 
(WHtR)) on risk of obesity-related cancers in the long-term Framingham 
Offspring Study.  
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3.2 Methods 
3.2.1 Study Population 
Adults between ages 45–69 years in the Framingham Offspring Study 
(n=3944) were included in this analysis. The Framingham Offspring Study is a 
second generation prospective cohort of the offspring of subjects participating in 
the Framingham Heart Study. The Offspring Study began in 1971 with the 
enrollment of 5,135 subjects,85  5124 of whom attended the first exam. Exams 1 
through 8 were conducted during the following respective date periods: 1971–
1975, 1979–1983,1983–1987,1987–1991,1991–1995,1995–1998, 1998–2001, and 2005–
2008. At each examination visit, occurring approximately every four years, data 
on the following variables were collected: anthropometry, urinalysis, blood 
chemistries, blood pressure, medical history, and lifestyle habits. At each visit, 
subjects were asked to report any diseases or conditions that had occurred since 
their last visit.  
3.2.2 Exposure Variables 
Heights and weights were measured at each visit using a standard beam 
balance.54 To calculate visit-specific BMIs, each visit’s weight measurement (in 
kilograms) was divided by mean adult height (meters, squared) from all 
measures taken between 21 and 60 years of age. WC and hip circumference (HC) 
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were measured starting at exam 4. If either WC or HC were missing at that exam, 
then exam 5 measurements were substituted for the missing values whenever the 
subject’s change in weight between exams 3 and 5 did not exceed 10 pounds. 
WC, HC, and WHtR were used as anthropometric indicators of central adiposity. 
WC was measured around the umbilicus in a horizontal plane with the subject 
standing upright. WHtR was calculated by dividing WC by height. 
3.2.3 Outcome Variables 
Obesity-related cancer outcomes have been selected based on previously-
published studies and include the following: female reproductive (post-
menopausal breast, uterine, endometrial, and ovarian), colon, rectal, stomach, 
liver, gallbladder, pancreatic, kidney, thyroid, esophageal adenocarcinoma, 
leukemia, non-Hodgkin’s lymphoma and multiple myeloma.107;138 Post-
menopausal breast cancers excluded tumors in the skin of the breast and 
carcinoma in situ. Although the 2007World Health Organization/American 
Institute for Cancer Research report did not include ovarian or gastric cancers as 
obesity-related tumors, other publications since that time suggest 
otherwise.3;61;122;173 Also, in recent years, some evidence suggests that excess body 
fat is associated with liver cancer so we have included these in our analyses.96;160   
For colorectal cancer, tumors in the proximal colon, distal colon, and 
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rectum were included. Proximal colon cancer includes cancer in the cecum, 
ascending colon, hepatic flexure, transverse colon, and splenic flexure. Distal 
colon cancer includes cancer in the descending and sigmoid colon. Appendiceal 
carcinomas were excluded. Diagnoses were confirmed from pathology, 
laboratory, and clinical records. Cancer diagnosis date was taken from available 
pathology reports. When this was not available or when the diagnosis occurred 
before the confirmatory pathological test was completed, the diagnosis date was 
taken from other records, as has been previously described.90 All self-reported 
cancer was confirmed by outside medical and pathological records. Cancer cases 
were coded using the International Classification of Diseases for Oncology (ICD-
O).171 
For the analysis of BMI and obesity-related cancers, there were 120 and 
190 relevant cancers included for men and women, respectively. For the analysis 
of WC and WHtR in which follow-up started at exam 4 or later, there were 104 
and 163 obesity-related cancers for men and women, respectively. 
3.2.4 Potential Confounding Variables 
Potential confounders that were evaluated and included in the final 
multivariable models were as follows: age (years), sex, cigarettes per day, grams 
of alcohol per week, average adult height (inches), education (less than high 
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school, high school graduate, some college, or college graduate), and a physical 
activity index created by summing self-reported moderate and vigorous activity, 
where each type of activity was weighted by oxygen consumption.84The final WC 
and WHtR predictive models also controlled for BMI and hip circumference 
(HC) while final models for BMI and cancer risk included WC and HC as 
covariates. 
Other potential confounders examined but not used in the final 
multivariable models included energy intake macronutrient intakes (percent 
energy from total fat, carbohydrates, and protein), and other dietary factors 
(fiber; iron; fruits and vegetables, legumes; soy; dairy; poultry and fish; meat, 
franks, and organ meats); these variables did not confound the association 
between body fat and cancer risk. Since duration and intensity of smoking may 
better capture any confounding effect of smoking, pack-years of smoking was 
also examined, but it did not confound the association more than cigarettes per 
day. Therefore, it did not replace cigarettes per day in the final model.  
Alcohol use disorder (AUD) at baseline was also investigated as a 
confounder and was not used in the final models. Subjects were classified in 
Framingham with respect to prevalent alcohol use disorders on the basis of a 
physician diagnoses from medical/hospital records, qualitative descriptions of 
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alcohol abuse in drinking history in the medical, hospital, or Framingham 
records, and quantitative data on amount consumed. 
To assess the possibility of a competing risk with obesity-related cancers, 
the existence of cardiovascular disease (CVD) at baseline was added as a control. 
CVD included the following events: cerebrovascular accident, coronary heart 
disease, myocardial infarction, angina pectoris, coronary insufficiency, 
atherothrombotic infarction, transient ischemic attack, intermittent claudication, 
and congestive heart failure. Baseline CVD did not affect the risk estimates, so it 
was not part of the final models.  
3.2.5 Statistical Analysis 
Men and women ages 45–69 years were included at the first exam at 
which they met the age criteria, and had available BMI (and waist circumference 
measurements when needed), as well as all of the covariates of interest for the 
final models. For the analyses of BMI, there were 3944 subjects included; the 
sample size was reduced to 3818 for the final models that included WC or HC as 
covariates. For the primary analyses of WC and WHtR as exposures variables, 
3723 subjects were available.  
Due to the non-linear nature of the relation between body fat and cancer 
risk, exposure categories were created for each body fat measure using 
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sensitivity analyses to identify the optimal cutoff values. Category-specific 
follow-up time was calculated from the time of body fat measurement to the first 
of the following outcomes: obesity-related cancer occurrence, death, loss to 
follow up, or the date of exam visit 8. To eliminate the possibility that the effects 
could be biased as a result of an excess of preclinical cancers occurring among 
the leaner subjects, I performed analyses with follow-up time starting 3 or 6 years 
after the time of the baseline body fat measurements.  
BMI was first examined in quintiles, comparing obesity-related cancer 
rates across quintile categories. Additional analyses were conducted with other 
BMI cutoff values including standard definitions for overweight (25 kg/m2 ≤ BMI 
< 30 kg/m2) and obesity (BMI ≥ 30 kg/m2). Further analyses were run comparing 
results including and excluding subjects with a BMI<20 kg/m2 and subjects with 
type 2 diabetes mellitus. Finally, analyses were also stratified by smoking status 
(<14 pack-years vs. ≥14 pack-years).  
The same types of sensitivity analyses were conducted to identify the 
appropriate reference group and cut-off values for WHtR and WC. For these 
analyses, sex-specific cutoff values were also explored.  HC was assessed in 
quintiles, and the referent group chosen by a sensitivity analysis.  
Cox proportional hazards were performed with time (years) to the 
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development of first obesity-related cancer as the outcome of interest. Separate 
analyses assessing BMI and obesity-related cancer were also conducted 
excluding pancreatic and ovarian cancer cases. Total cancer (all cancer types 
except non-melanoma skin cancer) was also an outcome that was investigated in 
the analysis assessing the effect of BMI on total cancer risk. There were 116 and 
183 total cancer cases in men and women, respectively. Person-years of follow-up 
time were calculated by subtracting the date of study entry from the date at 
which a subject was censored (date of last study exam, date of death, date of 
obesity-related cancer diagnosis, or loss to follow up). Cancer incidence per 1,000 
person-years was calculated by dividing the number of obesity-related cancers 
by the total person-time in a given exposure category. The proportional hazards 
assumption was tested in all multivariable models. No violations were found.  
3.3 Results 
3.3.1 BMI and Cancer Risk 
Table 3.1 presents characteristics of the study population at baseline by 
conventional BMI categories: normal weight (BMI <25 kg/m2), overweight (BMI 
25-<30 kg/m2), and obese (BMI ≥30 kg/m2). Mean alcohol intake in men was 
similar across BMI categories, but women with a lower BMI had slightly higher 
alcohol intakes. Men smoked more than women. Education level in men was 
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unrelated to BMI but women with higher BMIs had lower education levels. The 
prevalences of dyslipidemia, HBP, and diabetes and impaired fasting glucose 
increased in a linear fashion with BMI. 
Table 3.1. Baseline characteristics according to standard BMI categories 
 Men Women 
  18.5–<25 25–<30 30+ 18.5–<25 25–<30 30+ 
  N=401 N=969 N=446 N=968 N=632 N=402 
  Mean (s.d.) Mean (s.d.) 
BMI (kg/m2) 23.3 (1.4) 27.4 (1.4) 33.4 (3.2) 22.4 (1.6) 27.1 (1.4) 35.2 (4.7) 
Age (years) 52.3 (6.5) 52.2 (6.6) 51.4 (5.8) 51.1 (6.0) 52.2 (6.4) 52.6 (6.7) 
WC (in.) 35.1 (2.5) 38.5 (2.4) 44.0 (3.7) 29.8 (3.0) 34.1 (3.3) 41.3 (5.0) 
WHtR 0.51 (0.03) 0.56 (0.03) 0.64 (0.05) 0.47 (0.04) 0.54 (0.05) 0.65 (0.08) 
HC (in.) 37.9 (1.8) 40.0 (1.9) 43.8 (3.0) 37.6 (2.2) 40.9 (2.4) 46.8 (4.3) 
Height (in.) 69.3 (2.5) 68.9 (2.6) 69.0 (2.6) 63.8 (2.3) 63.4 (2.3) 63.4 (2.4) 
Alcohol (g) 16.5 (19.9) 17.4 (22.1) 17.6 (25.2) 9.1 (13.1) 7.4 (12.9) 5.2 (10.1) 
Cigarettes /day 7.6 (13.6) 6.0 (12.9) 5.8 (13.1) 5.1 (10.4) 5.5 (10.6) 4.2 (10.2) 
Physical activity 
index 
14.0 (9.9) 13.3 (9.0) 13.7 (10.3) 12.6 (7.3) 11.9 (8.0) 11.2 (7.1) 
Glucose (mg/dL) 96.2 (22.5) 99.6 (24.6) 107.3 (33.5) 89.4 (12.4) 95.0 (22.1) 107.3 (38.4) 
S BP (mmHg) 124.2 (17.0) 127.8 (16.1) 131.9 (15.1) 118.8 (16.8) 125.3 (17.5) 132.3 (18.2) 
DBP (mmHg) 77.4 (9.8) 81.2 (9.1) 84.6 (8.8) 74.4 (9.3) 77.9 (9.4) 81.6 (9.8) 
  N (Column Percent) N (Column Percent) 
Educ. > H.S. 64.8% 66.1% 63.9% 61.5% 53.2% 48.0% 
IFG or T2DM1 30.4% 35.0% 50.7% 10.9% 24.4% 43.5% 
T2DM 3.2% 5.7% 11.4% 1.1% 2.9% 12.2% 
Dyslipidemia2 35.4% 54.2% 65.7% 26.8% 48.3% 67.4% 
HBP3 27.2% 37.8% 57.6% 18.8% 29.9% 49.8% 
1  IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication.  
2  Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
3  High blood pressure identified using modified JNC-7 criteria. 
 
 
  
  
52 
3.3.1.1 Determination of BMI Categories and Beginning of Follow-up 
The range of BMI within each quintile is shown in Table 3.2. The 
conventional cutoff value for overweight (BMI ≥25 kg/m2) fell into quintile 2 (Q2) 
for men and Q3 for women.  
Table 3.2. Mean BMI and ranges within quintiles 
BMI N Min Max Mean (s.d.) 
Men       
   Quintile 1 375 18.5 24.8 23.1 (1.4) 
   Quintile 2 375 24.8 26.5 25.7 (0.5) 
   Quintile 3 377 26.5 28.3 27.4 (0.5) 
   Quintile 4 377 28.3 30.8 29.4 (0.7) 
   Quintile 5 376 30.8 53.0 34.1 (3.2) 
Women       
   Quintile 1 413 18.6 22.2 20.8 (1.0) 
   Quintile 2 412 22.2 24.1 23.1 (0.6) 
   Quintile 3 413 24.1 26.4 25.2 (0.7) 
   Quintile 4 414 26.4 30.1 28.1 (1.0) 
   Quintile 5 412 30.1 54.1 35.2 (4.7) 
 
Table 3.3 suggests that for both men and women, obesity-related cancer rates 
started increasing in Q4. However, rates are also higher in Q1, suggesting for 
both men and women that there may be a “J-shaped” relation between BMI and 
cancer risk. In attempt to understand the higher obesity-related cancer rates in 
Q1, we carried out a series of sub-analyses exploring confounding and reverse 
causality as possible explanations. First, since the lowest body weight could be a 
consequence of preclinical cancer or other diseases, those with BMI<20 kg/m2 at 
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baseline were dropped from the analysis. Secondly, those with diabetes at 
baseline were excluded. In both of these analyses, the J-shaped relation across the 
quintiles remained in men and women. Finally, to determine whether the 
relationship was changed when accounting for smoking, subjects were stratified 
by smoking: <14 pack-years and ≥14 pack years. The J-shaped relation between 
BMI and obesity-related cancer rates was more pronounced in women with a 
smoking history of ≥14 pack-years while the opposite was true for men (where 
the J-shaped curve was more pronounced in men smoking <14 pack-years). 
However, these sub-analyses suffer from limited power when stratifying by both 
smoking and sex. 
Table 3.3. Incidence of obesity-related cancer among selected subgroups 
 All subjects BMI≥20 <14 pack-years ≥ 14 pack-years 
BMI N Cases1 
I/1000 
py N Cases1 
I/1000 
py N Cases1 
I/1000 
py N Cases1 
I/1000 
py 
Men                    
  Quintile 1 375 24 4.22 358 23 4.23 175 11 4.07 199 13 4.37 
  Quintile 2 375 22 3.89 375 22 3.89 190 9 3.08 185 13 4.76 
  Quintile 3 377 20 3.38 377 20 3.38 185 5 1.79 192 15 4.81 
  Quintile 4 377 25 4.38 377 25 4.38 190 8 2.81 186 17 5.98 
  Quintile 5 376 29 5.33 376 29 5.33 174 14 5.74 201 15 5.04 
Women              
  Quintile 1 413 35 5.61 323 27 5.42 278 22 5.27 135 13 6.31 
  Quintile 2 412 29 4.56 412 29 4.56 280 22 5.03 131 7 3.53 
  Quintile 3 413 33 5.14 413 33 5.14 255 22 5.54 158 11 4.48 
  Quintile 4 414 45 7.30 414 45 7.30 248 30 8.07 164 15 6.23 
  Quintile 5 412 48 8.06 412 48 8.06 273 29 7.33 138 18 9.01 
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Total cancer (except non-melanoma skin cancer) rates by BMI quintiles are 
shown in the Appendix Table A.1. As with obesity-related cancers, there was a J-
shaped relation between BMI and total cancer rates in women, particularly 
among the heavier smokers (≥14 pack-years), but not in men (overall or in any of 
the sub-analyses). 
Given the J-shaped relationship described above, Q2 for BMI was chosen 
as the referent group, rather than Q1. As shown in Table 3.4, mean BMI for men 
in Q2 was 25.7 (range: 24.8–26.5) and mean BMI for women was 23.1 (range: 
22.2–24.1). In Table 3.3, the similar cancer rates in Q2 and Q3 of BMI led us to 
combine those categories for added power.  
3.3.1.2 Effect of BMI on Obesity-Related Cancer 
Cancer is a disease with a long preclinical period that can be characterized 
by weight loss. To eliminate the possibility that preclinical illness impacted 
might explain the increased cancer risk in the lowest BMI category, additional 
analyses were performed delaying the start of follow-up for cancer occurrence by 
three years after baseline BMI was measured.  
Table 3.4 displays the obesity-related cancer rates and effect estimates 
calculated with follow-up starting at the time of the baseline BMI measurement 
and then three years later. In general, a reduction of cancer rates in the leanest 
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subjects after excluding some years of follow-up after baseline might suggest that 
preclinical cancers were raising the cancer rates among the leanest subjects (as a 
result of reverse causality). This is not the case in table 3.4. There was no 
attenuation of the rates among the lean or reduction in hazard ratios in any 
category after excluding the initial three years of follow up. Secondly, cancer 
rates increased similarly across BMI categories, suggesting no differential loss of 
subjects. Therefore, all additional analyses are shown with follow-up time 
starting at baseline.  
Table 3.4. Effect of BMI on obesity-related cancer before and after excluding 
initial follow-up time 
 Follow-up Time Starting at Baseline BMI 
BMI Category N PY Cases I/1000 py HR1(95% CI) 
Men           
   18.5–<24.5 332 5010 24 4.79 1.50 (0.89, 2.52) 
   24.5–<28 (Ref) 743 11378 36 3.16 1.00 
   28–<31 440 6718 35 5.21 1.70 (1.07, 2.71) 
   31+ 365 5295 25 4.72 1.67 (1.00, 2.80) 
Women      
   18.5–<22 383 5742 33 5.75 1.16 (0.76, 1.75) 
   22–<26.5 (Ref) 867 13447 68 5.06 1.00 
   26.5–<30 394 5892 39 6.62 1.32 (0.89, 1.95) 
   30+ 420 6061 50 8.25 1.62 (1.12, 2.35) 
Men Follow-up Time Starting 3 Years after Baseline BMI 
   18.5–<24.5 324 4009 21 5.24 1.48 (0.85, 2.58) 
   24.5–<28 (Ref) 724 9120 32 3.51 1.00 
   28–<31 429 5370 33 6.15 1.81 (1.11, 2.95) 
   31+ 357 4204 22 5.23 1.66 (0.96, 2.87) 
Women      
   18.5–<22 378 4593 32 6.97 1.39 (0.90, 2.15) 
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   22–<26.5 (Ref) 846 10835 55 5.08 1.00 
   26.5–<30 385 4711 35 7.43 1.48 (0.97, 2.25) 
   30+ 409 4804 45 9.37 1.86 (1.25, 2.78) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake, and physical activity. 
 
Table 3.5 evaluates the effect of adjusting for WC and HC in the BMI 
analysis; these analyses were conducted in a subset of 3818 subjects with non-
missing WC and HC. The subject number, cases, PY, and rates for each category 
are in appendix table A.3. Men whose BMI was between 24.5 and 28.0 kg/m2 had 
the lowest rates of obesity-related cancers. Men with a BMI of 18.5–<24.5 kg/m2 
had a 64% greater obesity-related cancer risk compared with men with a 
somewhat higher BMI (24.5–<28.0 kg/m2 ); after adjusting for HC (but not WC) 
the increased risk for the leanest men was slightly attenuated. In contrast, 
overweight men (BMI 28–<31 and ≥31 kg/m2) had a higher risk of cancer after 
adjusting for HC (HR=1.93; 95% CI: 1.16–3.21 and HR=2.22; 95%CI: 1.12–4.43, 
respectively). Sensitivity analyses in women found that the lowest cancer rates 
occurred among women whose BMI was between 22 and 26.5 kg/m2. After 
adjusting for WC, obese women had about an 80% increased risk of obesity-
related cancer. In contrast with men, WC rather than HC was a stronger 
confounder in women. 
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Table 3.5. The effect of BMI on obesity-related cancer risk adjusting for waist 
and hip circumference measures 
 
Adjusted Adjusted Plus WC Adjusted Plus HC 
BMI Category HR (95% CI)1 HR (95% CI) HR (95% CI) 
All Subjects2      
   18.5–<24.5 (m), 22(w) 1.32 (0.95, 1.83) 1.29 (0.91,1.83) 1.31 (0.93, 1.86) 
   24.5–<28 (m), 22–<26.5 (w) 1.00 1.00 1.00 
   28–<31 (m), 26.5–<30 (w) 1.54 (1.14, 2.09) 1.58 (1.14, 2.19) 1.55 (1.12, 2.14) 
   31+ (m), 30+ (w) (1.23, 2.26) 1.76 (1.13, 2.73) 1.68(1.09, 2.57) 
Men       
   18.5–<24.5 1.64 (0.97, 2.79) 1.67 (0.94, 2.96) 1.52 (0.87, 2.67) 
   24.5–<28 (Ref) 1.00 1.00 1.00 
   28–<31 1.80 (1.12, 2.92) 1.78 (1.06, 3.00) 1.93(1.16, 3.21) 
   31+ 1.86 (1.10, 3.14) 1.79 (0.87, 3.69) 2.22 (1.12, 4.43) 
Women    
   18.5–<22 1.13 (0.74, 1.73) 1.08 (0.69, 1.70) 1.14 (0.73, 1.79) 
   22–<26.5 (Ref) 1.00 1.00 1.00 
   26.5–<30 1.40 (0.94, 2.08) 1.46 (0.95, 2.25) 1.38 (0.90, 2.12) 
   30+ 1.60 (1.10, 2.34) 1.81 (1.03, 3.18) 1.56 (0.88, 2.75) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2  Excludes 126 subjects who were missing WC or HC, see appendix table A.3 for subject number, 
case number, person-years and rates. 
 
These same analyses were also performed to assess the effect of BMI on total 
cancers. (Appendix Table A.2) Overall, after adjusting for potential confounders 
the relative risk of BMI on total cancers in men and women is much lower than 
that for obesity-related cancers.  
In an analysis using conventional BMI categories (Table 3.6), the 
heterogeneity in cancer risk within the BMI category of 25–<30 kg/m2 in men 
resulted in a finding of no adverse effects among these men traditionally defined 
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as overweight. The risk of obesity-related cancer in obese men was confounded 
by HC, while in women the estimated effects were confounded by WC.  
Table 3.6. Standard BMI categories on incidence of obesity-related cancer after 
adjusting for waist circumference or hip circumference 
BMI Category N1 PY Cases I/1000 py HR2 (95%CI) HR3 (95%CI) 
All Subjects         
   18.5–<25  1369 21012 99 4.71 1.00 1.00 
   25–<30  1601 24735 116 4.69 1.11 (0.84, 1.47) 1.19 (0.87, 1.65) 
   ≥30 848 12320 84 6.82 1.60 (1.19, 2.15) 1.89 (1.18, 3.04) 
Men       
   18.5–<25  401 6116 27 4.41 1.00 - 
   25–<30  969 15143 52 3.43 0.80 (0.50, 1.27) 0.90 (0.54, 1.51) 
   ≥30 446 6510 37 5.68 1.44 (0.87, 2.39) 1.98 (0.96, 4.08) 
Women       
   18.5–<25  968 14896 72 4.83 1.00 1.00 
   25–<30  632 9592 64 6.67 1.36 (0.97, 1.91) 1.49 (1.01, 2.21) 
   ≥30 402 5810 47 8.09 1.64 (1.13, 2.39) 2.06 (1.12, 3.79) 
1 Excludes 126 subjects who were missing WC or HC. 
2 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
grams of alcohol intake, and physical activity. 
3 Additionally adjusted for WC in all subjects and in women and HC in men. 
 
Finally, we carried out separate analyses (data not shown) to evaluate 
whether prevalent CVD might constitute a competing risk among obese subjects, 
since they may have higher rates of CVD and die prior to the development of 
obesity-related cancer. The addition of time-dependent CVD status did not alter 
the effect.  
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3.3.2 WHtR and Obesity-Related Cancer Risk 
Tables 3.7 – 3.11 explore the relationship between WHtR as a simple 
anthropometric measure of central adiposity and obesity-related cancer risk. 
Cutoff values for WHtR were selected using sensitivity analyses. 
Table 3.7 presents characteristics of the study population at baseline by 
WHtR categories: <0.51, 0.51– <0.58, and ≥0.58. Mean BMI and WC increased with 
increasing WHtR categories. Men and women in the lowest WHtR category were 
more educated than those in the higher categories. The prevalence of 
dyslipidemia in men and women in the highest WHtR category was more than 
double that of the leanest subjects. About 50% of men and women with 
WHtR≥0.58 had IFG or diabetes and more than 50% had hypertension.  
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Table 3.7. Baseline characteristics according to WHtR category 
 
Men Women 
 
<0.51 0.51 – <0.58 ≥0.58 <0.51 0.51 – <0.58 ≥0.58 
WHtR Category N=258 N=855 N=659 N=959 N=528 N=464 
 
Mean (s.d.) Mean (s.d.) 
BMI (kg/m2) 23.4 (1.9) 26.7 (1.9) 31.7 (3.7) 23.1 (2.3) 27.1 (3.0) 33.7 (5.5) 
WC (in.) 33.8 (1.9) 37.7 (1.9) 43.1 (3.4) 29.2 (2.2) 34.5 (1.9) 41.4 (4.4) 
WHtR  0.48 (0.02) 0.54 (0.02) 0.63 (0.04) 0.46 (0.03) 0.54 (0.02) 0.66 (0.07) 
Age (years) 52.2 (6.6) 53.8 (7.1) 53.9 (7.1) 52.7 (6.8) 52.8 (6.8) 54.9 (7.4) 
Height (in.) 69.8 (2.5) 69.1 (2.6) 68.6 (2.5) 63.9 (2.3) 63.6 (2.43) 63.2 (2.3) 
Alcohol intake (g) 14.8 (19.0) 15.7 (20.4) 16.2 (23.0) 7.8 (11.4) 6.9 (10.6) 5.7 (10.8) 
Cigarettes /day 6.2 (11.9) 4.7 (11.3) 6.4 (13.2) 3.8 (8.7) 5.2 (10.5) 4.7 (10.5) 
Physical activity 
index 
14.8 (11.1) 14.7 (10.3) 14.5 (11.0) 14.1 (8.7) 13.5 (8.3) 12.6 (8.4) 
Glucose (mg/dL) 94.1 (20.2) 100.3 (27.4) 105.5 (33.3) 89.1 (12.9) 94.7 (19.7) 109.4 (42.7) 
SBP (mmHg) 122.8 (16.9) 129.3 (17.2) 133.0 (16.9) 120.9 (18.4) 125.4 (17.8) 133.6 (19.5) 
DBP (mmHg) 76.1 (10.0) 80.7 (9.2) 83.1 (9.5) 74.4 (9.4) 77.2 (9.5) 80.3 (10.1) 
  N (Column Percent) N (Column Percent) 
Educ. > H.S. 192 (74.4%) 578 (67.6%) 395 
(59.9%) 
586 (61.1%) 304 (57.6%) 214 (46.1%) 
IFG or T2DM1 77 (29.8%) 352 (41.2%) 328 
(49.8%) 
118 (12.3%) 139 (26.3%) 225 (48.5%) 
T2DM 7 (2.7%) 49 (5.7%) 75 
(11.4%) 
8 (0.8%) 15 (2.8%) 60 (12.9%) 
Dyslipidemia2 84 (32.6%) 459 (53.7%) 444 
(67.4%) 
271 (28.3%) 297 (56.3%) 326 (70.3%) 
HBP3 62 (24.0%) 362 (42.3%) 380 
(57.7%) 
222 (23.2%) 172 (32.6%) 245 (52.8%) 
1 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
2 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
3 High blood pressure identified using modified JNC-7 criteria. 
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3.3.2.1 WHtR Quintiles: Rates and Effects on Obesity-Related Cancer 
Mean values and ranges for the WHtR quintiles are shown in Table 3.8. 
Table 3.9 shows the rates of obesity-related cancers according to these quintiles. 
In both men and women, those in the lowest WHtR quintile (Q1) had higher 
cancer rates than those in Q2; in men, rates in Q1 were also higher than those in 
Q3. For men, as WHtR increased from 0.52 to 0.86, cancer risk rose in a linear 
fashion (2.89, 3.19, 4.86, and 6.44 cases per 1000 py, in Q2 to Q5, respectively). 
Comparable rates for women were 5.09, 6.25, 6.02, and 7.89, respectively. Again, 
excluding the first 3 years of follow-up after baseline did not attenuate increased 
risk associated with being in Q1. 
Table 3.8. Range of WHtR and HC within quintiles 
WHtR Quintile N Min Max Mean (s.d.) 
Men     
   Quintile 1 357 0.40 0.52 0.49 (0.02) 
   Quintile 2 348 0.52 0.55 0.53 (0.01) 
   Quintile 3 363 0.55 0.57 0.56 (0.01) 
   Quintile 4 345 0.58 0.61 0.59 (0.01) 
   Quintile 5 359 0.61 0.86 0.66 (0.04) 
Women     
   Quintile 1 392 0.37 0.45 0.43 (0.02) 
   Quintile 2 388 0.45 0.49 0.47 (0.01) 
   Quintile 3 389 0.49 0.54 0.51 (0.01) 
   Quintile 4 390 0.54 0.59 0.56 (0.02) 
   Quintile 5 392 0.60 1.04 0.67 (0.06) 
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Table 3.9. Effect of WHtR quintiles on incidence of obesity-related cancer 
before and after excluding initial follow-up time 
 
Follow-up Starting at Baseline 
WHtR Quintile N PY Cases 
I/1000 
py HR1 (95% CI) 
Men        
   Quintile 1 357 4764 22 4.62 1.73 (0.88, 3.39) 
   Quintile 2 (Ref) 348 4843 14 2.89 1.00 
   Quintile 3 363 5018 16 3.19 1.11 (0.54, 2.28) 
   Quintile 4 345 4531 22 4.86 1.78 (0.91, 3.49) 
   Quintile 5 359 4657 30 6.44 2.24 (1.18, 4.25) 
Women      
   Quintile 1 392 5657 35 6.19 1.29 (0.78, 2.13) 
   Quintile 2 (Ref) 388 5299 27 5.09 1.00 
   Quintile 3 389 5278 33 6.25 1.26 (0.75, 2.09) 
   Quintile 4 390 4979 30 6.02 1.25 (0.74, 2.10) 
   Quintile 5 392 4817 38 7.89 1.57 (0.95, 2.59) 
       
Men Follow-up Starting 3 Years after Baseline 
   Quintile 1 345 3636 20 5.50 1.64 (0.82, 3.25) 
   Quintile 2 (Ref) 338 3779 14 3.70 1.00 
   Quintile 3 352 3890 13 3.34 0.91 (0.43, 1.94) 
   Quintile 4 335 3509 20 5.70 1.61 (0.81, 3.20) 
   Quintile 5 346 3580 27 7.54 2.01 (1.05, 3.87) 
Women        
   Quintile 1 384 4478 30 6.70 1.37 (0.78, 2.40) 
   Quintile 2 (Ref) 377 4145 21 5.07 1.00 
   Quintile 3 381 4081 28 6.86 1.38 (0.78, 2.44) 
   Quintile 4 381 3810 26 6.82 1.42 (0.80, 2.52) 
   Quintile 5 377 3658 33 9.02 1.87 (1.07, 3.25) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, 
 cigarettes/day, alcohol intake, and physical activity. 
 
For the Cox proportional Hazard’s models, we used quintile 2 as the referent for 
all of these analyses. Men in Q5 of WHtR had more than a two-fold increased 
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risk of obesity-related cancer; hazard ratios were somewhat weaker in women. 
Table 3.10 shows that cancer risks in men with the larger WHtRs were 
strengthened when adjusting for HC.  
Table 3.10 Effect of WHtR quintiles on the incidence of obesity-related cancer 
after adjusting for hip circumference 
 Adjusted Adj. plus HC 
WHtR Quintile HR1 (95% CI) HR (95% CI) 
All Subjects    
   Quintile 1 1.46 (0.98, 2.19) 1.48 (0.98, 2.24) 
   Quintile 2 (Ref) 1.00 1.00 
   Quintile 3 1.20 (0.79, 1.81) 1.19 (0.78, 1.81) 
   Quintile 4 1.43 (0.95, 2.16) 1.40 (0.91, 2.16) 
   Quintile 5 1.79 (1.21, 2.65) 1.71 (1.03, 2.84) 
Men   
   Quintile 1 1.73 (0.88, 3.39) 1.59 (0.79, 3.18) 
   Quintile 2 (Ref) 1.00 1.00 
   Quintile 3 1.11 (0.54, 2.28) 1.18 (0.57, 2.45) 
   Quintile 4 1.78 (0.91, 3.49) 2.01 (0.98, 4.11) 
   Quintile 5 2.24 (1.18, 4.25) 2.94 (1.27, 6.78) 
Women   
   Quintile 1 1.29 (0.78, 2.13) 1.36 (0.81, 2.29) 
   Quintile 2 (Ref) 1.00 1.00 
   Quintile 3 1.26 (0.75, 2.09) 1.20 (0.72, 2.02) 
   Quintile 4 1.25 (0.74, 2.10) 1.14 (0.66, 1.98) 
   Quintile 5 1.57 (0.95, 2.59) 1.25 (0.64, 2.46) 
1  Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake, and physical activity. 
 
3.3.2.2 WHtR Categories: Rates and Effects on Obesity-Related Cancer 
A non-significant relative risk was found in men and a 49% increased risk 
in women WHtR≥ 0.58, respectively compared with men and women with 
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WHtR≤ 0.58. (Table 3.11) 
Table 3.11. Effect of WHtR on incidence of obesity-related cancer 
     Adjusted Adj. plus HC 
WHtR Category N PY Cases 
I/1000 
py HR1 (95% CI) HR (95% CI) 
All Subjects          
   WHtR<0.51 1217 16959 87 5.13 1.00 1.00 
   WHtR 0.51–<0.58 1383 18568 86 4.63 1.07 (0.78, 1.47) 1.07 (0.76, 1.52) 
   WHtR ≥0.58 1123 14318 94 6.57 1.47 (1.07, 2.01) 1.48 (0.94, 2.33) 
Men       
   WHtR<0.51 258 3503 14 4.00 1.00 1.00 
   WHtR 0.51–<0.58 855 11699 42 3.59 0.80 (0.43, 1.47) 0.85 (0.44, 1.63) 
   WHtR ≥0.58 659 8610 48 5.57 1.28 (0.69, 2.35) 1.49 (0.66, 3.37) 
Women       
   WHtR<0.51 959 13456 73 5.43 1.00 1.00 
   WHtR 0.51–<0.58 528 6868 44 6.41 1.22 (0.84, 1.78) 1.20 (0.79, 1.81) 
   WHtR ≥0.58 464 5707 46 8.06 1.49 (1.02, 2.18) 1.43 (0.82, 2.51) 
1  Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake, and physical activity. 
 
3.3.3 Waist Circumference (WC) and Obesity-Related Cancer Risk 
Tables 3.12 – 3.14 show the effects of WC alone, rather than WHtR on 
obesity-related cancer risk. Since any ratio measure such as WHtR includes two 
factors, each of which is measured with a certain amount of error, it is very 
possible that the effects of such a ratio measure will be attenuated due to excess 
random error. Therefore, waist circumference alone may be a better indicator of 
risk, particularly when controlling for height in the multivariable model. 
Table 3.12 shows characteristics of the study population at baseline by sex-
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specific WC categories. Mean BMI and WC was greater in the higher WC 
category. Men with WC of 40 inches or less consumed less alcohol and smoked 
fewer cigarettes per day than men with a higher WC. Both men and women in 
the upper WC category had a lower mean HDL and higher TG and fasting 
glucose levels as well as higher risks of dyslipidemia, IFG/diabetes, and 
hypertension. 
Table 3.12. Baseline characteristics according to WC category 
 Men Women 
WC Category WC ≤ 40 in. WC > 40 in. WC ≤ 34 in. WC > 34 in. 
  N=1176 N=596 N=1200 N=751 
  Mean (s.d.) Mean (s.d.) 
BMI (kg/m2) 26.1 (2.4) 32.0 (3.8) 23.7 (2.7) 31.4 (5.6) 
WC (inches) 36.8 (2.3) 43.7 (3.0) 30.0 (2.5) 39.3 (4.5) 
WHtR 0.54 (0.04) 0.63 (0.05) 0.47 (0.04) 0.62 (0.07) 
Age (years) 53.7 (7.0) 53.4 (7.0) 53.0 (6.9) 53.7 (7.1) 
Height (inches) 68.7 (2.5) 69.6 (2.6) 63.5 (2.3) 63.9 (2.4) 
Alcohol (g) 14.9 (19.9) 17.4 (23.5) 7.6 (11.2) 6.2 (10.9) 
Cigarettes/ day 5.0 (11.3) 6.6 (13.6) 4.3 (9.4) 4.5 (10.1) 
Physical activity index 15.0 (10.6) 14.0 (11.0) 14.0 (8.6) 12.9 (8.4) 
Glucose (mg/dL) 98.9 (25.9) 106.2 (34.0) 90.0 (14.4) 104.1 (36.4) 
SBP (mmHg) 128.2 (17.7) 132.7 (16.3) 121.8 (18.4) 130.5 (19.2) 
DBP (mmHg) 79.6 (9.8) 83.5 (9.1) 74.8 (9.4) 79.4 (10.0) 
  N (Column Percent) N (Column Percent) 
Educ. >H.S. 784 (66.7%) 381 (63.9%) 720 (60.00%) 384 (51.13%) 
IFG or T2DM1 455 (38.7%) 302 (50.67%) 173 (14.42%) 309 (41.15%) 
T2DM 62 (5.3%) 69 (11.6%) 15 (1.25%) 68 (9.05%) 
Dyslipidemia2 589 (50.1%) 398 (66.8%) 404 (33.67%) 490 (65.25%) 
HBP3 464 (39.5%) 340 (57.1%) 296 (24.67%) 343 (45.67%) 
1  IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
2  Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
3  High blood pressure identified using modified JNC-7 criteria. 
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3.3.3.1 Effect of WC Categories on Obesity-Related Cancer  
Table 3.13 shows results from our sensitivity analyses of different WC 
cutoff values for men and women. Here, men with WC ≥42 inches had nearly 
double the adjusted relative risk of obesity-related cancer, and men with a WC 
between 40 and 42 inches had no excess risk. After adjusting for HC, men in the 
highest WC category had more than a 4-fold increased risk of these cancers. 
Adjusting for BMI or HC in women strongly attenuated the effects which could 
be due to collinearity. In men, the Spearman correlation coefficient between WC 
categories and HC (continuous) was 0.81 and in women, the correlation was 0.79; 
the correlation coefficients between WC categories and BMI were similar 
(Spearman ρ= 0.83 and ρ= 0.77 for men and women, respectively). 
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Table 3.13. Effect of WC on the incidence of obesity-related cancer 
     Adjusted Adj. plus WC Adj. plus HC 
WC Category N PY Cases 
I/1000 
py HR1 (95% CI) HR (95% CI) HR (95% CI) 
All Subjects (men, women)         
   <35, <28 (Ref) 459 6562 27 4.11 1.00 1.00 1.00 
   35–<38, 28–<31  935 12920 65 5.03 1.22 (0.78, 1.91) 1.23 (0.78, 1.95) 1.23 (0.78, 1.95) 
   38–<40, 31–<34  824 11091 50 4.51 1.08 (0.67, 1.73) 1.10 (067, 1.81) 1.10 (0.67, 1.81) 
   40–<42, 34–<38 683 8994 51 5.67 1.39 (0.87, 2.22) 1.43 (0.84, 2.43) 1.43 (0.84, 2.43) 
    ≥42, ≥38 822 10277 74 7.20 1.78 (1.14, 2.78) 1.87 (1.01, 3.45) 1.87 (1.01, 3.45) 
Men        
   <35 (Ref) 215 2913 10 3.43 1.00 1.00 1.00 
    35–<38  489 6767 27 3.99 1.09 (0.53, 2.26) 1.28 (0.60, 2.74) 1.34 (0.63, 2.84) 
   38–<40  376 5079 14 2.76 0.72 (0.32, 1.65) 0.95 (0.38, 2.37) 1.04 (0.43, 2.53) 
   40–<42  277 3712 15 4.04 1.04 (0.46, 2.34) 1.50 (0.57, 3.96) 1.68 (0.66, 4.25) 
    ≥42  415 5341 38 7.11 1.94 (0.96, 3.95) 3.46 (1.18, 
10.21) 
4.26 (1.54, 11.75) 
Women        
   <28 (Ref) 244 3649 17 4.66 1.00 1.00 1.00 
   28–<31  446 6153 38 6.18 1.31 (0.74, 2.33) 1.23 (0.68, 2.20) 1.24 (0.69, 2.23) 
   31–<34  448 6013 36 5.99 1.23 (0.69, 2.20) 1.07 (0.57, 1.99) 1.12 (0.60, 2.07) 
   34–<38  406 5282 36 6.82 1.46 (0.82, 2.62) 1.18 (0.60, 2.31) 1.25 (0.64, 2.44) 
    ≥38  407 4935 36 7.29 1.52 (0.84, 2.74) 1.00 (0.41, 2.43) 1.15 (0.50, 2.64) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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Finally in Table 3.14, we dichotomized the WC variable to enhance statistical 
power and to cross-classify this variable with markers of metabolic health in the 
next chapter. Although no choice is ideal, I chose to combine subjects in upper 
two categories of WC vs. those in the lower three. To assess whether pre-clinical 
illness impacted the results, I again excluded cases occurring within three years 
of baseline. This analysis led to a loss of 14% of cases (in the first 3 years) in the 
low WC category and 12% loss of cases in the high WC category. Therefore, we 
concluded that there was little evidence of preclinical illness affecting the results, 
leading us to carry out the remaining analyses with follow-up time starting at 
baseline rather than 3 years later. In these analyses, there was a 91% statistically 
significant increased risk of obesity-related cancer in men with WC >40 inches 
and a non-statistically significant 29% increased risk in women with WC >34 
inches. As in Table 3.13, adjusting for HC or BMI strengthened the relative risk in 
men and attenuated it in women.  
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Table 3.14. Effect of WC on the incidence of obesity-related cancer before and 
after excluding initial follow-up time 
 Follow-up Starting at Baseline WC Exposure 
     Adjusted Adj.  plus HC 
WC Category N PY Cases 
I/1000 
py HR1 (95% CI) HR (95% CI) 
All Subjects       
   WC ≤40 (m), >34(w) 2376 32812 150 4.57 1.00 1.00 
   WC >40 (m), >34(w) 1347 17032 117 6.87 1.49 (1.17,1.91) 1.55 (1.13, 2.14) 
Men       
   WC ≤40 1176 16126 55 3.41 1.00 1.00 
   WC >40  596 7687 49 6.37 1.91 (1.29, 2.83) 2.59 (1.53, 4.36) 
Women       
   WC ≤34 1200 16686 95 5.69 1.00 1.00 
   WC >34  751 9345 68 7.28 1.29 (0.94, 1.78) 1.16 (0.76, 1.77) 
       
All Subjects Follow-up Starting 3 Years after Baseline WC Exposure 
   WC ≤40 (m), >34(w) 2310 25554 129 5.05 1.00 1.00 
   WC >40 (m), >34(w) 1306 13011 103 7.92 1.57 (1.20, 2.04) 1.69 (1.20, 2.39) 
Men        
   WC ≤40 1136 12478 50 4.01 1.00 1.00 
   WC >40  580 5916 44 7.44 1.85 (1.22, 2.81) 2.66 (1.54, 4.60) 
Women        
   WC ≤34 1174 13076 79 6.04 1.00 1.00 
   WC >34  726 7095 59 8.32 1.45 (1.02, 2.04) 1.31 (0.83, 2.07) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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3.3.4 Effect of HC Quintiles on Obesity-Related Cancer  
Table 3.15 shows the ranges for HC quintiles, and Table 3.16 shows rates 
and hazards ratios for each quintiles with follow up starting at baseline and after 
eliminating three years of initial follow-up. As a result of the U- or J-shaped 
relationships in the rates across quintiles, Q2 was chosen as the referent group. 
Because there was no reduction in the rates or hazard ratios after eliminating 3 
years of follow up, there is no suggestion of preclinical illness affecting the 
estimates at baseline. Table 3.17 combines Q2 and Q3 as the referent group. Men 
in the both lowest and highest HC quintiles had at least double the risk of 
obesity-related cancer. To evaluate the effect of HC independent of overall WC, 
we included WC in the final model. In men, this led to an attenuation of the 
effect of a high HC, while men with the smallest hips in relation to their waist 
size had 2.68 times the risk of cancer (95% CI: 1.46–4.89) compared with men of 
more average hip size. Adjusting for WC also attenuated the effect of HC in men 
in Q4 and Q5.  No effect of HC was seen in women. 
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Table 3.15. Range of hip circumference within quintiles 
HC Quintile N Min Max 
All Subjects 
   Quintile 1 740 31.50 38.00 
Quintile 2 724 37.00 39.25 
Quintile 3 730 39.00 40.80 
Quintile 4 783 41.00 43.75 
Quintile 5 746 43.00 65.50 
Men 
   Quintile 1 398 32.50 38.00 
Quintile 2 296 38.25 39.25 
Quintile 3 331 39.50 40.80 
Quintile 4 392 41.00 42.80 
Quintile 5 355 43.00 59.00 
Women 
   Quintile 1 342 31.50 36.75 
Quintile 2 428 37.00 38.75 
Quintile 3 399 39.00 40.75 
Quintile 4 391 41.00 43.75 
Quintile 5 391 44.00 65.50 
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Table 3.16. Effect of HC on the incidence of obesity-related cancer before and 
after excluding initial follow-up time 
 Follow-up Starting at Baseline HC Exposure 
     Adjusted Adj. plus WC 
HC Quintiles N PY Cases I/1000 py HR1 (95% CI) HR (95% CI) 
All Subjects          
   Quintile 1 740 10106 55 5.44 1.45 (0.97, 2.18) 1.51 (0.99, 2.28) 
   Quintile 2 (Ref) 724 9976 42 4.21 1.00 1.00 
   Quintile 3 730 9823 45 4.58 1.12 (0.74, 1.71) 1.09 (0.71, 1.67) 
   Quintile 4 783 10314 66 6.40 1.62 (1.10, 2.39) 1.51 (0.99, 2.30) 
   Quintile 5 746 9625 59 6.13 1.57 (1.05, 2.33) 1.35 (0.79, 2.29) 
Men       
   Quintile 1 398 5340 29 5.43 2.08 (1.05, 4.09) 2.45 (1.22, 4.94) 
   Quintile 2 (Ref) 296 4086 12 2.94 1.00 1.00 
   Quintile 3 331 4491 12 2.67 0.94 (0.42, 2.09) 0.83 (0.37, 1.87) 
   Quintile 4 392 5262 27 5.13 1.80 (0.91, 3.57) 1.42 (0.68, 2.96) 
   Quintile 5 355 4634 24 5.18 1.98 (0.98, 4.00) 1.17 (0.47, 2.94) 
Women       
   Quintile 1 342 4766 26 5.46 1.12 (0.66, 1.90) 1.13 (0.66, 1.93) 
   Quintile 2 (Ref) 428 5891 30 5.09 1.00 1.00 
   Quintile 3 399 5332 33 6.19 1.23 (0.75, 2.02) 1.22 (0.74, 2.03) 
   Quintile 4 391 5052 39 7.72 1.55 (0.96, 2.50) 1.52 (0.90, 2.57) 
   Quintile 5 391 4991 35 7.01 1.42 (0.87, 2.32) 1.36 (0.69, 2.67) 
 Follow-up Starting 3 Years after Baseline HC Exposure 
All Subjects             
   Quintile 1 717 7859 48 6.11 1.41 (0.91, 2.18) 1.49 (0.95, 2.32) 
   Quintile 2 (Ref) 703 7739 37 4.78 1.00 1.00 
   Quintile 3 714 7611 39 5.12 1.10 (0.70, 1.73) 1.05 (0.67, 1.66) 
   Quintile 4 762 7952 59 7.42 1.65 (1.09, 2.49) 1.48 (0.94, 2.32) 
   Quintile 5 720 7405 49 6.62 1.49 (0.97, 2.29) 1.19 (0.67, 2.12) 
Men       
   Quintile 1 383 4125 27 6.55 2.11 (1.04, 4.28) 2.55 (1.23, 5.29) 
   Quintile 2 (Ref) 284 3123 11 3.52 1.00 1.00 
   Quintile 3 322 3481 11 3.16 0.91 (0.39, 2.11) 0.79 (0.34, 1.84) 
   Quintile 4 383 4079 25 6.13 1.78 (0.87, 3.64) 1.35 (0.63, 2.91) 
   Quintile 5 344 3586 20 5.58 1.74 (0.83, 3.67) 0.94 (0.35, 2.51) 
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Women       
   Quintile 1 334 3734 21 5.62 0.99 (0.56, 1.78) 1.01 (0.56, 1.84) 
   Quintile 2 (Ref) 419 4616 26 5.63 1.00 1.00 
   Quintile 3 392 4130 28 6.78 1.23 (0.72, 2.10) 1.20 (0.70, 2.08) 
   Quintile 4 379 3873 34 8.78 1.61 (0.97, 2.69) 1.54 (0.88, 2.72) 
   Quintile 5 376 3819 29 7.59 1.45 (0.85, 2.47) 1.32 (0.63, 2.75) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
 
Table 3.17.  Effect of HC on incidence of obesity-related cancer 
     Adjusted Adj. plus WC 
HC Quintiles N PY Cases I/1000 py HR1 (95% CI) HR (95% CI) 
All Subjects         
  Quintile 1 740 10106 55 5.44 1.37 (0.97, 1.94) 1.45 (1.01, 2.09) 
  Quintile 2+3 (Ref) 1454 19800 87 4.39 1.00  
  Quintile 4 783 10314 66 6.40 1.53 (1.11, 2.10) 1.44 (1.02, 2.03) 
  Quintile 5 746 9625 59 6.13 1.48 (1.06, 2.06) 1.28 (0.81, 2.01) 
Men       
  Quintile 1 398 5340 29 5.43 2.15 (1.24, 3.72) 2.68 (1.46, 4.89) 
  Quintile 2+3 (Ref) 627 8577 24 2.80 1.00 1.00 
  Quintile 4 392 5262 27 5.13 1.86 (1.07, 3.24) 1.58 (0.88, 2.83) 
  Quintile 5 355 4634 24 5.18 2.05 (1.16, 3.64) 1.32 (0.61, 2.85) 
Women       
  Quintile 1 342 4766 26 5.46 1.01 (0.63, 1.60) 1.03 (0.63, 1.68) 
  Quintile 2+3 (Ref) 827 11223 63 5.61 1.00 1.00 
  Quintile 4 391 5052 39 7.72 1.40 (0.94, 2.08) 1.36 (0.88, 2.10) 
  Quintile 5 391 4991 35 7.01 1.28 (0.84, 1.94) 1.19 (0.67, 2.14) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
 
3.3.5 Proportion of Risk  Attributable to Anthropometric Measures 
Obesity-related cancer incidence rates, rate differences (RD), and the 
attributable proportion (AP) of cancers due to excess body fat (i.e., higher WC, 
WHtR, and BMI) are shown in Appendix Table A.4. Men in Q5 of WC and WHtR 
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had the highest absolute risk, and the attributable proportion or risk of being in 
these quintiles was 55%. In contrast, women in Q5 of BMI had the highest 
absolute risk and the proportion of risk attributed to being in that quintile was 
43%.  
3.4 Discussion 
In this analysis of 45–69 year old men and women in the Framingham 
Offspring Cohort, those in higher categories of BMI, WHtR, and WC had an 
increased risk of obesity-related cancers. Men and women with higher BMI had, 
respectively, a 60% and 80% higher risk of obesity-related cancer when using 
sex-specific BMI cutoffs. Men with a BMI in the range of 24.5 to <28 had the 
lowest rates of these cancers and women whose BMI was between 22.0 and 26.5 
had the lowest rates. These analyses also suggest that HC is an important 
confounder of the relationship between BMI and cancer risk in men, but not 
women. In addition, men with the lowest HC had more than twice the risk of 
obesity-related cancer. This was not the case in women, perhaps suggesting that 
body shape may be a stronger risk factor for cancer in men than in women.  
We explored the use of two anthropometric measures of centrally-located 
body fat in these analyses—WHtR and WC. The results suggest that central body 
fat is a stronger cancer risk factor for men than is for women. In the BMI and 
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WHtR analyses (but not WC), men and women with the lowest quintile of body 
fat had somewhat higher cancer risks. However, the risk of these obesity-related 
cancers rose in a generally linear fashion from Q2 through Q5. In all of these 
analyses, we explored the possibility that reverse causality might be responsible 
for the excess risk among the leanest men and women. We excluded subjects 
with prevalent diabetes, alcoholism, and cancer cases occurring in the 3–6 years 
after the end of the measurement of body fat but none of these analyses yielded 
an explanation for these higher rates in the leanest subjects. We carried out sub-
analyses excluding pancreatic cancers to eliminate the possibility that preclinical 
thinness might be contaminating the lowest body fat group 103;124 but found no 
attenuation of the results in any of these analyses. Finally, we stratified by 
smoking and found that the excess cancer risk was not different for smokers and 
non-smokers (even after accounting for past smoking and amount smoked). 
Confounding by unknown or unmeasured factors cannot be ruled out.  
3.4.1 Contribution to Existing Literature on BMI and Obesity-Related Cancer 
These analyses support existing published epidemiologic data showing 
that obesity is a strong risk factor for a cluster of cancers. This is one of few 
studies that attempted to restrict the outcome to a pre-defined set of obesity-
related cancers, identified from published literature.138;170 The lower total cancer 
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risks associated with obesity in this study support the evidence that obesity is 
more strongly associated with a particular subset of cancers than cancer in 
general. 
These results also support our earlier study examining the effects of 
obesity on incident obesity-related cancer in the original Framingham Heart 
Study cohort.114 In the earlier study, we found a 90% increased risk in overweight 
men and a two-fold increase risk of obesity-related cancers in obese men 
compared with those with a BMI <25 kg/m2. This is consistent with findings in 
the present study in that obese men had a HC-adjusted 98% increased risk of 
obesity-related cancer. Another recent analysis of 39,909 men in the Health 
Professional Follow-up Study (HPFS) found that men at age 21 with BMI ≥30 
kg/m2 had a 90% increased risk of obesity-related cancers (colorectal, pancreatic, 
and esophageal cancers). Those with a BMI between 25–29.9 kg/m2 had 24–36% 
increased risk.37  Notably, their referent group (<22.9 kg/m2) was lower than those 
in the current study.  
The current study also support results from the Million Women Study, 136 
in which the relative risk of many individual obesity-related cancers was evident 
only in obese women (BMI ≥ 30 kg/m2). It is also worth noting that their reference 
group was 22.5–24.9 kg/m2, close to the range 22–26.5 kg/m2 used in this current 
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study. In the Million Women Study, women having a BMI ≥30 kg/m2 had more 
than double the risk of esophageal and endometrial cancer and around a 50% 
increased risk of kidney cancer; RR estimates ranged from 25%–37% increased 
risk for pancreatic cancer, post-menopausal breast cancer, and leukemia. In that 
study, weak adverse effects were seen for non-Hodgkin’s lymphoma and ovarian 
cancer and no association was observed between BMI and colorectal cancer or 
malignant melanoma. Since BMI has been linked with colon or colorectal cancer 
in a number of previous studies, it is possible that increasingly widespread colon 
cancer screening programs (with concurrent removal of colon polyps) may be 
responsible for the reduced risk of these cancers among the obese in more recent 
studies since obese individuals may be targeted for more intense screening and 
removal of pre-cancerous adenomas.  
One of the first meta-analyses to study the effect of a higher BMI and 
several individual cancers138 found that for every 5 kg/m2 increase in BMI in men, 
risks for esophageal adenocarcinoma, thyroid, colon, and renal cancers increased 
by 24 to 52%; weaker, effects were found for leukemia, non-Hodgkin’s 
lymphoma, malignant melanoma, multiple myeloma, and rectal cancers. In 
women, a 5-unit increase in BMI was linked with a 34 to 59% increased risk for 
esophageal adenocarcinoma, endometrial, gallbladder, and renal cancers, with 
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weaker, positive associations were seen for leukemia, non-Hodgkin’s lymphoma, 
pancreatic, colon, thyroid, and postmenopausal breast cancer. There was no 
association between increased BMI and ovarian cancer. A 2009 meta-analysis61 
concluded that overweight and obesity were associated with increased risks of 
endometrial, colorectal, kidney, and pancreatic cancers. In our analyses the 
cancers selected as obesity-related are consistent with the conclusions of these 
meta-analyses. 
Women with a BMI ≥ 30 kg/m2 in the obese category had higher rates and 
absolute risk of obesity-related cancer than women the higher WC or WHtR 
category. One consideration is possibly a higher volume of intra-abdominal fat 
(the hypothesized pro-inflammatory adipose compartment) needed in women to 
achieve the higher risk of WC. Another consideration is the inclusion of 
postmenopausal breast and endometrial cancer (respectively 40% and 12% of 
obesity-related cancers in women) in addition to other cancer types included for 
men. There are other contributing causes to female cancers or other cancers in 
women than what is reflected in intra-abdominal fat, imprecisely measured by 
WC. It is possible that BMI is a better marker of other risk factors (e.g. estrogen 
levels) that contribute to obesity-related cancers in women.  
One of the most often-studied cancers in relation to obesity is post-
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menopausal breast cancer. Some studies have found only mild associations with 
postmenopausal breast cancer; and this may be due to some not accounting for 
the potential modifying effect of hormone replacement therapy (HRT) across 
studies. Other studies have found that overweight and obese women who never 
used HRT had increased risk of postmenopausal breast cancer. 91;116;117;139   A 
limitation of the Framingham Offspring Study is the unavailability of HRT data.  
3.4.2 Contribution to Existing Literature on Waist Measures and Obesity-Related 
Cancer 
The results on the effect of WC and WHtR on obesity-related cancer in this 
analysis are similar to those seen in the recently published study by Moore et al114 
of 55–69 year olds in the Framingham Heart Study Cohort. In that analysis, men 
with a WC ≥ 94 cm (37 in.) had a 3.9 fold increased risk (compared with men 
with WC < 84 cm (33 in.)); women with WC ≥ 36 inches had a non-statistically 
significant 30% increased risk (compared with women with a WC < 81 cm (32 
in.)). However, the effects in the FOS are somewhat weaker that those found in 
the original cohort for comparable levels of WC and WHtR. This may be due in 
part to the differences in the distributions of WC and WHtR as a result of the 
emerging obesity epidemic. FOS subjects in the referent groups had more body 
fat than those in the original cohort. These higher rates of cancer in the referent 
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categories in FOS will lead to attenuation of the effects of obesity. 
In our analyses, we also explored the effects of WHtR on risk for obesity-
related cancer since differences in WC alone may not capture differences in 
abdominal fat when height is not considered. Schneider et al.148 observed that 
shorter individuals with the same WC had higher hemoglobin A1C levels, 
plasma glucose, triglyceride levels, and systolic blood pressure. Thus, we 
hypothesized that WHtR might be a better predictor of obesity-related cancer 
than WC. This was not the case when subjects were stratified by WHtR. 
Adjusting for HC strengthened the effect of WHtR and WC in men but 
appeared to attenuate the effects in women in these analyses. We attempted to 
control for HC since a larger HC has been used as a surrogate measure for a 
larger fat distribution around the gluteofemoral area. Gluteofemoral fat is 
thought to be protective against metabolic and cardiovascular risks,104 which are 
positively associated with some markers of inflammation that may also be 
involved in carcinogenesis. However, in FOS, HC was highly correlated with 
both WC and WHtR in women (r=0.79 and r=0.75, respectively), thus the HC-
adjusted effects may be falsely attenuated for women. Adjusting for HC in men 
did not attenuate the effect estimates, perhaps in part because HC was slightly 
less correlated between WC and WHtR categories (r=0.77 and 0.69 respectively) 
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in men than in women. However, it is HC is most likely an important 
confounder of waist size in men as a result of its stronger independent 
association with cancer risk in men than in women. 
The most common obesity-related cancer among women in our analysis 
was post-menopausal breast cancer. Other studies, such as the WHI and the 
Nurses’ Health Study have shown WC to be associated with an increased risk of 
post-menopausal breast cancer.70;116 In the Nurse’s Health study adjusting for 
BMI or HC did not appreciably alter this effect, as was the case in this current 
study in FOS. In the EPIC cohort, women whose WC was 35 inches or larger had 
about a 70% increased risk of colon cancer. 132  In all these studies the effect of a 
larger WC was modified by HRT use. 
One unique contribution of these results is the finding in men that a lower 
HC was a strong risk factor for obesity-related cancer. To my knowledge, no 
study has examined the independent effects of HC on obesity-related cancers as 
a whole. Body shape may indicate how fat is distributed in an individual, and 
the results of these analyses suggest that this could be as relevant as overall 
obesity in terms of obesity-related cancer risk.   
3.4.3 Mechanisms and Body Fat Measures  
The mechanism by which obesity promotes cancer risk may be linked 
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with the role of adipose tissue in the promotion of chronic, low-grade 
inflammation. Excess adiposity increases insulin and estrogen levels as well as 
other pro-inflammatory factors influencing immune function and creating a 
tumor-promoting microenvironment.14;45;71;135 Within the central body fat 
compartment, visceral fat (which constitutes about 15% of total fat mass)105;154 is 
generally considered to be more metabolically active and pro-inflammatory 
relative to abdominal subcutaneous fat, which is greater in volume.46  Both have 
been shown to be associated with cardiometabolic risk.46;100,161   In theory, 
anthropometric measures of central body fat such as WC or WHtR would be 
stronger predictors of obesity-related cancer risk than would BMI. However, WC 
and WHtR are imperfect measures of abdominal, and particularly visceral, 
adiposity.  
BMI, WHtR, and WC were all strongly associated with obesity-related 
cancer in men, especially after adjusting for HC. Since men more readily 
distribute excess body fat in the abdominal and visceral regions, this may lead to 
higher obesity-related cancer risks in men than in women. In women, a BMI ≥ 30 
kg/m2 especially when controlling for WC, was more strongly associated with 
obesity-related cancer than were waist-related measures. Another consideration 
is that within a given BMI range there could be wide variably of WC, particularly 
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in women.38;118 Therefore, controlling for WC in women may strengthen the 
independent effect of BMI.  
3.4.4 Strengths and Limitations 
The strengths of this study are its prospective design and the carefully-
collected and updated ascertainment of incident cancers. This is also one of few 
studies to assess the effects of BMI, WHtR, and WC adjusting for HC. Another 
important strength of this study is the standardized assessment of the 
anthropometric measures of body fat every four years compared with some 
studies which have relied on self-report. 
There are a number of limitations to this study as well. An important 
limitation is that there is no precise measurement of visceral adiposity. The use of 
WC as an indicator of central adiposity will likely introduce non-differential 
misclassification of the exposure, thereby attenuating the observed effects of 
visceral body fat on cancer risk. Another limitation of the study is its small 
number of obesity-related cancer cases, yielding limited power for these 
analyses. Finally, the study is lacking data on some potentially important 
confounders such as use of hormone replacement therapy.  
Another limitation is that only 22% of men had a BMI < 25 kg/m2 (in 
contrast to 48% in women), reducing the power necessary to observe an effect of 
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BMI using the conventional definitions of overweight and obesity. Another 
power limitation was especially in lean subjects with metabolic abnormalities. 
Further limitations include the one time measures of WC and HC, which could 
affect the precision of the RR estimates, and HRT use was not available to assess 
any potential effect modification.  
3.4.5 Conclusions 
Two methodological lessons emerged. First, the controlling for HC is 
likely to alter the effect of a body fat measure in men but not in women; and it 
could be a better adjustment in men than is BMI. Second,  awareness of the 
potential moderate risk in lower category body fat measures and should inform 
the referent group selection in future studies looking at the effects of any body 
fat measure and cancer risk. These also may be sex-specific.  
Cancer is a complex set of diseases, with a multiplicity of modifiable and 
non-modifiable factors contributing to its development. But incomplete 
understanding of the promotion of cancer does not necessarily prevent the 
conclusion that surrogate measures of excess body fat are predictors of obesity-
related cancers considered as a whole. There is an interpretative limitation of 
which body fat measure best predictor of obesity-related stem from the 
weaknesses of the body fat measures discussed above and uncertain nature of 
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biological mechanisms involved. Consistent evidence shows that excess body fat 
is associated with environment of chronic inflammation, including the potential 
of pro-inflammatory levels of circulating oncogenic insulin.105;135;142 However, the 
process of insulin resistance occurs in lean as well as in the obese. Another part 
of the dissertation has attempted to address whether there are independent or 
combined effects of overweight and metabolic dysfunction. 
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Chapter 4 
Modification of the Effect of Anthropometric Variables on Cancer Risk by 
Metabolic Abnormalities 
4.1 Introduction 
Obesity is a recognized public health problem. Overweight and obesity 
are frequently accompanied by metabolic syndrome, a cluster of metabolic 
abnormalities that are risk factors for cardiovascular disease and type 2 diabetes 
mellitus (T2DM).9;60 Overweight and obesity and T2DM are also each associated 
with increased risk for certain cancers.170    
Not all individuals who are overweight or obese develop metabolic 
dysfunction, a phenomenon that has been termed “metabolically healthy 
obesity” (MHO).133;155;164 MHO is not a fixed phenotype, and prevalence estimates 
of MHO depend on the criteria used.164  Those with MHO are generally 
considered to be those with a BMI ≥30 kg/m2 but who do not have 
cardiometabolic risk factors such as glucose dysregulation, insulin resistance, 
low HDL-C, elevated triglyceride (TG) levels, or high blood pressure. Thus, they 
are assumed to have a lower risk of cardiovascular disease and diabetes despite 
obesity.155  Compared with obese subjects who do have cardiometabolic risk 
factors, those with MHO may have less adipose tissue dysfunction and less 
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obesity-related inflammation, perhaps as a result of having more lower-body 
rather than upper-body obesity.23 In the previous chapter of this dissertation, I 
have shown that data from the Framingham Offspring Study support other 
studies showing that obesity is an important risk factor for a number of different 
cancers. However, whether those with MHO have a lower risk of developing 
cancer compared with overweight subjects who are not metabolically healthy is 
unknown. The hypothesis is that they do have a lower risk.  
In a previous publication by Moore et al.114, normal weight subjects who 
had abnormal random glucose had no higher risk of obesity-related cancer than 
those with normal glucose levels. However, that study did not have fasting 
glucose levels, thus allowing potential non-differential misclassification and a 
bias toward the null in studying the effects of glucose dysregulation and cancer 
risk. The Framingham Offspring Study has systematic measurements of fasting 
glucose. Therefore, I will use these data to address the questions of whether 
normal weight subjects with metabolic dysfunction (particularly impaired fasting 
glucose levels) will have a higher risk of obesity-related cancer.  
4.2 Methods  
4.2.1 Study Population 
Adults between ages 45–69 years in the Framingham Offspring Study 
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(n=3818) were included in these analyses. The Framingham Offspring Study is a 
second generation prospective cohort that includes offspring of subjects 
participating in the original Framingham Heart Study. The Offspring Study 
began in 1971 with the enrollment of 5,135 subjects,85  5124 of whom attended the 
first exam. Exams 1 through 8 were conducted during the following date ranges: 
1971–1975, 1979–1983,1983–1987,1987–1991,1991–1995,1995–1998, 1998–2001, and 
2005–2008. At each examination visit, occurring approximately every four years, 
data on the following variables were collected: anthropometric measures of body 
fat, urinalysis, blood chemistries, blood pressure, medical history, and lifestyle 
habits.  At each visit, subjects were asked to report any diseases or conditions 
that had occurred since their last visit.  
4.2.2 Exposure Variables 
Mean height from all measures prior to age 60 was used when calculating 
each visit-specific BMI. Height (inches) and weight (pounds) were measured at 
each visit using a standard beam balance.54  WC was measured starting at exam 4 
and used along with waist-to-height ratio as an indicator of central/abdominal 
adiposity. WC was measured once around the umbilicus with the subject 
standing. WHtR was calculated by dividing WC from each exam visit by 
subject’s average adult height. 
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Lipid levels at each exam were derived from blood specimens of subjects 
fasting at least 12 hours and the detailed methods have been described in 
previous studies.109;146  Plasma HDL-C concentrations were determined through a 
heparin-manganese chloride precipitation procedure measured using an AA2 
Auto Analyzer (Technicon Instruments Corporation, Tarrytown, NY)53 described 
in  the Lipid Research Clinics Program.1  The plasma HDL-C concentration was 
determined by subtracting the precipitating portions of LDL and VLDL. 
Triglycerides were measured through enzymatic methods previously 
described.108  HDL and triglyceride data were used starting at exam 3. A subject 
was classified as having normal HDL if HDL-C ≥40 (men), ≥50 mg/dl (women) 
and low HDL if HDL-C <40 (men), <50 mg/dL (women). A subject was classified 
as having dyslipidemia if they took lipid-lowering medication, had an HDL-C 
<40 (men), <50 mg/dL (women) or triglyceride level ≥150 mg/dL at their baseline 
exam.2   
IFG and T2DM were diagnosed using the standard Framingham 
Offspring Study protocols. Since fasting status was unknown at exams 1 and 2, 
IFG was defined as a glucose >125 mg/dl, and subjects were considered to have 
T2DM if they had a glucose ≥200 mg/dl or were taking diabetes medications (oral 
hypoglycemic medication or insulin). For subsequent exams, IFG was defined as 
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a fasting glucose level between 100 to 125 mg/dl (after fasting at least 10 hours), 
and subjects were considered to have T2DM if they had a fasting (≥10 hours) 
glucose of ≥126 mg/dl or were taking diabetes medications (oral hypoglycemic 
medication or insulin). Subjects were also considered to have T2DM if they 
reported a medical history of diabetes and had glucose from 126–199 mg/dl, even 
if fasting status was unknown. To further account for misclassification of 
diabetes at earlier exams due to absent data on fasting, subjects with a diagnosis 
of diabetes at exam 3 were considered to have had diabetes at exam 2 if their 
glucose level at that exam was 126–199 mg/dl and they had <7% weight gain 
between exams 2 and 3. For some analyses, those with IFG and T2DM were 
combined to indicate the presence of any glucose dysregulation.  
Blood pressure was measured once by a nurse and once by a Framingham 
physician on the left arm while the subject was seated.54 The mean of two 
measures for SBP and DSP were used to define HBP status according to modified 
JNC-7 criteria as follows: use of medication for hypertension; SBP ≥160 or DBP 
≥95; or SBP ≥140 or DBP ≥90 where SBP was ≥130 or DBP was ≥ 85 within the 
previous two exams. 
Finally, a variable reflecting the presence of “metabolic dysfunction” was 
created and defined as having at least two of the following individual metabolic 
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abnormalities: glucose dysregulation (IFG or T2DM), dyslipidemia, or HBP.  
4.2.3 Outcome Variables 
The primary outcome of interest is total obesity-related cancer incidence. 
Obesity-related cancers were selected based on previously-published studies and 
included the following: female reproductive (post-menopausal breast, uterine, 
cervical, endometrial, and ovarian), colon, rectal, stomach, liver, gallbladder, 
pancreas, kidney, thyroid, esophageal adenocarcinoma, leukemias, non-Hodgkin 
lymphoma and multiple myeloma.3;61;96;107;122;138;160;173 For colorectal cancer, tumors 
in the proximal colon, distal colon, and rectum were included. Proximal colon 
cancer includes cancer in the cecum, ascending colon, hepatic flexure, transverse 
colon, and splenic flexure. Distal colon cancer includes cancer in the descending 
and sigmoid colon. Appendiceal carcinomas were excluded. Female breast 
cancer excludes tumors in the skin of the breast. Cancer diagnosis date was taken 
from available pathology reports. Diagnoses were confirmed from pathology, 
laboratory, and clinical records.90 The cancer diagnosis date was taken from other 
reports when pathology reports were unavailable or when diagnosis occurred 
before the pathological test.102 All self-reported cancer was confirmed by outside 
medical and pathological records. Cancer cases were coded using the 
International Classification of Diseases for Oncology (ICD-O).  
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4.2.4 Potential Confounding Variables 
The following potential confounders were included in the multivariable 
models: age (years), sex, cigarettes per day, grams of alcohol per week, average 
adult height (inches), education (less than high school, high school, some college, 
or college graduate), and physical activity index. These potential confounders 
were previously described in chapter 3 of this dissertation. Additionally, the WC 
and WHtR models also controlled for hip circumference. In separate analyses, 
dietary variables described in chapter 2 were examined as potential confounders 
but not retained in the final models (since no confounding existed).  
4.2.5 Analysis 
Men and women ages 45–69 years were selected for inclusion when they 
first met the age requirement, had BMI and waist circumference variables (for 
these respective analyses), all metabolic variables of interest, and other covariates 
used in the analysis. For the BMI and the central adiposity (WC and WHtR) 
analyses there were 3818 and 3723 subjects, respectively.  
As delineated in chapter 3, WHtR and WC exposure category cutoff 
values were selected using sensitivity analyses. To assess whether the effect of 
body fat (BMI, WC, and WHtR) was modified by metabolic dysfunction, we 
cross-classified each dichotomous body fat measure with each metabolic 
  
93 
variables of interest. The final cutoff values for body fat were as follows:  BMI 
≥30 kg/m2 versus <30 kg/m2; WHtR ≥0.58 versus <0.58; and WC >34 (women), > 40 
(men) versus ≤34 (women), ≤40 (men). Prevalent metabolic abnormalities 
included individual risk factors and composite variables as follows: IFG (yes/no), 
low HDL-C (yes/no), high TG (yes/no), glucose dysregulation (IFG or 
T2DM/neither), dyslipidemia (low HDL, high TG, or lipid-lowering meds/no), 
HBP (yes/no), and metabolic dysfunction (2 or more versus 0–1 abnormalities). 
The TG/HDL ratio has been recently studied in comparison with other lipid 
markers as an indicator of metabolic and coronary heart disease risk;11;86;106;145 a 
level of 2.5 or higher for women and 3.0 or higher for men (versus <2.5, <3.0, 
respectively) has been used in these analyses as a marker of metabolic risk. 
The combined effects of body fat and metabolic dysfunction on risk of 
obesity-related cancer were assessed using Cox proportional hazards models, 
with time (years) to the development of first obesity-related cancer as the 
outcome. Person-years of follow-up time were calculated as time to the first of 
the following events: last exam, death, obesity-related cancer diagnosis, or loss to 
follow up. Cancer incidence per 1,000 person-years was calculated by dividing 
the number of obesity-related cancers by the total amount of person-time of 
follow up in a given exposure category. The validity of the proportional hazards 
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assumption was checked for all models. No violations were found. 
4.3 Results 
4.3.1  Effect of Metabolic Dysfunction on Obesity-Related Cancer Risk 
Overall, the strongest effect (HR=1.33; 95% CI: 1.00–1.77) of metabolic 
abnormalities on cancer risk was seen in subjects having 2 or more (versus fewer) 
metabolic abnormalities (Tables 4.1–4.3). For individual variables, subjects with a 
higher TG/HDL ratio (≥3.0 or higher and ≥2.5 or higher for women) had more 
than a 25% increased risk of obesity-related cancer (HR=1.26; 95% CI: 1.00–1.60). 
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Table 4.1. The effect metabolic indicators and dysfunction on the incidence of 
obesity-related cancer in men and women combined 
Metabolic Variable N PY Cases 1/1000 py HR1 (95% CI) 
All Subjects       
   No IFG-DM2 2697 42027 210 5.00 1.00 
   IFG-DM 1121 16039 89 5.55 1.11 (0.86, 1.43) 
   Nl HDL3 2377 36378 179 4.92 1.00 
   Low HDL 1441 21689 120 5.53 1.17 (0.92, 1.48) 
   Nl TG4 2681 41259 209 5.07 1.00 
   High TG 1137 16808 90 5.35 1.07 (0.83, 1.37) 
   No Dyslipidemia5 2023 31159 150 4.81 1.00 
   Dyslipidemia 1795 26907 149 5.54 1.19 (0.94, 1.50) 
   TG/HDL <3.0(m), <2.5(w) 2354 36244 173 4.77 1.00 
   TG/HDL ≥3.0(m), ≥2.5(w) 1464 21823 126 5.77 1.26 (1.00, 1.60) 
   Nl Blood Pressure6 2515 38183 181 4.74 1.00 
   HBP 1303 19883 118 5.93 1.09 (0.86, 1.40) 
   0–1 MetDys7      3150 48688 238 4.89 1.00 
   2+ MetDys 668 9379 61 6.50 1.33 (1.00, 1.77) 
1 Adjusted for all subjects adjusted for sex, age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m),<50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
 
 
 
 
 
 
  
  
96 
Table 4.2. The effect metabolic indicators and dysfunction on the incidence of 
obesity-related cancer in men 
Metabolic Variable N PY Cases 1/1000 py HR1 (95% CI) 
Men        
   No IFG-DM2 1129 17990 70 3.89 1.00 
   IFG -DM 687 9779 46 4.70 1.15 (0.79, 1.67) 
   Nl HDL3 1081 16733 69 4.12 1.00 
   Low HDL 735 11035 47 4.26 1.15 (0.79, 1.68) 
   Nl TG4 1128 17514 71 4.05 1.00 
   High TG 688 10254 45 4.39 1.05 (0.72, 1.53) 
   No Dyslipidemia5 856 13311 53 3.98 1.00 
   Dyslipidemia 960 14457 63 4.36 1.13 (0.78, 1.64) 
   TG/HDL<3.0  949 14767 55 3.72 1.00 
   TG/HDL≥3.0  867 13001 61 4.69 1.29 (0.89, 1.86) 
   Nl Blood Pressure6 1084 16814 62 3.69 1.00 
   HBP 732 10954 54 4.93 1.08 (0.74, 1.57) 
   0–1 MetDys7      1416 22238 86 3.87 1.00 
   2+ MetDys 400 5530 30 5.43 1.35 (0.89, 2.05) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m),<50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table 4.3. The effect metabolic indicators and dysfunction on the incidence of 
obesity-related cancer in women 
Metabolic Variable N PY Cases 
1/1000 
py HR1 (95% CI) 
Women        
   No IFG-DM2 1568 24038 140 5.82 1.00 
   IFG -DM 434 6260 43 6.87 1.10 (0.78, 1.55) 
   Nl HDL3 1296 19645 110 5.60 1.00 
   Low HDL 706 10654 73 6.85 1.18 (0.87, 1.60) 
   Nl TG4 1553 23745 138 5.81 1.00 
   High TG 449 6553 45 6.87 1.09 (0.77, 1.53) 
   No Dyslipidemia5 1167 17848 97 5.43 1.00 
   Dyslipidemia 835 12450 86 6.91 1.22 (0.91, 1.64) 
   TG/HDL <2.5  1405 21477 118 5.49 1.00 
   TG/HDL ≥2.5  597 8821 65 7.37 1.26 (0.92, 1.72) 
   Nl Blood Pressure6 1431 21369 119 5.57 1.00 
   HBP 571 8929 64 7.17 1.12 (0.81, 1.55) 
   0–1 MetDys7      1734 26449 152 5.75 1.00 
   2+ MetDys 268 3849 31 8.05 1.30 (0.88, 1.93) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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4.3.2  Combined Effect of BMI and Metabolic Abnormalities on Obesity-Related 
Cancer Risk   
Number of subjects, number of cases, person-years, and rates for all 
analyses combining a given body fat measure with each metabolic variable are 
shown in appendix tables A.10 to A.15.  Tables 4.4–4.6 show the combined effects 
of BMI and various metabolic abnormalities, including blood glucose level, HDL, 
TG, dyslipidemia, high blood pressure, and metabolic dysfunction (i.e., 2 or more 
abnormalities), on obesity-related cancer risk. Results for men (Table 4.5) indicate 
that a BMI ≥30 kg/m2 combined with having IFG or diabetes,  low HDL, high TG, 
dyslipidemia, HBP, or 2 or more attributes of metabolic variable was associated 
with at least a doubling of the risk of obesity-related cancer compared to men 
with BMI <30 kg/m2 without the corresponding metabolic abnormality. Obese 
men without metabolic dysfunction generally had a weaker, non-statistically 
significant increased risk of obesity-related cancers (see HC- adjusted models). 
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Table 4.4. Effect of obesity modified by metabolic indicators and dysfunction 
on the incidence of obesity-related cancer in men 
 
   
Adjusted Adj. plus WC Adj. plus HC 
Overweight Status/ 
Metabolic Indicator PY Cases 
I/1000 
py HR1 (95% CI) HR (95% CI) HR (95% CI) 
BMI/IFG-DM2           
BMI <30/No IFG-DM 14654 55 3.75 1.00 1.00 1.00 
BMI <30/IFG-DM 6604 24 3.63 0.91 (0.56, 1.48) 0.92 (0.57, 1.50) 0.92 (0.57, 1.48) 
BMI ≥30/No IFG-DM 3335 15 4.50 1.36 (0.77, 2.43) 1.56 (0.79, 3.06) 1.75 (0.90, 3.42) 
BMI ≥30/IFG-DM 3174 22 6.93 1.90 (1.16, 3.12) 2.22 (1.17, 4.21) 2.49 (1.36, 4.59) 
BMI/HDL-C3       
BMI <30/Nl HDL 13699 53 3.87 1.00 1.00 1.00 
BMI <30/Low HDL 7560 26 3.44 0.97 (0.60, 1.56) 0.99 (0.61, 1.60) 1.00 (0.62, 1.61) 
BMI ≥30/Nl HDL                      3034 16 5.27 1.48 (0.84, 2.61) 1.69 (0.85, 3.35) 1.93 (0.99, 3.76) 
BMI ≥30/Low HDL                    3475 21 6.04 1.85 (1.11, 3.08) 2.11 (1.12, 4.00) 2.41 (1.29, 4.48) 
BMI/TG4       
BMI <30/Nl TG 14216 55 3.87 1.00 1.00 1.00 
BMI <30/High TG 7043 24 3.41 0.82 (0.51, 1.33) 0.84 (0.52, 1.36) 0.84 (0.52, 1.36) 
BMI  ≥30/Nl TG                    3298 16 4.85 1.32 (0.75, 2.32) 1.49 (0.75, 2.95) 1.71 (0.88, 3.32) 
BMI  ≥30/High TG                 3212 21 6.54 1.86 (1.12, 3.09) 2.10 (1.11, 3.98) 2.40 (1.30, 4.43) 
BMI/Dyslipidema5       
BMI <30/No dyslip. 10970 44 4.01 1.00 1.00 1.00 
BMI <30/dyslip. 10288 35 3.40 0.85 (0.55, 1.33) 0.87 (0.55, 1.36) 0.87 (0.56, 1.36) 
BMI  ≥30/No dyslip. 2341 9 3.84 1.00 (0.48, 2.05) 1.12 (0.49, 2.57) 1.29 (0.57, 2.89) 
BMI  ≥30/dyslip. 4169 28 6.72 1.91 (1.19, 3.08) 2.14 (1.15, 3.97) 2.47 (1.36, 4.47) 
BMI/HBP6       
BMI <30/No HBP 13939 48 3.44 1.00 1.00 1.00 
BMI <30/HBP 7320 31 4.23 0.92 (0.58, 1.47) 0.94 (0.59, 1.50) 0.93 (0.58, 1.48) 
BMI  ≥30/No HBP                 2876 14 4.87 1.47 (0.81, 2.68) 1.67 (0.83, 3.38) 1.87 (0.95, 3.69) 
BMI  ≥30/HBP            3634 23 6.33 1.75 (1.06, 2.89) 2.02 (1.05, 3.86) 2.33 (1.25, 4.36) 
BMI/MetDys7       
BMI <30/0,1 MetDys 14278 54 3.78 1.00 1.00 1.00 
BMI <30/2,3 MetDys 6981 25 3.58 0.80 (0.49, 1.29) 0.81 (0.50, 1.32) 0.81 (0.50, 1.31) 
BMI ≥30/0,1 MetDys 2710 11 4.06 1.13 (0.59, 2.18) 1.28 (0.60, 2.71) 1.45 (0.70, 3.03) 
BMI ≥30/2,3 MetDys 3799 26 6.84 1.86 (1.16, 2.98) 2.12 (1.14, 3.94) 2.46 (1.36, 4.46) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
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4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m),<50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
 
Non-obese men, regardless of the presence of metabolic dysfunction had 
no increased risk. In additional models, we also controlled for WC and HC. HC 
in particular strengthened the estimates effects on cancer risk. Obese men with 
metabolic abnormalities had 2–2.5 times the risk of obesity-related cancer. These 
results suggest that the effect of obesity seems to be modified by the presence of 
metabolic abnormalities although the confidence intervals are somewhat wide 
around these combined estimates. 
The same analysis of effect modification was conducted in men using a 
cut-point of BMI ≥28 kg/m2 (see Appendix Table A.8)). In these analyses, the 
jointly exposed also had the strongest risk of obesity-related cancer.  
Table 4.6 shows the effects of overweight (BMI ≥25 kg/m2) with and 
without metabolic abnormalities on risks of obesity-related cancer in women. 
Overall, overweight women had a moderately increased risk of these cancers of 
interest, and there was no consistent evidence of modification of these effects by 
metabolic abnormalities (either individually or using the composite measure of 
metabolic dysfunction). In addition, women who were not overweight (BMI <25 
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kg/m2) but who had 2 or more metabolic abnormalities had a 91% risk of obesity-
related cancers. After controlling separately for WC and HC, we found that the 
addition of WC to the models led to slight strengthening of many of the HR 
estimates while the addition of HC slightly attenuated the estimates. 
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Table 4.5. Effect of obesity modified by metabolic indicators and dysfunction 
on the incidence of obesity-related cancer in women 
    
Adjusted Adj. plus WC Adj. plus HC 
Overweight Status/ 
Metabolic indicator PY Cases 
I/1000 
py HR1 (95% CI) HR  (95% CI) HR (95% CI) 
BMI/IFG-DM2           
BMI <25 /No IFG-DM 13341 63 4.72 1.00 1.00 1.00 
BMI <25 / IFG-DM 1555 9 5.79 1.14 (0.56, 2.30) 1.14 (0.57, 2.31) 1.14 (0.56, 2.29) 
BMI ≥25 /No IFG -DM 10697 77 7.20 1.51 (1.08, 2.12) 1.53 (1.02, 2.30) 1.44 (0.96, 2.15) 
BMI ≥25 /IFG-DM 4705 34 7.23 1.43 (0.93,2.19) 1.46 (0.85, 2.49) 1.34 (0.80, 2.23) 
BMI/HDL-C3       
BMI <25 /Nl HDL 11578 55 4.75 1.00 1.00 1.00 
BMI <25 /Low HDL   3318 17 5.12 1.05 (061, 1.82) 1.06 (0.61, 1.83) 1.05 (0.61, 1.82) 
BMI ≥25 /Nl HDL    8066 55 6.82 1.42 (0.98, 2.07) 1.47 (0.95, 2.26) 1.37 (0.89, 2.11) 
BMI ≥25 /Low HDL   7336 56 7.63 1.55 (1.05, 2.28) 1.62 (0.99, 2.64) 1.48 (0.93, 2.35) 
BMI/TG4       
BMI <25 /Nl TG 13314 60 4.51 1.00 1.00 1.00 
BMI <25 /High TG   1582 12 7.59 1.57 (0.84, 2.93) 1.57 (0.84, 2.94) 1.58 (0.85, 2.94) 
BMI ≥ 25 /Nl TG    10431 78 7.48 1.66 (1.18, 2.32) 1.66 (1.11, 2.49) 1.56 (1.04, 2.35) 
BMI ≥ 25 /High TG 4972 33 6.64 1.36 (0.88, 2.10) 1.36 (0.80, 2.33) 1.27 (0.77, 2.11) 
BMI/Dyslipidemia5       
BMI <25 /No Dyslip. 10924 49 4.49 1.00 1.00 1.00 
BMI <25 /Dyslip. 3972 23 5.79 1.25 (0.76, 2.06) 1.26 (0.76, 2.07) 1.25 (0.76, 2.06) 
BMI ≥25 /No Dyslip. 6924 48 6.93 1.54 (1.03, 2.29) 1.58 (1.01, 2.47) 1.47 (0.94, 2.31) 
BMI ≥25 /Dyslip. 8478 63 7.43 1.59 (1.08, 2.33) 1.66 (1.01, 2.71) 1.51 (0.95, 2.39) 
BMI/HBP6       
BMI <25 /No HBP 11985 50 4.17 1.00 1.00 1.00 
BMI <25 /HBP 2911 22 7.56 1.57 (0.94, 2.62) 1.57 (0.94, 2.62) 1.56 (0.94, 2.61) 
BMI ≥25 /No HBP   9384 69 7.35 1.76 (1.22, 2.54) 1.77 (1.16, 2.72) 1.66 (1.08, 2.55) 
BMI ≥25 /HBP   6018 42 6.98 1.48 (0.97, 2.27) 1.49 (0.89, 2.51) 1.38 (0.83, 2.29) 
BMI/MetDys7       
BMI <25 /0,1 MetDys 13246 57 4.30 1.00 1.00 1.00 
BMI <25 /2,3 MetDys 1650 15 9.09 1.91 (1.07, 3.39) 1.92 (1.08, 3.42) 1.90 (1.07, 3.38) 
BMI ≥25 /0,1 MetDys 9771 68 6.96 1.62 (1.14, 2.31) 1.68 (1.11, 2.54) 1.56 (1.03, 2.35) 
BMI ≥25 /2,3 MetDys  5631 43 7.64 1.64 (1.09, 2.48) 1.74 (1.03, 2.94) 1.55 (0.94, 2.56) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
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3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
 
The same analyses were conducted in women using a cut-point of BMI ≥ 
30 kg/m2 (see Appendix Table A.9). Furthermore, increased relative risks were 
only seen in the obese with metabolic abnormalities, of which the strongest 
effects observed in obese women with metabolic dysfunction, dyslipidemia, and 
low HDL. In contrast with the findings in women with BMI <25 kg/m2 and at 
least 2 attributes of metabolic dysfunction, women with BMI <30 kg/m2 and at 
least 2 attributes of metabolic dysfunction showed no increased risk as a result of 
the higher cancer rates found in women whose BMI was between 25 and 30 
kg/m2.  
To increase the power for the analyses in Tables 4.4 and 4.5, we combined 
men and women (adjusting for sex in the multivariable models) in Table 4.6. 
These results are generally more stable and suggest a modest amount of effect 
modification of the BMI effects, particularly by HDL and dyslipidemia. 
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Table 4.6. Effect of BMI modified by metabolic indicators and dysfunction on 
the incidence of obesity-related cancers in men and women combined 
 Adjusted Adj. plus WC Adj. plus HC 
Obese (m), Overweight (w) 
Status/ Metabolic Indicator HR1 (95% CI) HR (95% CI) HR (95% CI) 
BMI/IFG or T2DM2    
BMI <30(m), <25(w)/No IFG-DM 1.00 1.00 1.00 
BMI <30(m), <25(w)/ IFG-DM 0.97 (0.65, 1.44) 0.98 (0.66, 1.45) 0.97 (0.66, 1.44) 
BMI ≥ 30(m), ≥25(w)/No IFG-DM 1.47 (1.11, 1.95) 1.55 (1.10, 2.17) 1.50 (1.08, 2.10) 
BMI ≥ 30(m), ≥25(w)/IFG-DM 1.55 (1.12, 2.14) 1.65 (1.10, 2.48) 1.58 (1.07, 2.33) 
BMI/HDL-C3    
BMI <30(m), <25(w)/Nl HDL 1.00 1.00 1.00 
BMI <30(m), <25(w)/ Low HDL 1.00 (0.70, 1.43) 1.01 (0.70, 1.44) 1.00 (0.70, 1.43) 
BMI ≥30(m), ≥25(w)/Nl HDL  1.41 (1.04, 1.92) 1.50 (1.05, 2.14) 1.45 (1.01, 2.06) 
BMI ≥30(m), ≥25(w)/Low HDL     1.61 (1.19, 2.17) 1.73 (1.18, 2.54) 1.65 (1.14, 2.38) 
BMI/TG4    
BMI <30(m), <25(w)/Nl TG 1.00 1.00 1.00 
BMI <30(m), <25(w)/High TG 1.02 (0.69, 1.49) 1.02 (0.70, 1.50) 1.02 (0.69, 1.49) 
BMI ≥30(m), ≥25(w)/Nl TG    1.55 (1.17, 2.05) 1.61 (1.15, 2.26) 1.57 (1.12, 2.21) 
BMI ≥30(m), ≥25(w)/High TG  1.46 (1.05, 2.03) 1.54 (1.03, 2.32) 1.49 (1.01, 2.19) 
BMI/Dyslipidemia5    
BMI <30(m), <25(w)/No dyslip. 1.00 1.00 1.00 
BMI <30(m), <25(w)/Dyslip. 1.00 (0.72, 1.40) 1.02 (0.73, 1.42) 1.01 (0.72, 1.40) 
BMI ≥30(m), ≥25(w)/No dyslip. 1.36 (0.97, 1.91) 1.45 (0.99, 2.12) 1.40 (0.96, 2.04) 
BMI ≥30(m), ≥25(w)/Dyslip. 1.62 (1.21, 2.18) 1.76 (1.20, 2.59) 1.67 (1.16, 2.39) 
BMI/HBP6    
BMI <30(m), <25(w)/No HBP 1.00 1.00 1.00 
BMI <30(m), <25(w)/HBP 1.17 (0.83, 1.66) 1.18 (0.83, 1.67) 1.17 (0.83, 1.66) 
BMI ≥ 30(m), ≥25(w)/No HBP  1.67 (1.24, 2.26) 1.75 (1.22, 2.49) 1.69 (1.19, 2.41) 
BMI ≥ 30(m), ≥25(w)/HBP  1.49 (1.08, 2.06) 1.57 (1.05, 2.35) 1.51 (1.03, 2.23) 
BMI/MetDys7    
BMI <30(m), <25(w)/0,1 MetDys 1.00 1.00 1.00 
BMI <30(m), <25(w)/2,3 MetDys 1.11 (0.76, 1.61) 1.13 (0.77, 1.64) 1.11 (0.77, 1.62) 
BMI ≥ 30(m), ≥25(w)/0,1 MetDys 1.47 (1.09, 1.97) 1.56 (1.10, 2.21) 1.51 (1.07, 2.12) 
BMI ≥ 30(m), ≥25(w)/2,3 MetDys 1.64 (1.20, 2.23) 1.79 (1.20, 2.66) 1.69 (1.16, 2.47) 
1 Adjusted for all subjects adjusted for sex, age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
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4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
 
4.3.3 Combined Effect of Central Body Fat Measures and Metabolic 
Abnormalities on Obesity-Related Cancer Risk 
Tables 4.7–4.9 show the combined effects of WHtR and metabolic 
abnormalities (i.e., glucose dysregulation, dyslipidemia, HBP, and multiple 
metabolic factors) on obesity-related cancer risk. For both men and women the 
adverse effects of a high WHtR (≥0.58) were strengthened by the presence of IFG 
or diabetes. The HRs for the effects of 2 or more metabolic abnormalities are not 
different from that for IFG/diabetes alone as a predictor of obesity-related cancer 
risk. As with the earlier BMI analyses, when WHtR is adjusted for HC in men the 
HR estimates are strengthened, while the effects are attenuated in women (which 
could be due to greater collinearity in women). There is evidence of interaction of 
WHtR and IFG/diabetes in both men and women. 
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Table 4.7.  Effect of WHtR modified by metabolic indicators and dysfunction 
on the incidence of obesity-related cancer in men and women combined 
     Adjusted Adj. plus HC 
WHtR/Metabolic Indicator N PY Cases 
I/1000 
py HR1 (95% CI) HR (95% CI) 
WHtR /IGF or T2DM2          
   WHtR <0.58 / No IFG-DM 1914 26477 133 5.02 1.00 1.00 
   WHtR <0.58 / IFG-DM 686 9050 40 4.42 0.89 (0.62, 1.27) 0.88 (0.62, 1.27) 
   WHtR ≥0.58 / No IFG-DM 570 7487 42 5.61 1.21 (0.85, 1.73) 1.20 (0.79, 1.82) 
   WHtR ≥0.58 / IFG-DM 553 6831 52 7.61 1.53 (1.10, 2.14) 1.51 (1.00, 2.27) 
WHtR /HDL3       
   WHtR <0.58 / Nl HDL 1701 23142 126 5.44 1.00 1.00 
   WHtR <0.58 / Low HDL 899 12385 47 3.79 0.69 (0.49, 0.97) 0.69 (0.49, 0.97) 
   WHtR ≥0.58 / Nl HDL 470 5851 35 5.98 1.16 (0.79, 1.70) 1.12 (0.72, 1.75) 
   WHtR ≥0.58 / Low HDL 653 8466 59 6.97 1.32 (0.96, 1.82) 1.28 (0.86, 1.90) 
WHtR /TG4       
   WHtR <0.58 / Nl TG 1952 26927 133 4.94 1.00 1.00 
   WHtR <0.58 / High TG 648 8600 40 4.65 0.94 (0.65, 1.34) 0.93 (0.65, 1.34) 
   WHtR ≥0.58 / Nl TG 560 7121 50 7.02 1.51 (1.08, 2.11) 1.49 (0.99, 2.25) 
   WHtR ≥0.58 / High TG 563 7197 44 6.11 1.27 (0.90, 1.81) 1.26 (0.83, 1.91) 
WHtR /Dysliipidemia5       
   WHtR <0.58 / No Dyslip. 1489 20375 106 5.20 1.00 1.00 
   WHtR <0.58 / Dyslip. 1111 15151 67 4.42 0.85 (0.62, 1.15) 0.84 (0.62, 1.15) 
   WHtR ≥0.58 / No Dyslip. 353 4431 28 6.32 1.27 (0.83, 1.94) 1.23 (0.76, 2.01) 
   WHtR ≥0.58 / Dyslip. 770 9887 66 6.68 1.34 (0.97, 1.84) 1.30 (0.88, 1.93) 
WHtR /HBP6       
   WHtR <0.58 / Nl HBP  1782 24137 110 4.56 1.00 1.00 
   WHtR <0.58 / High HBP 818 11390 63 5.53 1.00 (0.72, 1.38) 1.00 (0.72, 1.38) 
   WHtR ≥0.58 / Nl HBP 498 6329 40 6.32 1.49 (1.03, 2.15) 1.46 (0.95, 2.24) 
   WHtR ≥0.58 / High HBP 625 7988 54 6.76 1.36 (0.97, 1.93) 1.34 (0.88, 2.05) 
WHtR /MetDys7       
   WHtR <0.58 /0,1 MetDys 1872 25704 123 4.79 1.00 1.00 
   WHtR <0.58 /2+ MetDys 728 9823 50 5.09 0.97 (0.69, 1.37) 0.97 (0.69, 1.37) 
   WHtR ≥0.58 /0,1 MetDys 461 6007 33 5.49 1.24 (0.84, 1.83) 1.22 (0.78, 1.92) 
   WHtR ≥0.58 /2+ MetDys 662 8311 61 7.34 1.52 (1.10, 2.10) 1.50 (1.00, 2.24) 
1 Adjusted for all subjects adjusted for sex, age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
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3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table 4.8. Effect of WHtR modified by metabolic indicators and dysfunction 
on the incidence of obesity-related cancer in men 
 Adjusted Adj. plus HC 
WHtR/Metabolic Indicator HR1 (95% CI) HR (95% CI) 
WHtR/IGF or T2DM2     
     WHtR <0.58/ No IFG-DM 1.00 1.00 
     WHtR <0.58/ IFG-DM 0.81 (0.47, 1.41) 0.82 (0.47, 1.42) 
     WHtR ≥0.58/ No IFG-DM 1.25 (0.73, 2.14) 1.43 (0.76, 2.69) 
     WHtR ≥0.58/ IFG-DM 1.57 (0.95, 2.60) 1.82 (0.98, 3.39) 
WHtR/HDL3   
     WHtR <0.58/ Nl HDL 1.00 1.00 
     WHtR <0.58/ Low HDL 0.62 (0.35, 1.11) 0.63 (0.35, 1.13) 
     WHtR ≥0.58/ Nl HDL 1.21 (0.71, 2.07) 1.37 (0.72, 2.58) 
     WHtR ≥0.58/ Low HDL 1.37 (0.83, 2.26) 1.56 (0.84, 2.89) 
WHtR/ TG4   
     WHtR <0.58/ Nl TG 1.00 1.00 
     WHtR <0.58/ High TG 0.71 (0.39, 1.30) 0.71 (0.39, 1.30) 
     WHtR ≥0.58/ Nl TG 1.40 (0.84, 2.34) 1.60 (0.86, 2.97) 
     WHtR ≥0.58/ High TG 1.35 (0.81, 2.25) 1.55 (0.84, 2.86) 
WHtR/ Dyslipidemia5   
     WHtR <0.58/ No Dyslip. 1.00 1.00 
     WHtR <0.58/ Dyslip. 0.72 (0.42, 1.22) 0.72 (0.42, 1.23) 
     WHtR ≥0.58/ No Dyslip. 1.16 (0.62, 2.15) 1.32 (0.65, 2.68) 
     WHtR ≥0.58/ Dyslip. 1.38 (0.84, 2.27) 1.58 (0.86, 2.90) 
WHtR/ HBP6   
     WHtR <0.58/ Nl HBP  1.00 1.00 
     WHtR <0.58/ High HBP 1.06 (0.62, 1.82) 1.07 (0.62, 1.85) 
     WHtR ≥0.58/ Nl HBP 1.87 (1.06, 3.32) 2.12 (1.09, 4.11) 
     WHtR ≥0.58/ High HBP 1.39 (0.81, 2.38) 1.59 (0.82, 3.09) 
WHtR/ MetDys7   
     WHtR <0.58/0,1 MetDys 1.00 1.00 
     WHtR <0.58/2+ MetDys 0.97 (0.57, 1.67) 0.98 (0.57, 1.69) 
     WHtR ≥0.58/0,1 MetDys 1.46 (0.82, 2.60) 1.66 (0.85, 3.24) 
     WHtR ≥0.58/2+ MetDys 1.54 (0.93, 2.55) 1.78 (0.95, 3.32) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
  
109 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table 4.9. Effect of WHtR modified by metabolic indicators and dysfunction 
on the incidence of obesity-related cancer in women 
 Adjusted Adj. plus HC 
WHtR/Metabolic Indicator HR1 (95% CI) HR (95% CI) 
WHtR/IGF or T2DM2     
     WHtR <0.58/ No IFG-DM 1.00 1.00 
     WHtR <0.58/ IFG-DM 0.99 (0.61, 1.59) 0.98 (0.61, 1.58) 
     WHtR ≥0.58/ No IFG-DM 1.24 (0.77, 2.00) 1.13 (0.64, 2.00) 
     WHtR ≥0.58/ IFG-DM 1.53 (0.97, 2.41) 1.39 (0.78, 2.46) 
WHtR/HDL3   
     WHtR <0.58/ Nl HDL 1.00 1.00 
     WHtR <0.58/ Low HDL 0.74 (0.49, 1.12) 0.73 (0.48, 1.11) 
     WHtR ≥0.58/ Nl HDL 1.11 (0.63, 1.96) 0.98 (0.51, 1.90) 
     WHtR ≥0.58/ Low HDL 1.33 (0.87, 2.04) 1.18 (0.69, 2.03) 
WHtR/ TG4   
     WHtR <0.58/ Nl TG 1.00 1.00 
     WHtR <0.58/ High TG 1.15 (0.74, 1.80) 1.14 (0.73, 1.78) 
     WHtR ≥0.58/ Nl TG 1.60 (1.03, 2.49) 1.47 (0.84, 2.60) 
     WHtR ≥0.58/ High TG 1.24 (0.75, 2.05) 1.15 (0.64, 2.08) 
WHtR/ Dyslipidemia5   
     WHtR <0.58/ No Dyslip. 1.00 1.00 
     WHtR <0.58/ Dyslip. 0.94 (0.64, 1.37) 0.92 (0.63, 1.35) 
     WHtR ≥0.58/ No Dyslip. 1.39 (0.77, 2.51) 1.24 (0.62, 2.48) 
     WHtR ≥0.58/ Dyslip. 1.33 (0.87, 2.04) 1.19 (0.69, 2.06) 
WHtR/ HBP6   
     WHtR <0.58/ Nl HBP  1.00 1.00 
     WHtR <0.58/ High HBP 0.99 (0.66, 1.49) 0.98 (0.65, 1.48) 
     WHtR ≥0.58/ Nl HBP 1.32 (0.80, 2.18) 1.21 (0.67, 2.18) 
     WHtR ≥0.58/ High HBP 1.43 (0.90, 2.26) 1.28 (0.72, 2.31) 
WHtR/ MetDys7   
     WHtR <0.58/0,1 MetDys 1.00 1.00 
     WHtR <0.58/2+ MetDys 1.01 (0.65, 1.57) 0.99 (0.64, 1.55) 
     WHtR ≥0.58/0,1 MetDys 1.12 (0.65, 1.95) 1.03 (0.54, 1.94) 
     WHtR ≥0.58/2+ MetDys 1.57 (1.02, 2.42) 1.43 (0.82, 2.49) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
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4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m),<50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
 
The analyses from Tables 4.7–4.9 are repeating in Tables 4.10–4.12, using 
WC in place of WHtR. When adjusting for HC, men with WC >40 had more than 
double the risk of obesity-related cancer regardless of the prevalence of 
metabolic anomalies. Women with WC >34 and IFG/diabetes had a marginally 
significant 46% increased risk of obesity-related cancer. The effect of WC appears 
to be modified by prevalent IFG/diabetes or metabolic dysfunction in men and 
women, but the interaction effect is most evident in women who also have 
IFG/diabetes or at least two attributes of metabolic dysfunction. 
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Table 4.10. Effect of WC modified by metabolic indicators and dysfunction on 
the incidence of obesity-related cancer in men and women combined 
 Adjusted Adj. plus HC Adj. plus BMI 
WC/Metabolic Indicator HR1 (95% CI) HR (95% CI) HR (95% CI) 
WC/IGF  or T2DM2       
   WC ≤40(m), 34(w))/ No IFG-DM 1.00 1.00 1.00 
   WC ≤40(m), 34(w))/ IFG-DM 0.80 (0.54, 1.19) 0.80 (0.54, 1.20) 0.80 (0.54, 1.20) 
   WC > 40 (m), 34(w)/ No IFG-DM 1.28 (0.93, 1.76) 1.33 (0.91, 1.95) 1.30 (0.88, 1.92) 
   WC > 40 (m), 34 (w)/ IFG-DM 1.58 (1.15, 2.17) 1.65 (1.12, 2.43) 1.61 (1.07, 2.43) 
WC/HDL-C3 
      WC ≤ 40(m), 34(w)/ Nl HDL 1.00 1.00 1.00 
   WC ≤ 40(m), 34(w)/Low  HDL 0.74 (0.51, 1.07) 0.74 (0.52, 1.07) 0.74 (0.51, 1.07) 
   WC > 40(m), 34(w)/ Nl HDL 1.44 (1.03, 2.01) 1.49 (1.00, 2.21) 1.43 (0.96, 2.15) 
   WC > 40(m), 34(w)/ Low HDL 1.30 (0.95, 1.78) 1.34 (0.92, 1.97) 1.29 (0.86, 1.94) 
WC/ TG4 
      WC ≤ 40(m), 34(w)/ Nl TG  1.00 1.00 1.00 
   WC ≤ 40(m), 34(w)/ High TG 0.80 (0.53, 1.20) 0.80 (0.54, 1.21) 0.80 (0.53, 1.20) 
   WC > 40(m), 34(w)/ Nl TG 1.47 (1.08, 2.00) 1.52 (1.04, 2.22) 1.47 (0.99, 2.17) 
   WC > 40(m), 34(w)/ High TG 1.37 (0.99, 1.90) 1.42 (0.97, 2.09) 1.37 (0.91, 2.06) 
WC/ Dyslipidemia5 
      WC ≤ 40(m), 34(w)/ No Dyslip. 1.00 1.00 1.00 
   WC ≤ 40(m), 34(w)/ Dyslip. 0.82 (0.58, 1.15) 0.82 (0.59, 1.15) 0.82 (0.58, 1.15) 
   WC > 40(m), 34(w)/ No Dyslip. 1.40 (0.96, 2.04) 1.45 (0.94, 2.25) 1.40 (0.90, 2.18) 
   WC > 40(m), 34(w)/ Dyslip. 1.37 (1.01, 1.86) 1.41 (0.97, 2.05) 1.36 (0.91, 2.03) 
WC/ HBP6 
      WC ≤ 40(m), 34(w)/ Nl HBP  1.00 1.00 1.00 
   WC ≤ 40(m), 34(w)/ High HBP 1.01 (0.72, 1.43) 1.01 (0.72, 1.43) 1.01 (0.71, 1.43) 
   WC > 40(m), 34(w)/ Nl HBP 1.61 (1.15, 2.25) 1.66 (1.12, 2.46) 1.61 (1.08, 2.40) 
   WC > 40(m), 34(w)/ High HBP 1.41 (1.02,1.97) 1.47 (0.98,2.20) 1.42 (0.92, 2.18) 
WC/ MetDys7 
      WC ≤ 40(m), 34(w)/0,1 MetDys 1.00 1.00 1.00 
   WC ≤ 40(m), 34(w)/2+ MetDys 0.91 (0.63, 1.32) 0.92 (0.63, 1.33) 0.92 (0.63, 1.33) 
   WC > 40(m), 34(w)/0,1 MetDys  1.33 (0.94, 1.87) 1.38 (0.93, 2.06) 1.35 (0.90, 2.03) 
   WC > 40(m),34(w)/2+ MetDys  1.56 (1.14, 2.12) 1.63 (1.11, 2.38) 1.59 (1.05, 2.39) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
  
113 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table 4.11. Effect of WC modified by metabolic indicators and dysfunction on 
the incidence of obesity-related cancer in men 
 Adjusted Adj. plus BMI Adj. plus HC 
WC/Metabolic Indicator HR1 (95% CI) HR (95% CI) HR (95% CI) 
WC/IGF -T2DM2       
   WC ≤40/ No IFG-DM 1.00 1.00 1.00 
   WC ≤40/ IFG-DM 0.84 (0.48, 1.47) 0.85 (0.48, 1.48) 0.84 (0.48, 1.47) 
   WC > 40 / No IFG-DM 1.72 (1.00, 2.94) 2.13 (1.11, 4.08) 2.30 (1.22, 4.31) 
   WC > 40/ IFG-DM 1.86 (1.12, 3.08) 2.37 (1.24, 4.54) 2.57 (1.38, 4.78) 
WC/HDL-C3    
   WC ≤ 40/ Nl HDL 1.00 1.00 1.00 
   WC ≤ 40/Low  HDL 0.73 (0.42, 1.29) 0.75 (0.42, 1.33) 0.75 (0.42, 1.32) 
   WC > 40/ Nl HDL 1.81 (1.08, 3.04) 2.21 (1.16, 4.20) 2.44 (1.30, 4.56) 
   WC > 40/ Low HDL 1.62 (0.96, 2.71) 2.02 (1.04, 3.96) 2.20 (1.17, 4.13) 
WC/ TG4    
   WC ≤ 40/ Nl TG  1.00 1.00 1.00 
   WC ≤ 40/ High TG 0.62 (0.33, 1.15) 0.63 (0.34, 1.18) 0.63 (0.34, 1.17) 
   WC > 40/ Nl TG 1.66 (1.00, 2.77) 2.04 (1.08, 3.86) 2.25 (1.21, 4.18) 
   WC > 40/ High TG 1.67 (1.01, 2.76) 2.08 (1.09, 3.97) 2.25 (1.23, 4.14) 
WC/ Dyslipidemia5    
   WC ≤ 40/ No Dyslip. 1.00 1.00 1.00 
   WC ≤ 40/ Dyslip. 0.70 (0.41, 1.20) 0.72 (0.42, 1.24) 0.71 (0.42, 1.22) 
   WC > 40/ No Dyslip. 1.50 (0.82, 2.74) 1.84 (0.90, 3.78) 2.02 (1.00, 4.07) 
   WC > 40/ Dyslip. 1.69 (1.03, 2.77) 2.13 (1.11, 4.07) 2.30 (1.25, 4.23) 
WC/ HBP6    
   WC ≤ 40/ Nl HBP  1.00 1.00 1.00 
   WC ≤ 40/ High HBP 0.99 (0.58, 1.71) 1.04 (0.60, 1.79) 1.03 (0.60, 1.77) 
   WC > 40/ Nl HBP 2.30 (1.30, 4.08) 2.84 (1.42, 5.66) 3.04 (1.57, 5.89) 
   WC > 40/ High HBP 1.69 (0.99, 2.88) 2.15 (1.07, 4.32) 2.33 (1.21, 4.51) 
WC/ MetDys7    
   WC ≤ 40/0,1 MetDys 1.00 1.00 1.00 
   WC ≤ 40/2+ MetDys 0.88 (0.51, 1.52) 0.91 (0.53, 1.58) 0.90 (0.52, 1.55) 
   WC > 40/0,1 MetDys  1.73 (0.97, 3.08) 2.15 (1.08, 4.29) 2.32 (1.19, 4.52) 
   WC > 40/2+ MetDys  1.86 (1.13, 3.07) 2.40 (1.24, 4.65) 2.58 (1.39, 4.80) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
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4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table 4.12. Effect of WC modified by metabolic indicators and dysfunction on 
the incidence of obesity-related cancer in women 
 Adjusted Adj. plus HC Adj. plus BMI 
WC/Metabolic Indicator HR1(95% CI) HR (95% CI) HR (95% CI) 
WC/IGF -T2DM2       
   WC ≤34/ No IFG-DM 1.00 1.00 1.00 
   WC ≤34/ IFG-DM 0.85 (0.47, 1.54) 0.84 (0.47, 1.52) 0.84 (0.46, 1.51) 
   WC > 34/ No IFG-DM 1.12 (0.75, 1.67) 1.02 (0.63, 1.64) 0.99 (0.61, 1.62) 
   WC > 34/ IFG-DM 1.46 (0.97, 2.21) 1.31 (0.78, 2.19) 1.25 (0.73, 2.16) 
WC/HDL-C3    
   WC ≤ 34/ Nl HDL 1.00 1.00 1.00 
   WC ≤ 34/Low  HDL 0.77 (0.48, 1.24) 0.77 (0.48, 1.23) 0.76 (0.47, 1.23) 
   WC > 34/ Nl HDL 1.23 (0.79, 1.92) 1.09 (0.65, 1.85) 1.06 (0.62, 1.80) 
   WC > 34/ Low HDL 1.18 (0.79, 1.76) 1.05 (0.64, 1.71) 0.99 (0.59, 1.67) 
WC/ TG4    
   WC ≤ 34/ Nl TG  1.00 1.00 1.00 
   WC ≤ 34/ High TG 1.11 (0.65, 1.89) 1.10 (0.65, 1.87) 1.09 (0.64, 1.85) 
   WC > 34/ Nl TG 1.37 (0.93, 2.02) 1.23 (0.76, 2.00) 1.19 (0.64, 1.95) 
   WC > 34/ High TG 1.25 (0.80, 1.93) 1.13 (0.67, 1.89) 1.07 (0.62, 1.85) 
WC/ Dyslipidemia5    
   WC ≤ 34/ No Dyslip. 1.00 1.00 1.00 
   WC ≤ 34/ Dyslip. 0.95 (0.62, 1.46) 0.94 (0.61, 1.45) 0.93 (0.61, 1.44) 
   WC > 34/ No Dyslip. 1.35 (0.83, 2.18) 1.20 (0.68, 2.11) 1.16 (0.65, 2.05) 
   WC > 34/ Dyslip. 1.23 (0.83, 1.83) 1.10 (0.68, 1.79) 1.04 (0.62, 1.75) 
WC/ HBP6    
   WC ≤ 34/ Nl HBP  1.00 1.00 1.00 
   WC ≤ 34/ High HBP 1.08 (0.68, 1.70) 1.07 (0.68, 1.68) 1.06 (0.67, 1.67) 
   WC > 34/ Nl HBP 1.35 (0.89, 2.05) 1.22 (0.75, 1.99) 1.18 (0.72, 1.94) 
   WC > 34/ High HBP 1.29 (0.84, 1.99) 1.14 (0.67, 1.94) 1.08 (0.61, 1.90) 
WC/ MetDys7    
   WC ≤ 34/0,1 MetDys 1.00 1.00 1.00 
   WC ≤ 34/2+ MetDys 1.03 (0.61, 1.73) 1.02 (0.61, 1.70) 1.01 (0.60, 1.69) 
   WC > 34/0,1 MetDys  1.17 (0.76, 1.79) 1.06 (0.64, 1.76) 1.04 (0.62, 1.73) 
   WC > 34/2+ MetDys  1.43 (0.96, 2.13) 1.28 (0.77, 2.12) 1.23 (0.72, 2.11) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
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4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
 
4.4 Discussion 
4.4.1 Summary of Results 
In these analyses, we explored the combined effects of anthropometric 
measures of body fat (BMI, WHtR, and WC) and metabolic dysfunction on the 
risk of obesity-related cancers. The goal of this analysis was to investigate 
whether obese subjects who were “metabolically unhealthy” had a higher risk of 
obesity-related cancer than did similarly obese subjects who were “metabolically 
healthy”. There is no consensus in the literature regarding the definition of 
“metabolically healthy obesity” so in these analyses, we explored several 
definitions of metabolic health including attributes of the metabolic dysfunction 
individually or in combination. Another reason for exploring several definitions 
of metabolic health is that it is unknown which attributes of metabolic health are 
potentially important in obesity-related cancer risk. Cancer processes involve 
growth signals and inflammatory markers also produced during metabolic 
dysregulation.71 
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In these analyses, men with a BMI above 30 kg/m2 had more than twice 
the risk of obesity-related cancers after adjusting for hip circumference and other 
confounders. There was some evidence that metabolically unhealthy obese (BMI 
>30 k/m2) men (i.e., those with glucose dysregulation or dyslipidemia) had 
somewhat higher risks of obesity-related cancers than metabolically healthy 
obese men. For women, the increased risk of obesity-related cancer rose starting 
with a BMI above 25 kg/m2; but in contrast with men, there was no apparent 
effect modification by metabolic dysfunction. Women with a BMI of 25 kg/m2 
and higher had more than a 50% increased risk of obesity-related cancers, 
regardless of the presence of metabolic dysfunction. Further, there was no 
confounding of the BMI effects by HC in women. These results may suggest that 
metabolic dysfunction has a greater role in promoting obesity-related cancer in 
men, possibly as a result of their tendency to store fat viscerally.  In contrast, 
women tend to have more lower-body obesity, and may be relatively protected. 
 WHtR and WC were used as indicators of central adiposity in these 
analyses, and while both were associated with an increased risk of obesity-
related cancer, WC was the stronger of the two measures in men while WHtR 
was stronger in women. After adjusting for hip circumference, men with a WC 
above 40 inches and who also had IFG/T2DM had more than a 2.5-fold increased 
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cancer risk. There was, in general, only limited evidence for effect modification in 
these analyses (for men and women) in association with prevalent IFG/T2DM or 
dyslipidemia, and none associated with HBP.  
4.4.2 Epidemiological Literature and Results 
4.4.2.1 Metabolic Syndrome and Particular Obesity-Related Cancers 
Some studies have suggested that metabolic syndrome is a risk factor for 
some common cancers. In a meta-analysis by Esposito et al.41 metabolic 
syndrome was associated with liver, colorectal, and bladder cancers in men and 
endometrial, pancreatic, rectal, colorectal, and postmenopausal breast cancer in 
women. Others have found a particular association with breast cancer risk.20 4;5 A 
nested case-control study4 found that both low HDL-C (<50 mg/dL) and high TG 
(≥150 mg/dL) were associated with about a 60% increased risk of post-
menopausal breast cancer; and another5 found about a 90% increased risk among 
women with a high fasting glucose (≥100 mg/dl).  
Other studies have suggested a particular interdependence of higher 
levels of body fat with abnormal levels of metabolic variables in the risk of 
reproductive cancers in women. In a Norwegian cohort, serum glucose (non-
fasting) ≥ 5.6 mmol/l led to increased risk of endometrial cancer only among 
women with a BMI ≥25 kg/m2 while hypertension was associated with in 
  
120 
increased risk only in obese women (BMI ≥30 kg/m2).49 In the EPIC cohort, higher 
TG and fasting glucose levels doubled the risk of endometrial cancer in 
postmenopausal women.36 The Metabolic Syndrome and Cancer Project also 
found a positive association between metabolic syndrome and endometrial 
cancer in women whose BMI was in the two highest quintiles; no association was 
found for individual metabolic components of the metabolic syndrome.21 In that 
cohort, no association was found between metabolic syndrome and ovarian 
cancer.22  
A nested case-control analysis within the EPIC cohort found that an 
increased cancer risk associated with increasing numbers of factors associated 
with metabolic syndrome (except WC).36 An analysis carried out in the Women’s 
Health Initiative found that fasting glucose levels ≥99.5 mg/dl were associated 
with more than a two-fold increase risk of colon cancer.80  
An important distinction between the current study and previous studies 
is that most of the earlier studies failed to directly assess the independent and 
combined effects of metabolic dysfunction. Thus, the current study makes an 
important contribution to the understanding of the roles of both obesity and 
metabolic dysfunction on cancer risk.  
While the construct of metabolic syndrome is controversial, it is possible 
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that the clustering of metabolic abnormalities in combination with obesity may 
be more pro-inflammatory and therefore more strongly associated with cancer 
risk than individual metabolic derangements.81 It has also been suggested that 
individuals who are not overweight or obese but who develop IFG or diabetes 
may suffer from a different, and perhaps more detrimental, type of metabolic 
dysfunction.34;56 In the current study, we found that overweight women (BMI 
>25kg/m2) had a 60–70% increased risk of obesity-related cancer regardless of the 
presence of metabolic dysfunction. However, we did find that normal weight 
women (BMI <25kg/m2) with metabolic dysfunction had the same elevated risk 
of developing obesity-related cancers as overweight women with metabolic 
abnormalities. This was not true, however, for non-obese men (BMI <30kg/m2) 
with two or more metabolic abnormalities, who had no excess risk of cancer. 
Further, both men and women with a lower WHtR or WC had no excess risk of 
cancer, even when metabolic abnormalities were present. Therefore, these results 
provide no evidence in men (and limited evidence in women) to suggest that 
metabolic dysfunction apart from obesity leads to an excess risk of these typically 
obesity-related cancers.   
4.4.2.2 Blood Glucose and Obesity-Related Cancer 
Extensive epidemiologic evidence supports the association between 
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various measures of body fat as well as prevalent T2DM and cancer risk. Few 
studies have attempted to distinguish the risk contribution of body fat 
distribution from its concurrent metabolic abnormalities on obesity-related 
cancer risk. A recent study in the Framingham Heart Study by Moore et al.114 
found a modifying effect of abnormal glucose levels in overweight subjects (BMI 
≥25 kg/m2). Men and women who were overweight with normal glucose levels 
(<125 mg/dL random glucose) had a 50% greater cancer risk and those with 
abnormal glucose (≥125 mg/dL random glucose) who had double the risk of 
obesity-related cancers. Similar effect modification was observed for random 
glucose levels and WHtR categories in that study. (See Appendix for this 
publication.)   
A recent study also in Framingham Offspring Study127 adults over 20 
years of age, found a marginally statistically significant associations of impaired 
fasting glucose (IFG >110 mg/dl) and total obesity-related cancer (including those 
of the gastrointestinal tract, blood, bone, spleen, female reproductive tract, 
genitourinary organs, and thyroid gland). In the current study,  there was no 
effect of IFG >100 mg/dL/T2DM on obesity-related cancer. In addition women 
with a BMI >25 regardless of the presence of IFG/T2DM had an increased risk of 
obesity-related cancer, indicating that being overweight rather than having 
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IFG/DM is the relevant risk factor. The study by Perakh et al.127 also found no 
effect of IFG >110 mg/dl on breast cancer but a strong effect on colon cancer risk 
[2.20 (1.48, 3.27)]. In women, a hemoglobin A1c between 5.72–14.57% was 
associated with nearly a two-fold increased risk of breast cancer [1.95 (1.07, 
3.54)].  
4.4.2.3 HDL and Cancer 
HDL-C has been shown to be inversely associated with chronic disease, 
but its inverse association with cancer has been inconsistent and its meaning 
elusive.50;57;67;75;102;111;115;143  Therefore, HDL-C has only been putatively regarded as 
a marker of the overall risk of chronic disease.143 Various lifestyle factors such as 
alcohol consumption and physical activity levels are associated with increased 
HDL-C levels and these may be responsible for uncontrolled confounding in 
some earlier studies.  
Early studies have shown mixed results on the association between low 
HDL-C levels and risk of breast cancer.67;115  One study50 found that higher HDL-
C levels (1.41–1.64 mmol/L and >1.64 mmol) led to 45–55% lower risks of 
postmenopausal breast cancer among women with a BMI ≥ 25 kg/m2. In the EPIC 
cohort HDL-C was also inversely associated with endometrial cancer.36 Higher 
estrogen levels have been associated with lower HDL-C levels, possibly related 
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to its regulation of hepatic lipase.30;36;50;62;129 Since the association of BMI and 
postmenopausal breast cancer could be attributable to increases in estradiol,88;142 
HDL-C may serve as a marker of estradiol levels rather than a marker of 
metabolic dysfunction per se. Therefore, the protective effects of higher HDL-C 
on postmenopausal breast and endometrial cancer risk may relate to a more 
favorable hormonal profile.  
In the current study, we adjusted for lifestyle factors in the multivariable 
analysis that may be associated with HDL-C as well as cancer risk. We found no 
association between HDL-C and cancer risk except in overweight/obese 
individuals. In women, there was no modification of the effect of overweight on 
cancer risk by HDL-C. However, obese men (BMI >30kg/m2) with a low HDL had 
a higher cancer risk than obese men with normal HDL levels. Overall, when also 
considering the combined effects of higher WC and WHtR and low-HDL, this 
study provides no evidence that HDL-C is independently associated with the 
risk of obesity-related cancers and limited evidence that a low HDL may 
potentiate the adverse effect of obesity on risk of these cancers in men.  
4.4.3 Strengths and Limitations 
The present analysis differed in two main ways from previous analyses of 
metabolic dysfunction and cancer. First, we directly examined the independent 
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and combined effects of anthropometric measures of body fat and various 
metabolic abnormalities and metabolic dysfunction. Second, we explored the 
effects of body composition through exploring independent effects of waist, hip 
and BMI. The study has many important strengths including the availability of 
replicate measures of BMI and metabolic variables. In addition, the careful, 
systematic, prospective assessment of cancer occurrence is another important 
strength of the study, giving us more complete ascertain of incident cancers than 
some previous studies. The long-term follow-up also strengthens these results.  
There are also limitations associated with the current analyses, and one is 
the limited power in certain subgroups. Since metabolic abnormalities are less 
common among normal-weight individuals, the small sample size in this 
particular subgroup led to limited power for this analysis. Another limitation is 
that we had small numbers of cases of many of the obesity-related cancers. 
Therefore we were not able to evaluate individual cancers within the overall 
group of obesity-related cancers.  
Another limitation of this study is the premise of “metabolically healthy 
obesity” itself. A recent meta-analysis infers that metabolically healthy obesity is 
a transient phenotype and that those with this phenotype simply are sub-
clinically unhealthy.89 This analysis did not account for the development of 
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metabolic dysfunction after baseline in evaluating an association between 
phenotypes combining anthropometric measures of body fat and metabolic 
variables in relation to obesity-related cancer. The hypothesized underlying 
biological cause of obesity-related cancer is chronic inflammation produced by 
excess body fat and metabolic abnormalities. Therefore, epidemiologically, 
durations or time-frame of exposures, rather than baseline measures, may be 
more relevant hypothesized risk factors.37;79 
Another limitation is the selection of cancers as obesity-related.  Common 
cancers, such as postmenopausal breast cancer, could have prevalent causal 
factors complementary to higher body weight but may also be unrelated 
mechanistically to the development of metabolic dysfunction. The strength of the 
association depends on their prevalence of these potential unknown confounders 
and the ability to control for them.  Additionally, the established risk factors such 
as late age at first birth or early age of menarche were not available in FOS.  We 
were also lacking data on estrogen and progesterone sensitivity of these cancers. 
Hormone replacement therapy has been shown to be an important modifier of 
the BMI effect on cancer risk6;91;116 but this was also unavailable. 
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4.4.4 Conclusion 
The aim of these analyses was to separate the effects of anthropometric 
measures of body fat from the potential effect of metabolic abnormalities on 
obesity-related cancer.  The results show that overweight women and obese men 
have greater risk of obesity-related cancer regardless of the presence of metabolic 
abnormalities.  Men and women who had metabolic dysfunction had a 30% 
increased risk of obesity-related cancer.  There is limited evidence that metabolic 
abnormalities modify the risk of overweight, obesity, or higher WC and WHtR. 
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Chapter 5 
Modification of the Effect of Weight Gain on Cancer Risk by Metabolic 
Dysfunction 
5.1 Introduction 
Excess body fat is considered to be a modifiable risk factor for particular 
cancers.138 However, few studies have examined the effect of the change in body 
weight (weight loss or gain) on obesity-related cancer risk. Earlier studies 
focused on the effect of weight change on post-menopausal breast cancer. 6;40;116 
The only prospective study to date that has attempted to look at weight change 
and multiple obesity-related cancers is an analysis from the Health Professional’s 
Follow-Up study, which found that weight loss decreased risk of obesity-related 
cancers (colorectal, pancreatic, and esophageal).37  
The changes in inflammatory and hormonal markers that accompany 
weight loss or gain may impact cancer risk. Randomized controlled trials of 
intentional weight loss have been associated with reductions in CRP, TNF-α, and 
IL-6. These inflammatory markers have been hypothesized to be part of the 
mechanism linking adiposity-induced inflammation and risk of obesity-related 
cancers.27;43 Long-term weight gain may therefore reflect a longer duration of 
inflammation and accumulating dose of adipose tissue dysfunction, perhaps 
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underlying the long process of carcinogenesis. The pro-inflammatory 
cardiometabolic risk factors (i.e., IFG and dyslipidemia) that accompany weight 
gain may also promote obesity-related cancer risk. 
  The first objective of these analyses is to examine the independent and 
combined effects of weight gain prior to middle age and resultant metabolic 
dysfunction during middle age on risk of obesity-related cancers. A second 
objective is to examine whether overweight or obese prior to middle-age 
modifies the effect of prevalent overweight/obesity during the middle adult 
years on long-term risk of obesity-related cancer. Finally, we will explore 
whether these effects are modified by concurrent metabolic dysfunction.  
5.2 Methods  
5.2.1 Study Population 
As described in earlier chapters in this dissertation, the Framingham 
Offspring Study is a second generation prospective cohort of the offspring of 
subjects participating in the original Framingham Heart Study. The Offspring 
Study began in 1971 with the enrollment of 5,135 subjects.85  Exams 1 through 8 
were conducted during the following years, respectively: 1971–1975, 1979–
1983,1983–1987,1987–1991,1991–1995,1995–1998, 1998–2001, and 2005–2008. There 
were approximately eight years between the first two exams and four years 
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between each subsequent exam. Data on the following types of variables were 
collected: anthropometric variables, urinalysis, blood chemistries, blood 
pressure, medical history, and lifestyle habits. At each visit, subjects were asked 
to report any diseases or conditions that had occurred since their last visit.  
Subjects were included in these analyses if they had baseline weight and 
height (at exam 1 or later) and additional weight measurements  at least 10 years 
later(end of weigh change period), and if at the end of this weight change period  
they were  45–69 years of age or older and had complete data for metabolic 
variables of interest (HDL-C, triglycerides, blood glucose, and blood pressure) 
and potential confounders (age, height, physical activity, cigarettes per day, 
education, and alcohol intake). A total of 3850 subjects were available for these 
analyses.   
5.2.2 Exposure Variables 
All measures of height prior to age 60 were used in combination with each 
visit-specific weight measure to calculate BMI. Height (inches) and weight 
(pounds) were measured at each visit using a standard beam balance.54  For each 
subject, weight (pounds) was regressed on age (years) from baseline to the end of 
the weight change period to generate a subject-specific slope for weight change 
(pounds per year). Only subjects with a minimum of 10 years for the weight 
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change period were included. The slopes of weight change were used to 
categorize subjects as those who gained ≥ 1 lb./year, those who  remained weight 
stable (did not gain more than 1 lb./year), and those who lost ≥ 1 lb./year. The 
weight stable served as referent group. Eighty-seven percent of subjects entered 
the exam weight change period at exam 1 and 53.5% completed it at exam 3.  
(Figure 1) 
 
Figure 1 
 
 
For the second analyses associated with this aim, subjects were classified 
according to weight status at baseline and again at the end of the weight change 
period (10–20 years from baseline). (Figure 2) Specifically, women were classified 
as overweight (BMI ≥25 kg/m2) or not at baseline and again 10–20 years later 
while men were classified as obese (BMI ≥30 kg/m2) or not at both time points. 
Based on these classifications at two time points, each subject fell into one of the 
following categories: (a) normal weight at both time points, (b) normal weight at 
baseline and overweight/obese by the end of the weight change period, (c) 
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overweight/obese at both time points, or (d) overweight/obese at baseline and 
normal weight by the end of the weight change period. Since the rates of obesity-
related cancer were very similar in groups a and d, these two groups were 
combined as the referent group for these analyses.  
Figure 2 
 
 
IFG orT2DM status and other metabolic dysfunction variables were cross-
classified with weight change and obesity status variables to examine potential 
effect modification of weight change by metabolic abnormalities. The four 
metabolic variables (IFG-DM, HDL-C, dyslipidemia, and HBP) used to define 
metabolic dysfunction were described in chapter 4. Prevalent metabolic 
dysfunction was defined as the presence two or more metabolic abnormalities.  
5.2.3 Dependent Variable 
Obesity-related cancer outcomes were selected based on previously-
published studies and included the following: female reproductive (post-
menopausal breast, uterine, cervical, and endometrial, ovarian), colon, stomach, 
liver, gallbladder, pancreas, kidney, thyroid, esophageal adenocarcinoma, 
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leukemia, non-Hodgkin lymphoma and multiple myeloma.107;138 
For colorectal cancer, tumors in the proximal colon, distal colon, and 
rectum were included. Proximal colon cancer included cancer in the cecum, 
ascending colon, hepatic flexure, transverse colon, and splenic flexure. Distal 
colon cancer included cancer in the descending and sigmoid colon. Appendiceal 
carcinomas were excluded. Female breast cancer excluded tumors in the skin of 
the breast. Cancer diagnosis date was taken from available pathology reports. 
Diagnoses were confirmed from pathology, laboratory, and clinical records.90 The 
cancer diagnosis date was taken from other reports when pathology reports were 
unavailable or when diagnosis occurred before the pathological test.102 All self-
reported cancer was confirmed by outside medical and pathological records. 
Cancer cases were coded using the International Classification of Diseases for 
Oncology (ICD-O).  
5.2.4. Potential Confounding Variables 
To estimate the independent effect of weight change on obesity-related 
cancer, all analyses controlled for age (years), sex, cigarettes per day, grams of 
alcohol per week, average adult height (inches), education (less than high 
school”, “high school”, “some college”, or “college graduate”), and physical 
activity index. Physical activity index was created by summing self-reported 
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moderate and vigorous activity, where each type of activity was weighted by 
oxygen consumption. WC and WHtR models also controlled for hip 
circumference, measured once starting at exam 4.  
5.2.5. Analysis 
Men and women ages 45–69 years were selected when they met the age 
requirement, had BMI and waist circumference variables, and the other 
covariates included in the final analyses. The time they met these requirements is 
the same as the end of the weight change period described above.  Cox 
proportional hazards were calculated based on time (years) to the development 
of first obesity-related cancer. Person-years of follow-up time was calculated 
from the end of the weight change period to the first of the following events: date 
of last exam, date of death, loss to follow up, or date of obesity-related cancer 
diagnosis. Cancer incidence per 1,000 person-years was calculated by dividing 
the number of obesity-related cancers by the total number of person-years in a 
given exposure category. The proportional hazards assumptions were tested in 
all models and no violations of the assumption were found. 
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5.3 Results 
5.3.1. Individual and Combined Effects of Long-Term Weight Change and 
Metabolic Dysfunction 
Table 5.1 shows that 145 men and 90 women lost at least 1 lb./year; these 
subjects had a higher mean baseline BMI and were on average slightly older. 
Those who gained at least 1 lb./yr were slightly younger at baseline. At least 40% 
of men and 27% of women who gained at least 1 lb./yr had IFG or T2DM. At least 
50% of women who lost at least 1 lb./yr had high blood pressure, and at least 40% 
of all men in all categories had high blood pressure. 
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Table 5.1. Baseline characteristics of men and women according to weight change over 
a mean of 14 years 
 Men Women 
 Weight Change/Year Weight Change/Year 
 Wt. loss≥1 
lb./yr. Wt. stable1 
Wt. gain≥1 
lb./yr. 
Wt. loss≥1 
lb./yr. Wt. Stable1 
Wt. gain≥1 
lb./yr. 
  N=145 N=1,168 N=530 N=90 N=1,112 N=805 
 Mean (s.d.) Mean (s.d.) 
Age, baseline (y) 41.1 (7.6) 38.5 (8.0) 35.9 (7.6) 42.7 (6.4) 38.3 (7.9) 35.6 (7.1) 
BMI (kg/m2), 
baseline2 29.2 (4.1) 26.7 (3.2) 26.4 (3.8) 30.2 (7.3) 23.6 (4.0) 24.2 (4.5) 
Weight, baseline 
(lbs.) 196.6 (29.4) 179.9 (24.9) 180.4 (28.4) 174.4 (45.2) 134.7 (23.5) 139.9 (26.3) 
Measures at the start of 
follow-up 
      Age (y) 54.2 (6.7) 52.6 (6.6) 50.7 (5.9) 55.7 (6.0) 52.5 (6.6) 50.5 (5.6) 
BMI (kg/m2) 26.1 (3.8) 27.0 (3.2) 30.4 (4.5) 26.4 (6.4) 24.3 (3.9) 29.4 (5.6) 
Height (in.) 68.8 (2.4) 68.9 (2.6) 69.3 (2.6) 63.6 (2.1) 63.4 (2.4) 63.7 (2.3) 
Alcohol intake (g) 19.0 (32.4) 17.9 (22.2) 17.0 (21.8) 7.3 (15.1) 8.5 (12.9) 7.2 (12.6) 
Cigarettes /day 9.4 (15.9) 6.3 (12.7) 6.2 (13.2) 8.3 (13.2) 5.4 (10.5) 4.7 (10.5) 
Physical activity 
index 13.3 (8.9) 13.7 (9.8) 12.56 (8.9) 10.1 (7.5) 12.2 (7.4) 11.8 (7.5) 
Weight change/y -1.6 (0.56) 0.14 (0.51) 1.8 (0.81) -1.73 (0.89) 0.26 (0.49) 2.0 (1.0) 
SBP (mmHg) 128.8 (19.1) 127.5 (16.5) 129.7 (15.5) 131.2 (17.6) 122.6 (18.1) 125.2 (18.6) 
DBP (mmHg) 79.5 (10.0) 80.6 (9.6) 83.5 (9.2) 78.7 (8.2) 76.1 (9.7) 78.4 (10.2) 
  N (Column Percent) N (Column Percent) 
Educ. (>H.S.) 77 (53.1 %) 745 (63.8%) 365 (68.9%) 37 (41.1%) 623 (56.0%) 446 (55.4%) 
IFG or T2DM3 63 (43.5%) 410 (35.1%) 223 (42.1%) 28 (31.1%) 185 (16.6%) 218 (27.1%) 
T2DM 27 (18.6%) 59 (5.1%) 32 (6.0%) 15 (16.7%) 27 (2.4%) 30 (3.7%) 
Dyslipidemia4 59 (40.7%) 597 (51.1%) 329 (62.1%) 41 (45.6%) 387 (34.8%) 417 (51.8%) 
HBP5 59 (40.7%) 467 (40.0%) 233 (44.0%) 47 (52.2%) 307 (27.6%) 240 (29.8%) 
1 Wt. stable indicates weight loss or gain of <1 lb./yr. 
2 Baseline is at 10–20 years prior to the BMI measure taken at the beginning of follow-up. 
3 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
4 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
5 High blood pressure identified using modified JNC-7 criteria. 
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Table 5.2 shows that men and women who gained ≥ 1 lb./yr had a 39% 
increased risk (95%CI: 1.09–1.76) of obesity-related cancer. This effect was not 
confounded by baseline BMI. Subjects with prevalent IFG who gained ≥ 1 lb./yr 
had a 64% increased risk of obesity-related cancer (95% CI: 1.17–2.28). Those with 
prevalent metabolic dysfunction and weight gain had a 77% increase risk (95% 
CI: 1.21–2.59). (Tables 5.3 and 5.4) 
Table 5.2. Effect of weight change on incidence of obesity-related cancers 
     Model 1 Model 2 
Weight Change N PY Cases I/1000 py HR1 (95% CI) HR (95% CI)2 
All subjects 
      
Weight Loss3 235 3631 20 5.51 1.08 (0.68, 1.72) 1.05 (0.65, 1.69) 
Weight stable4 2280 35901 173 4.82 1.00 1.00 
Weight gain5 1335 19180 117 6.10 1.39 (1.09, 1.76) 1.38 (1.09, 1.76) 
Men 
      
Weight Loss  145 2210 12 5.43 1.25 (0.68, 2.31) 1.17 (0.62, 2.18) 
Weight stable 1168 18274 74 4.05 1.00 1.00 
Weight gain 530 7568 34 4.49 1.30 (0.86, 1.96) 1.32 (0.88, 2.00) 
Women 
      
Weight Loss  90 1421 8 5.63 0.89 (0.43, 1.85) 0.87 (0.41, 1.84) 
Weight stable 1112 17627 99 5.62 1.00 1.00 
Weight gain 805 11613 83 7.15 1.40 (1.04, 1.88) 1.39 (1.03, 1.87) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 Additionally adjusted for BMI and age at baseline. 
3 Weight loss of < 1 lb./yr.   
4 Weight stable was considered as weight loss or gain of < 1 lb./yr. 
5 Weight gain of ≥ 1 lb./yr. 
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Table 5.3. Combined effect of weight change and IFG or T2DM on incidence of 
obesity-related cancers 
    
 
Adjusted 
Weight Change/ IFG or T2DM1 N PY Cases I/1000 py HR2 (95% CI) 
All Subjects       
Weight loss or stability3/ No IFG-DM 1829 29293 145 4.95 1.00 
Weight gain4/ No IFG-DM 894 13195 71 5.38 1.22 (0.92, 1.63) 
Weight loss or stability/ IFG-DM 686 10238 48 4.69 0.96 (0.69, 1.34) 
Weight gain/ IFG-DM 441 5986 46 7.68 1.64 (1.17, 2.28) 
Men 
     
Weight loss or stability/ No IFG-DM 840 13587 55 4.05 1.00 
Weight gain/ No IFG-DM 307 4558 16 3.51 1.06 (0.61, 1.86) 
Weight loss or stability/ IFG-DM 473 6896 31 4.50 1.07 (0.69, 1.66) 
Weight gain/ IFG or T2DM 223 3009 18 5.98 1.60 (0.94, 2.73) 
Women 
     
Weight loss or stability/ No IFG-DM 989 15706 90 5.73 1.00 
Weight gain/ No IFG-DM 587 8636 55 6.37 1.24 (0.88, 1.74) 
Weight loss or stability/ IFG-DM 213 3342 17 5.09 0.81 (0.48, 1.37) 
Weight gain/ IFG-DM 218 2977 28 9.41 1.67 (1.09, 2.55) 
1 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
2 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
3 Weight loss of < 1 lb./yr.  Weight stable was considered as weight loss or gain of < 1 lb./yr. 
4 Weight gain of ≥ 1 lb./yr. 
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Table 5.4. Combined effect of weight change and metabolic dysfunction on the 
incidence of obesity-related cancers 
     Adjusted 
Weight Change /MetDys1 N PY Cases I/1000 py HR2 (95% CI) 
All Subjects       
Weight Loss or stability3/ 0,1 MetDys 2131 33908 161 4.75 1.00 
Weight gain/ 0,1 MetDys 1040 15219 85 5.59 1.31 (1.00, 1.71) 
Weight Loss or stability/ 2+ MetDys 384 5623 32 5.69 1.21 (0.83, 1.78) 
Weight gain/ 2+ MetDys 295 3962 32 8.08 1.77 (1.21, 2.59) 
Men 
     
Weight Loss or stability/ 0,1 MetDys 1047 16716 66 3.95 1.00 
Weight gain/ 0,1 MetDys 385 5681 22 3.87 1.15 (0.71, 1.87) 
Weight Loss or stability/ 2+ MetDys 266 3767 20 5.31 1.25 (0.76, 2.08) 
Weight gain/ 2+ MetDys 145 1887 12 6.36 1.85 (1.00, 3.44) 
Women 
     
Weight Loss or stability/ 0,1 MetDys 1084 17192 95 5.53 1.00 
Weight gain/ 0,1 MetDys 655 9537 63 6.61 1.34 (0.97, 1.85) 
Weight Loss or stability/ 2+ MetDys 118 1856 12 6.47 1.09 (0.60, 1.99) 
Weight gain/ 2+ MetDys 150 2075 20 9.64 1.74 (1.07, 2.82) 
1 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
2 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
3 Weight loss of < 1 lb./yr.  Weight stable was considered as weight loss or gain of < 1 lb./yr. 
4 Weight gain of ≥ 1 lb./yr 
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5.3.2. Individual and Combined Effects of Long-Term Overweight/Obesity Status 
Change and Metabolic Dysfunction on the Risk of Obesity-Related Cancer 
Of the men and women were overweight/obese at baseline, 97.3% of men 
and 98% of women remained overweight/obese. Baseline characteristics of men 
and women according weight status at baseline and follow up are shown in 
Table 5.5. Women not overweight at baseline were on average younger. At least 
33–42% of men within each category had IFG, and 55% of men who remained 
obese had IFG.  Thirty-five percent of men who were never obese and 65% who 
remained obese had HBP.  In women, 39% of those who remained overweight 
had IFG or T2DM, and 48–50% who were overweight at baseline had HBP. 
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Table 5.5.  Baseline characteristics of men and women according to obesity status 10–
20 years prior to and at baseline 
 Men Women 
 Baseline BMI1/BMI at the Start of 
Follow-up 
Baseline 1 BMI/BMI at the Start of 
Follow-up 
 BMI<30/ 
<30  
BMI<30/ 
≥30  
BMI≥30/ 
<30  
BMI≥30/ 
≥30  
BMI<25/ 
<25  
BMI<25/ 
≥25  
BMI≥25/ 
<25 
BMI≥25/ 
≥25 
  N=1,339 N=206 N=50 N=248 N=930 N= 468 N=40 N=569 
 Mean (s.d.) Mean (s.d.) 
BMI (kg/m2), 
baseline 
25.4 
 (2.4) 
27.8 
(1.8) 
31.1 
(1.1) 
32.9 
(2.6) 
21.3 
(1.7) 
22.9 
(1.5) 
26.4 
 (1.8) 
29.6  
(4.7) 
Age (y), baseline 
38.3 
 (8.1) 
35.6 
(7.5) 
39.2 
(8.3) 
38.1 
(7.4) 
36.6 
(7.3) 
35.5 
(7.4) 
40.9  
(7.5) 
40.2 
 (7.9) 
Measures at the start of follow-up            
Age (y) 
52.4 
(6.6) 
50.7 
(5.6) 
52.8 
(7.1) 
52.2 
(5.9) 
51.0 
(5.9) 
50.6 
(5.8) 
54.8 
 (6.8) 
54.0  
(6.7) 
BMI (kg/m2) 
26.1 
 (2.3) 
32.0 
(1.8) 
28.4 
(1.4) 
34.4 
(3.7) 
22.3 
(1.6) 
27.8 
(2.8) 
23.7 
 (1.0) 
32.2  
(5.4) 
Height (in.) 
69.0  
(2.6) 
69.1 
(2.8) 
68.9 
(2.9) 
68.8 
(2.6) 
63.8 
(2.3) 
63.6 
(2.3) 
63.5 
 (2.0) 
63.0 
 (2.4) 
Alcohol intake (g) 
17.6 
(21.7) 
19.2 
(23.0) 
14.2 
(25.6) 
17.7 
(29.1) 
9.3 
(13.3) 
7.2 
(11.7) 
8.3 
 (14.0) 
6.3  
(12.9) 
Cigarettes/ day 
6.7  
(13.2) 
5.3 
(12.7) 
6.6 
(13.8) 
6.4 
(13.7) 
5.3 
(10.6) 
4.7 
 (9.9) 
6.9  
(10.8) 
5.5  
(11.3) 
Physical activity 
index 
13.3  
(9.3) 
13.2 
(9.9) 
12.6 
(7.9) 
13.8 
(10.6) 
12.6 
(7.4) 
12.1 
(7.9) 
9.4 
 (5.4) 
10.8 
 (7.3) 
SBP (mmHg) 
127.1 
(16.6) 
130.4 
(15.6) 
123.3 
(15.8) 
133.6 
(15.7) 
119.1 
(17.2) 
123.8 
(17.1) 
128.0 
(15.8) 
132.0 
(18.6) 
DBP (mmHg) 
80.2 
 (9.6) 
84.8 
(9.4) 
78.5 
(8.6) 
84.9 
(8.9) 
74.5 
(9.4) 
77.9 
(9.8) 
77.5 
 (8.2) 
80.8 
 (9.6) 
 N (Column Percent) N (Column Percent) 
Educ. (>H.S.) 
871 
(65.1%) 
145 
(70.4%) 
32 
(64.0%) 
139 
(56.1%) 
564 
(60.7%) 
268 
(57.3%) 
22 
(55.0%) 
252 
(44.3%) 
IFG or T2DM2 
447 
(33.4%) 
91 
(44.2%) 
21 
(42.0%) 
137 
(55.2%) 
96 
(10.3%) 
104 
(22.2%) 
8 
 (20%) 
223 
(39.2%) 
T2DM 62 (4.6%) 
10 
(4.9%) 
8 
(16.0%) 
38 
(15.3%) 
6 
(0.65%) 
5 
 (1.1%) 
3 
 (7.5%) 
58 
(10.2%) 
Dyslipidemia3 
656 
(49.0%) 
131 
(63.6%) 
28 
(56.0%) 
170 
(68.6%) 
24 
(26.7%) 
17 
(42.5%) 
221 
(47.2%) 
359 
(63.1%) 
HBP4 
474 
(35.4%) 
103 
(50.0%) 
20 
(40.0%) 
162 
(65.3%) 
177 
(19.0%) 
120 
(25.6%) 
20 
 (50.0%) 
277 
(48.7%) 
1 Baseline BMI was measured 10–20 years prior to the BMI measure taken at the beginning of 
follow-up. 
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2  IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication 
3  Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men),<50 (women). 
4  High blood pressure identified using modified JNC-7 criteria. 
 
Men or women who became overweight or obese over 10–20 years had 
over double and 60% increased relative cancer risk, respectively. No relative 
effect was found in men who remained at BMI ≥ 30 kg/m2. Women who 
remained at BMI ≥ 25 kg/m2 had a marginally statistically significant 33% 
increased relative risk (95% CI: 0.94–1.88). (Table 5.6)  Table 5.7 shows that those 
who became overweight or obese over 10–20 years had a 66 to 78% increased 
risked risk of obesity- related cancer,  and those whose BMI status did not 
change who had IFG had a 51% increased risk.  Table 5.8 shows that among 
those who became overweight or obese, those with ≥2 attributes of metabolic 
dysfunction had twice the risk and those  with ≤1  attribute had a 72% increased 
risk, compared with those who did not become overweight/obese with ≤1 
attribute of metabolic dysfunction.  No relative risk was found among obese men 
and overweight women who remained obese or overweight who did not have 
IFG/T2DM (Table 5.7) or who had ≤1 attribute of metabolic dysfunction (Table 
5.8).    Appendix table A.16 shows that those who became overweight or obese 
had lower mean BMIs at baseline and by the beginning of follow-up. 
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Table 5.6. Effect of change in overweight (in women) or obesity (in men) status on the 
incidence of obesity-related cancer 
BMI at Baseline1/ BMI at Start of Follow-up N PY Cases I/1000 py HR2 (95% CI) 
All subjects       
Any BMI /BMI <30(m), 25(w) 2359 36415 157 4.31 1.00 
BMI<30 (m), 25(w) /BMI ≥30(m), 25(w) 674 9679 72 7.44 1.75 (1.31, 2.33) 
BMI≥30 (m), 25(w) /BMI ≥30(m), 25(w) 817 12617 81 6.42 1.30 (0.98, 1.72) 
Men       
Any BMI /BMI <30 1389 21411 82 3.83 1.00 
BMI <30/BMI ≥30 206 2864 20 6.98 2.18 (1.33, 3.56) 
BMI ≥30/BMI ≥30 248 3777 18 4.77 1.28 (0.76, 2.14) 
Women      
Any prior BMI /BMI <25 970 15005 75 5.00 1.00 
Prior BMI <25 /BMI ≥25 468 6815 52 7.63 1.60 (1.12, 2.28) 
Prior BMI ≥25 /BMI ≥25 569 8840 63 7.13 1.33 (0.94, 1.88) 
1 Baseline BMI was measured 10–20 years prior to the BMI measure taken at the beginning of 
follow-up. 
2 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
 
Table 5.7. Effect of change in overweight (in women) or obesity (in men) status 
modified by dysregulated glucose metabolism on the incidence of obesity-related 
cancer in men and women combined 
BMI at Baseline1/ BMI  at Follow-up/ IFG or 
T2DM2 N PY Cases 
I/1000 
py HR3 (95% CI) 
       
Any BMI /BMI <30 (m), 25(w) / No IFG -DM (Ref.) 1787 2817
8 
122 4.33 1.00 
Any BMI/BMI <30 (m), 25 (w) / IFG-DM 572 8237 35 4.25 1.00 (0.68, 1.47) 
BMI <30(m), 25(w) /BMI ≥30 (m), 25(w)/ No IFG-
DM 
479 6997 53 7.57 1.78 (1.28, 2.47) 
BMI <30(m), 25(w) /BMI ≥30 (m), 25(w)/ IFG-DM 195 2682 19 7.08 1.66 (1.02, 2.69) 
BMI ≥30(m), 25(w) /BMI ≥30 (m), 25(w)/ No IFG-
DM 
457 7312 41 5.61 1.14 (0.79, 1.63) 
BMI ≥30(m), 25(w) /BMI ≥30 (m), 25(w)/ IFG-DM 360 5305 40 7.54 1.51 (1.05, 2.17) 
1 Baseline BMI was measured 10–20 years prior to the BMI measure taken at the beginning of 
follow-up. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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Table 5.8. Effect of change in overweight (in women) or obesity (in men) status 
modified by metabolic dysfunction on obesity-related cancer in men and women 
combined 
BMI at Baseline1/ BMI  at Follow-up / MetDys2 N PY Cases 
I/1000 
py HR3 (95% CI) 
       
Any BMI5/BMI<30 (m), 25(w) / 0,1 MetDys (Ref.) 2063 32269 136 4.21 1.00 
Any BMI5/BMI<30 (m), 25(w) / 2+ MetDys 296 4146 21 5.06 1.24 (0.78, 1.98) 
BMI <30(m), 25(w) /BMI ≥30(m), 25(w)/ 0,1 MetDys 550 8003 58 7.25 1.72 (1.26, 2.36) 
BMI <30(m), 25(w) /BMI ≥30(m), 25(w)/ 2+ MetDys 124 1677 14 8.35 2.05 (1.18, 3.55) 
BMI ≥30(m), 25(w) /BMI ≥30(m), 25(w)/ 0,1 MetDys 558 8855 52 5.87 1.21 (0.87, 1.69) 
BMI ≥30(m), 25(w) /BMI ≥30(m), 25(w)/ 2+ MetDys 259 3762 29 7.71 1.58 (1.05, 2.38) 
 1 Baseline BMI was measured 10–20 years prior to the BMI measure taken at the beginning of 
follow-up. 
2 The metabolic dysfunctions are IFG (T2DM, fasting glucose>125 mg/dL, or 100–125 mg/dL; 
dyslipidemia(use of lipid-lowering medication  or TG≥150 or HDL<40 (m),<50 (w)); and HBP 
identified using modified JNC-7 criteria.) 
3 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
 
5.4. Discussion 
In this prospective cohort of 45–69 year old subjects, men and women who 
gained weight over an average of 14.3 years had an increased risk of obesity-
related cancers. To better interpret the effects of the weight gain separate from 
degree and duration of excess weight, the BMI status at the start of weight gain 
was considered. Those who became overweight or obese had a greater risk than 
those with long-term overweight or obesity.  In addition, this effect may be 
separate from the possible inflammatory effects of metabolic dysfunction that 
accompanies weight gain, since strong associations remained in those who 
became obese or overweight with or without the presence of abnormal glucose 
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levels or metabolic dysfunction. Furthermore, the adverse effect of weight gain 
does not seem to be explained by the level of obesity, since those who became 
overweight or obese had lower mean BMIs both at baseline and at the end of the 
weight gain period. 
When accounting for BMI status prior to weight gain, there is no evidence 
that metabolic disturbances modify the effect of weight gain.  The only evidence 
for effect modification by metabolic disturbances is found in the results that do 
not account for BMI status prior to measured weight change; these show a strong 
increased risk in those who gained at least one pound per year only among those 
who had IFG-T2DM or metabolic dysfunction.   
Only a few studies exist on weight or BMI gain and obesity-related 
cancers as a composite outcome. A recent study found only mild effects of  a 5% 
linear increase in weight from age 25 years  until  to middle age (ages 45–65 years) 
on  obesity-related cancer (colorectal, kidney, pancreatic, esophageal, and 
endometrial) [1.03 (1.01, 1.05) in women and 1.03 (0.99, 1.06) in men], 
postmenopausal breast cancer [1.04 (1.02, 1.06)], and endometrial cancer [1.07 
(1.03, 1.13)].63 The same study also found stronger effects of  a linear 5 kg/m2 
increase in BMI with postmenopausal breast [1.38 (1.20, 1.59)] and endometrial 
[1.83 (1.47, 2.26)] cancers. In the Health Professional’s Follow-up study, a weight 
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change of 10–14.9 kg and ≥ 15 kg between age 21 to when subjects reached ages 
40–75 years, was associated with a 16% and a 46%, respectively, of obesity-
related cancer (colorectal, renal, pancreatic, and esophageal) compared to men 
with stable weight (<2.5 kg weight change) [1.16 (0.98, 1.37 and 1.46 (1.23, 1.73), 
respectively].37 Neither one of these studies are inconsistent with the findings in 
this current study.  
Presently, the only meta-analysis on weight gain and individual obesity-
related cancers87 reported that for every 5 kg increase in weight there was an 11% 
increased risk of postmenopausal breast cancer (non-HRT users) (95%CI: 1.08, 
1.13), a 39% (95%CI: 1.29, 1.49) and 9% (95%CI: 1.02, 1.16) increased risk of 
postmenopausal endometrial cancer in non-HRT users and HRT users, 
respectively, and a 13% (95%CI: 1.03, 1.23) increased risk of ovarian cancer. They 
also reported an overall 6% (95%CI: 1.03, 1.10) increased risk of colon cancer in 
men. They found no overall association of weight gain and pancreatic cancer. 
However, this meta-analysis included only a few studies for some cancer 
outcomes (only 2 studies each for ovarian cancer, pancreatic cancer, and 
endometrial cancer by HRT use). Prior studies on weight change and colon 
cancer have shown mixed results, especially in women,10;119;140;147;156 and this could 
be affected by the protective effect of HRT use.10;144  So far, weight change has 
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consistently been shown to be a strong risk factor for endometrial cancer, 
especially in non-HRT users.157;162  
Among cancer types, the association between weight status/gain and 
postmenopausal breast cancer has been most frequently studied, in which 
interaction effects by hormone replacement therapy use (HRT) have been 
consistently observed.6;40;42;69;92;116;117  These studies show increased 
postmenopausal breast cancer risk among those who have never used HRT and 
reduced or null effects among those who have used HRT. For example, the 
National Institutes of Health-AARP study found increases in weight within four 
periods of life (during ages 18–35 years , 35–50 years, 50 years to current age, and 
18 years to current age) were each associated with an increased risk in 
postmenopausal breast cancer among never or former MHT users but not among 
current users. This included dose-response response association of weight gain 
between 2.0 to 39.9 kg among those 35–50 years [1.19 (0.98, 1.46); 1.41 (1.11, 1.79); 
1.64 (1.18, 2.30); 2.29 (1.51, 3.46)] and 50 years to the current age [1.32 (1.10, 1.59); 
1.45 (1.17, 1.81); 1.44 (1.04, 1.98); 1.89 (1.20, 2.97)].6  
The most important strength of this study is the availability of serial 
measurements of weight change rather than self-reported weight. In addition, 
the extensive and careful systematic follow up for the occurrence of cancer 
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among subjects in the study is another important advantage that minimizes the 
chances of both differential and non-differential misclassification of the outcome. 
A limitation is that there could be a lack of power in some of the subgroups for 
combining weight change and metabolic dysfunction. Therefore, sex-specific 
analyses were not conducted. Larger studies are needed for sex-specific analyses 
examining the combined effects of weight gain and metabolic dysfunction.  More 
power would especially be needed for examining sex-differences in the changes 
in abdominal obesity (as the hypothesized inflammatory region).  Another 
limitation is that information on HRT use was not available.  
Recent literature has debated the existence of “metabolically healthy 
obesity”.52;82;150 This invites the question as to whether the detrimental metabolic 
effects on various adiposity-related disease outcomes are possibly separate from 
that of fat gain. In regards to obesity-related cancer risk, the results of this 
analysis do not support the concept of “metabolically healthy obesity”.   The 
overall goal of this dissertation was to separate the effects of excess body fat from 
metabolic dysfunction on obesity-related cancer.   The results provide some 
evidence that the process of weight gain separate from concurrent metabolic 
dysfunction, and possibly not explained by the level of overweight or obesity, is 
its own risk factor for obesity-related cancer.  
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Chapter 6  
Synthesis of Results, Implications, and Future Directions 
Epidemiologic studies have consistently demonstrated that being 
overweight or obese are risk factors for developing certain cancers. The obesity-
cancer link is further supported by the biological evidence of shared 
inflammatory mechanisms underlying both excess adipose tissue and cancer 
development. Type 2 diabetes, which typically accompanies excess weight gain, 
is also a recognized risk factor for some cancers. Related metabolic abnormalities, 
such as low HDL and hypertension, have also been shown to be associated with 
cancer risk, 75;159 but the evidence is not as prolific or consistent. Few 
epidemiologic studies examine whether the effects of anthropometric measures 
of body fat or distribution on cancer risk are modified by metabolic 
abnormalities.  
The overall goal of this dissertation was to separate the effects of excess 
weight and body fat distribution from the potential effect of metabolic 
disturbances on obesity-related cancer. Since some publications suggest that 
particular types of cancer are more attributable to obesity than others, 28;138 I have 
combined sixteen cancer types into a single outcome of obesity-related cancer. 
The specific aims of this dissertation were to address three questions using the 
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Framingham Offspring cohort. Addressing these questions together may clarify 
whether the established cancer risk associated with obesity results from the 
excess fat accumulation itself or from related metabolic dysfunction.  
1. Does fat distribution as measured by anthropometric measures of 
central adiposity better capture the risk of excess fat on obesity-related 
cancer risk than does BMI? 
2. Is the risk of obesity-related cancer that is associated with higher 
anthropometric measures of body fat (BMI) or central body fat (WC, 
WHtR, HC) modified by prevalent metabolic abnormalities?  
3. Is weight gain (over approximately 14 years of follow up) a risk factor 
for obesity-related cancer, and is this effect modified by glucose 
dysregulation or metabolic dysfunction? 
Obesity is fundamentally characterized as having excess body fat. 
Although there are limitations in using any anthropometric measure to reflect its 
quantity, there is strong evidence that a BMI ≥30 kg/m2 and higher WC are linked 
with cardiovascular disease and metabolic dysregulation. Although BMI uses 
body weight in its definition, it is useful as a standard measure by which the 
results of this study may be compared to other studies. The possible value of 
central adiposity as measured by WC for estimating cancer risk is that it may 
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more specifically reflect metabolically-active fat stores that may be more harmful. 
WHtR is also a measure of central adiposity but attempts to more closely reflect 
body shape, in that for the same waist size a shorter person (closer to android 
body fat distribution) would hypothetically have a higher risk of obesity-related 
diseases than a taller person. However, unlike BMI172 and WC8 there are no 
established cut-off values for WHtR that identify health risk. One challenge for 
this dissertation was that there are few data that indicate a particular threshold 
for any of these anthropometric measures for identifying obesity-related cancer 
risk.  
In these analyses which use sex-specific categories and sex-specific 
reference ranges, and controlling for HC in men and WC in women, I found that 
cancer risk started to rise in men at BMI of 28 kg/m2 and in women at a BMI of 
26.5 kg/m2. Men and women who were obese (BMI≥30 kg/m2) had about a 2-fold 
increased risk of obesity-related cancer. Higher WC and lower HC were equally 
strong risk factors in men. This was not the case in women, in whom a higher 
WC had a moderate adverse effect on cancer risk, and a lower HC had no effect. 
In analyses examining the effect of WC, WHtR, and BMI, HC was a confounder 
in men. In contrast, the effects of BMI in women were confounded by WC but not 
HC. Theoretically, the adjustment for WC in analyses of BMI is designed to 
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isolate the effect of BMI from the location of central fat stores. The results of these 
analyses suggest that in addition to central body size, indicators of obesity-
related cancer risk may include body size or weight. However, WC is an 
imperfect adjustment of central body fat, which in addition to abdominal 
subcutaneous fat also includes the hypothesized more inflammatory region of 
visceral fat. The different cancer types seen among men and women could also 
be a factor in the results.  
It may be important to distinguish the effects of adjusting for HC in men 
as opposed to women. HC is more commonly positively associated with WC in 
women, such that women with a smaller HC also tend to have a smaller waist 
size. Because men more readily store fat around their waist, there is a greater 
likelihood that a smaller HC may not necessarily indicate a proportionally 
smaller waist size. Therefore, adjusting for HC may better distinguish body fat 
distribution in men than in women, which could explain why HC was a 
confounder of the results in men but not in women. Another possibility is that if 
HC is a marker for increased risk with T2DM76;128;151 or metabolic dysfunction in 
this data set, then metabolic dysregulation may be unrelated to obesity-related 
cancer in women.  
Overall the evidence for the effect measure modification of BMI, WC, and 
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WHtR by metabolic abnormalities in these analyses is tenuous. Although there 
was evidence in men of effect modification of obesity as measured by BMI ≥30 
kg/m2 by IFG-DM, low HDL, high TG, dyslipidemia, HBP, and metabolic 
dysfunction, this was not the case for higher WC or WHtR. It could be that a 
higher WC or WHtR may already capture metabolic dysfunction while BMI may 
not. There was no evidence of effect modification by metabolic dysfunction in 
overweight (BMI ≥25 kg/m2) women and only modest effect modification for 
higher WC and WHtR by IFG and metabolic dysfunction. As for men, this also 
does not preclude the possibility that the appearance of effect modification is that 
higher WC or WHtR and glucose dysregulation or metabolic dysfunction are 
markers for each other. The presence of metabolic dysfunction by itself 
(controlling for BMI) was also associated with modest increased in cancer risk in 
men and women. 
These analyses may suggest that effects of metabolic dysfunction were 
actually effects IFG/DM alone. The effect modification analyses support this 
possibility in that the estimates for the modifying effects of IFG-DM and total 
metabolic dysfunction were very similar.  However, type 2 diabetes is not a 
comparably strong a risk factor for all obesity-related cancer types. For example, 
in the published literature, the cancers most strongly associated with T2DM are 
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liver, pancreatic and endometrial cancers; those more moderately associated are 
colon, rectal, and breast cancer; and the least associated are kidney and non-
Hodgkin’s lymphoma.58;137 In theses analyses the obesity-related cancer outcomes 
vary in frequency and type and between men and women, affecting the overall 
strength or modification of the risk estimates. Since, metabolic dysregulation also 
accompanies weight gain, those who became overweight or obese without 
metabolic dysfunction may have simply not developed it yet; thus 
misclassification of metabolic status is possible.  
Cancer has a long preclinical period from the point of initiation to the 
point of diagnosis. As changes in inflammatory and hormonal markers involved 
in that process are chronic, their duration and dose may impact cancer risk. Since 
inflammatory mechanisms are the hypothesized to underlie development of 
adiposity-induced cancer, long-term weight gain may be a more relevant 
adiposity-related exposure than weight at a static point in time. The results 
support this hypothesis--those who gained over one pound per year had a 40% 
increased risk of obesity-related cancer compared with subjects who had a stable 
weight. 
 The second weight change variable used, compared two groups of 
subjects—those who became overweight or obese over 14 years and those who 
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were already overweight/obese and remained so—with those who remained lean 
throughout that time period serving as the referent group. This not only accounts 
for duration but also for the quantity of weight. Interestingly, those who became 
overweight or obese had the greatest increased risk of developing cancer. 
Subjects who were already overweight or obese at the beginning of following 
had a higher BMI at both the beginning and end of follow up and yet had a lower 
risk of cancer than those who gained weight. These findings were independent of 
metabolic dysfunction. This could suggest that the process of gaining weight 
itself, separate from the absolute level of BMI may be a risk factor for cancer.  
Like weight gain, metabolic dysregulation is a chronic exposure. The 
analyses of this dissertation were not able to account the duration of glucose 
impairment or metabolic dysfunction. In addition, the amount of weight gain 
needed to reach a certain level of metabolic dysfunction to hypothetically trigger 
a carcinogenic process will vary by individual. Therefore, more power is 
required to investigate this question and the question of whether changes in 
metabolic status may explain some of these results. Combining cancer types may 
also mask strong effects of metabolic dysfunction on certain cancers. Therefore, it 
would be beneficial to have sufficient power to study the effects on specific 
cancers. Future studies that seek to separate the individual and combined effect 
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of obesity, body fat distribution, and metabolic abnormalities, particularly on 
individual cancer outcomes, will require additional statistical power from large 
high quality data bases.   
To clarify the hypothetical role of metabolic dysfunction, future 
epidemiologic research should translate from what is known in the biochemical 
research. Specifically, molecular biomarkers of dysfunctional adipose tissue (i.e. 
adiponectin, markers of oxidative stress related to excess body fat) may be useful 
for examining whether such metabolic dysfunction modified the effects of excess 
body fat on obesity-related cancer risk. Future studies can also examine the role 
of circulating insulin in diabetic and non-diabetic subjects as a risk for obesity-
related cancer. An additional challenge is to account for the use of medications to 
treat IFG and diabetes as well as dyslipidemia which may themselves have 
competing effects on cancer risk (i.e. metformin may be protective, while insulin 
and insulin analogs may increase risk).58 Timing and duration of these exposures 
also require further study.  
More studies on weight gain, including the effect of weight gain modified 
by measures of metabolic abnormalities, are needed to affirm the results of this 
dissertation. Future studies with more direct measures of body fat and fat 
distribution in men and women are needed. These results do affirm the findings 
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of numerous studies that have found obesity to be a risk factor for certain 
cancers. These results also support the theory that the cancer risk from obesity 
may lie in the excess weight accumulation itself rather than associated metabolic 
dysfunction. Overall, the results of this dissertation support a role for BMI and 
body fat distribution as markers of obesity-related cancer risk while at the same 
time pointing to sex-specific differences in these factors as they relate to cancer 
risk.  
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Appendix 
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A.1:  Rates of all cancers among selected population subgroups by quintiles of baseline BMI 
 All subjects in data set Subjects w/ BMI≥20 Subjects w/o diabetes Subjects w/ <14 pack-yrs Subjects w/≥ 14 pack-yrs 
BMI N PY Cases1 
I/1000 
py N2 PY Cases2 
I/1000 
py N3 PY Cases2 
I/1000 
py N4 PY Cases 
I/1000 
py N4 PY Cases 
I/1000 
py 
All Subjects                        
   Q 1 788 11566 128 11.1 681 10094 112 11.1 774 11381 123 10.8 453 6751 54 8.0 334 4803 74 15.4 
   Q 2 787 11670 122 10.5 787 11670 122 10.5 765 11360 120 10.6 470 7087 61 8.6 316 4578 61 13.3 
   Q 3 790 11984 125 10.4 790 11984 125 10.4 761 11557 120 10.4 440 6636 47 7.1 350 5348 78 14.6 
   Q 4 791 11539 135 11.7 791 11539 135 11.7 756 11068 130 11.7 438 6393 65 10.2 350 5087 70 13.8 
   Q 5 788 11087 123 11.1 788 11087 123 11.1 691 9763 109 11.2 447 6229 67 10.8 339 4839 55 11.4 
Men                      
   Q 1 375 5389 72 13.4 358 5162 69 13.4 365 5257 70 13.3 175 2599 26 10.0 199 2777 46 16.6 
   Q 2 375 5377 76 14.1 375 5377 76 14.1 355 5094 74 14.5 190 2767 31 11.2 185 2610 45 17.2 
   Q 3 377 5608 77 13.7 377 5608 77 13.7 356 5326 73 13.7 185 2689 21 7.8 192 2919 56 19.2 
   Q 4 377 5408 75 13.9 377 5408 75 13.9 353 5100 73 14.3 190 2677 32 12.0 186 2712 43 15.9 
   Q 5 376 5227 63 12.1 376 5227 63 12.1 330 4613 55 11.9 174 2319 30 12.9 201 2889 33 11.4 
Women                      
   Q 1 413 6178 56 9.1 323 4932 43 8.7 409 6124 53 8.7 278 4151 28 6.7 135 2026 28 13.8 
   Q 2 412 6293 46 7.3 412 6293 46 7.3 410 6266 46 7.3 280 4320 30 6.9 131 1969 16 8.1 
   Q 3 413 6376 48 7.5 413 6376 48 7.5 405 6231 47 7.5 255 3947 26 6.6 158 2429 22 9.1 
   Q 4 414 6130 60 9.8 414 6130 60 9.8 403 5967 57 9.6 248 3716 33 8.9 164 2375 27 11.4 
   Q 5 412 5860 60 10.2 412 5860 60 10.2 361 5150 54 10.5 273 3910 37 9.5 138 1950 22 11.3 
1  Cases are incidence of any cancer except non-melanoma skin cancer. 2.  Form all subjects in the data set, 17 men and 90 women dropped 
with BMI <20. 3 From all subjects in the data set, 121 men and 76 women were dropped with type 2 diabetes at baseline.  
4  From all subjects in the data set, 3 men and 4 women were dropped who were missing pack-years smoking. 
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Table A.2. Effect of BMI on the incidence of all cancer types 
  Total Cancer Risk 
BMI Category N PY Cases1 I/1000 py HR2 (95% CI) 
All Subjects       
   18.5–<24.5(m), 22(w) 715 10431 120 11.5 1.14 (0.92, 1.42) 
   24.5–<28(m), 22–<26.5(w) (Ref) 1610 24163 246 10.2 1.00 
   28–<31(m), 26.5–<30(w) 834 12197 147 12.1 1.18 (0.96, 1.45) 
   31+(m), 30+(w) 785 11055 120 10.9 1.10 (0.88, 1.37) 
Men      
   18.5–<24.5 332 4732 69 14.6 1.12 (0.84, 1.50) 
   24.5–<28 (Ref) 743 10849 141 13.0 1.00 
   28–<31 440 6339 95 15.0 1.22 (0.94, 1.59) 
   31+ 365 5089 58 11.4 1.01 (0.74, 1.37) 
Women      
   18.5–<22 383 5699 51 8.9 1.15 (0.82, 1.60) 
   22–<26.5 (Ref) 867 13314 105 7.9 1.00 
   26.5–<30 394 5858 52 8.9 1.13 (0.81, 1.57) 
   30+ 420 5966 62 10.4 1.32 (0.96, 1.81) 
1 Cases are incidence of any cancer except non-melanoma skin cancer. 
2 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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Table A.3. The subject number, cases, person-years, and hazard rates for the 
analysis on the effect of BMI on obesity-related cancer risk adjusting for waist 
and hip circumference measures (Table 3.5) 
BMI Categories N1 PY Cases I/1000 py 
All Subjects      
     18.5–<24.5 (m), 22(w) 694 10505 55 5.24 
     24.5–<28 (m), 22–<26.5 (w) (Ref) 1562 24366 99 4.06 
     28–<31 (m), 26.5–<30 (w) 806 12233 73 5.97 
     31+ (m),30+ (w) 756 10963 72 6.57 
Men     
     18.5–<24.5 320 4874 24 4.92 
     24.5–<28 (Ref) 715 11160 33 2.96 
     28–<31 427 6582 34 5.17 
     31+ 354 5153 25 4.85 
Women     
     18.5–<22 374 5631 31 5.50 
     22–<26.5 (Ref) 847 13207 66 5.00 
     26.5–<30 379 5650 39 6.90 
     30+ 402 5810 47 8.09 
1 Excludes 126 subjects who were missing WC or HC. 
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Table A.4. Effect of BMI on obesity-related cancer before and after excluding 
initial follow-up time 
 Follow-up Starting at Baseline WHtR Exposure 
     Adjusted Adj. plus HC 
WHtR Category N PY Cases I/1000 py HR1 (95%CI) HR (95% CI) 
All Subjects          
   WHtR<0.50 1050 14692 74 5.04 1.00 1.00 
   WHtR 0.50–<0.57 1376 18602 90 4.84 1.12 (0.81, 1.55) 1.11 (0.78, 1.58) 
   WHtR ≥0.57 1297 16550 103 6.22 1.44 (1.04, 1.99) 1.41 (0.90, 2.20) 
Men       
   WHtR<0.50 194 2681 6 2.24 1.00 1.00 
   WHtR 0.50–<0.57 808 11067 43 3.89 1.57 (0.67, 3.70) 1.79 (0.74, 4.34) 
   WHtR ≥0.57 770 10065 55 5.46 2.27 (0.97, 5.32) 3.05 (1.12, 8.33) 
Women       
   WHtR<0.50 856 12010 68 5.66 1.00 1.00 
   WHtR 0.50–<0.57 568 7536 47 6.24 1.12 (0.77, 1.62) 1.04 (0.69, 1.56) 
   WHtR ≥0.57 527 6485 48 7.40 1.30 (0.89, 1.91) 1.08 (0.62, 1.88) 
 Follow-up Starting 3 Years after Baseline WHtR Exposure 
All Subjects       
   WHtR<0.50 1028 11521 63 5.47 1.00 1.00 
   WHtR 0.50–<0.57 1338 14363 80 5.57 1.17 (0.82, 1.65) 1.16 (0.79, 1.69) 
   WHtR ≥0.57 1250 12681 89 7.02 1.46 (1.03, 2.07) 1.43 (0.88, 2.33) 
Men       
   WHtR<0.50 191 2073 6 2.89 1.00 1.00 
   WHtR 0.50–<0.57 782 8555 39 4.56 1.40 (0.59, 3.32) 1.63 (0.67, 3.99) 
   WHtR ≥0.57 743 7766 49 6.31 1.95 (0.83, 4.60) 2.78 (1.00, 7.74) 
Women       
   WHtR<0.50 837 9449 57 6.03 1.00 1.00 
   WHtR 0.50–<0.57 556 5808 41 7.06 1.20 (0.80, 1.79) 1.09 (0.70, 1.69) 
   WHtR ≥0.57 507 4915 40 8.14 1.39 (0.92, 2.11) 1.10 (0.60, 2.02) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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Table A.5.  The comparison of rates of obesity-related cancer between 
quintiles of anthropometric measures of body fat and the attributable 
proportion of obesity-related cancer risk form from Waist Circumference, 
Waist-to-Height Ratio, and BMI 
` Waist Circumference Waist-to-Height Ratio BMI 
 
N Cases 
I/1000 
py RD1 AP2 N Cases 
I/1000 
py RD AP N Cases 
I/1000 
py RD AP 
All Subjects                   
   Q1 727 54 5.32 1.20 0.23 749 57 5.47 1.43 0.26 788 59 4.95 0.70 0.14 
   Q2 775 45 4.12 0.00 … 736 41 4.04 0.00 … 787 51 4.25 0.00 … 
   Q3 761 47 4.63 0.51 0.11 752 49 4.76 0.72 0.15 790 53 4.30 0.05 0.01 
   Q4 713 56 5.98 1.86 0.31 735 52 5.47 1.43 0.26 791 70 5.90 1.65 0.28 
   Q5 747 65 7.03 2.91 0.41 751 68 7.18 3.14 0.44 788 77 6.76 2.51 0.37 
Men                
   Q1 350 22 4.70 1.70 0.36 357 22 4.62 1.73 0.37 375 24 4.22 0.32 0.08 
   Q2 354 15 3.00 0.00 … 348 14 2.89 0.00 … 375 22 3.89 0.00 … 
   Q3 359 14 2.88 -0.12 -0.04 363 16 3.19 0.30 0.09 377 20 3.38 -0.51 -0.15 
   Q4 369 24 4.84 1.84 0.38 345 22 4.86 1.96 0.40 377 25 4.38 0.49 0.11 
   Q5 340 29 6.73 3.72 0.55 359 30 6.44 3.55 0.55 376 29 5.33 1.44 0.27 
Women                
   Q1 377 32 5.85 0.79 0.13 392 35 6.19 1.09 0.18 413 35 5.61 1.06 0.19 
   Q2 421 30 5.06 0.00 … 388 27 5.09 0.00 … 412 29 4.56 0.00 … 
   Q3 402 33 6.25 1.19 0.19 389 33 6.25 1.16 0.19 413 33 5.14 0.58 0.11 
   Q4 344 32 7.26 2.20 0.30 390 30 6.02 0.93 0.15 414 45 7.30 2.74 0.38 
   Q5 407 36 7.29 2.24 0.31 392 38 7.89 2.79 0.35 412 48 8.06 3.50 0.43 
1 RD (risk difference) is calculated as the rate in the given quintile - rate in quintile 2 (ref.) 
2 AP (attributable proportion) is calculated as RD in the given quintile/(rate in the given quintile) 
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Table A.6. Range of hip circumference within quintiles 
HC Quintile N Min Max 
All Subjects    
     Quintile 1 740 31.50 38.00 
     Quintile 2 724 37.00 39.25 
     Quintile 3 730 39.00 40.80 
     Quintile 4 783 41.00 43.75 
     Quintile 5 746 43.00 65.50 
Men     
     Quintile 1 398 32.50 38.00 
     Quintile 2 296 38.25 39.25 
     Quintile 3 331 39.50 40.80 
     Quintile 4 392 41.00 42.80 
     Quintile 5 355 43.00 59.00 
Women    
     Quintile 1 342 31.50 36.75 
     Quintile 2 428 37.00 38.75 
     Quintile 3 399 39.00 40.75 
     Quintile 4 391 41.00 43.75 
     Quintile 5 391 44.00 65.50 
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Table A.7. Effect of HC on obesity-related cancer before and after excluding 
initial follow-up time 
 Follow-up Starting at Baseline HC Exposure 
     Adjusted Adj. plus WC 
HC Quintiles N PY Cases I/1000 py HR1 (95% CI) HR (95% CI) 
All Subjects       
     Quintile 1 740 10106 55 5.44 1.45 (0.97, 2.18) 1.51 (0.99, 2.28) 
     Quintile 2 (Ref) 724 9976 42 4.21 1.00 1.00 
     Quintile 3 730 9823 45 4.58 1.12 (0.74, 1.71) 1.09 (0.71, 1.67) 
     Quintile 4 783 10314 66 6.40 1.62 (1.10, 2.39) 1.51 (0.99, 2.30) 
     Quintile 5 746 9625 59 6.13 1.57 (1.05, 2.33) 1.35 (0.79, 2.29) 
Men       
     Quintile 1 398 5340 29 5.43 2.08 (1.05, 4.09) 2.45 (1.22, 4.94) 
     Quintile 2 (Ref) 296 4086 12 2.94 1.00 1.00 
     Quintile 3 331 4491 12 2.67 0.94 (0.42, 2.09) 0.83 (0.37, 1.87) 
     Quintile 4 392 5262 27 5.13 1.80 (0.91, 3.57) 1.42 (0.68, 2.96) 
     Quintile 5 355 4634 24 5.18 1.98 (0.98, 4.00) 1.17 (0.47, 2.94) 
Women       
     Quintile 1 342 4766 26 5.46 1.12 (0.66, 1.90) 1.13 (0.66, 1.93) 
     Quintile 2 (Ref) 428 5891 30 5.09 1.00 1.00 
     Quintile 3 399 5332 33 6.19 1.23 (0.75, 2.02) 1.22 (0.74, 2.03) 
     Quintile 4 391 5052 39 7.72 1.55 (0.96, 2.50) 1.52 (0.90, 2.57) 
     Quintile 5 391 4991 35 7.01 1.42 (0.87, 2.32) 1.36 (0.69, 2.67) 
 Follow-up Starting 3 Years after Baseline HC Exposure 
All Subjects       
     Quintile 1 717 7859 48 6.11 1.41 (0.91, 2.18) 1.49 (0.95, 2.32) 
     Quintile 2 (Ref) 703 7739 37 4.78 1.00 1.00 
     Quintile 3 714 7611 39 5.12 1.10 (0.70, 1.73) 1.05 (0.67, 1.66) 
     Quintile 4 762 7952 59 7.42 1.65 (1.09, 2.49) 1.48 (0.94, 2.32) 
     Quintile 5 720 7405 49 6.62 1.49 (0.97, 2.29) 1.19 (0.67, 2.12) 
Men       
     Quintile 1 383 4125 27 6.55 2.11 (1.04, 4.28) 2.55 (1.23, 5.29) 
     Quintile 2 (Ref) 284 3123 11 3.52 1.00 1.00 
     Quintile 3 322 3481 11 3.16 0.91 (0.39, 2.11) 0.79 (0.34, 1.84) 
     Quintile 4 383 4079 25 6.13 1.78 (0.87, 3.64) 1.35 (0.63, 2.91) 
     Quintile 5 344 3586 20 5.58 1.74 (0.83, 3.67) 0.94 (0.35, 2.51) 
Women       
     Quintile 1 334 3734 21 5.62 0.99 (0.56, 1.78) 1.01 (0.56, 1.84) 
     Quintile 2 (Ref) 419 4616 26 5.63 1.00 1.00 
     Quintile 3 392 4130 28 6.78 1.23 (0.72, 2.10) 1.20 (0.70, 2.08) 
     Quintile 4 379 3873 34 8.78 1.61 (0.97, 2.69) 1.54 (0.88, 2.72) 
     Quintile 5 376 3819 29 7.59 1.45 (0.85, 2.47) 1.32 (0.63, 2.75) 
1 Adjusted for sex (for all subjects model), age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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Table A.8.  Effect of BMI ≥28 kg/m2 and BMI <28 kg/m2 modified by metabolic 
indicators and dysfunction in men 
        
     Adjusted Adj. plus WC Adj. plus HC 
BMI /Metabolic 
Indicator N PY Cases 
I/1000 
py HR1 (95% CI) HR (95% CI) HR (95%CI) 
BMI/IFG or T2DM2            
BMI <28/No IFG-DM 693 11057 43 3.89 1.00 1.00 1.00 
BMI <28 /IFG-DM 342 4976 14 2.81 0.67 (0.37, 1.23) 0.68 (0.37, 1.25) 0.67 (0.37, 1.23) 
BMI ≥28/No IFG-DM          436 6932 27 3.89 1.07 (0.66, 1.74) 1.18 (0.66, 2.09) 1.29 (0.74, 2.23) 
BMI ≥28 /IFG-DM            345 4803 32 6.66 1.75 (1.11, 2.78) 1.96 (1.09, 3.55) 2.19 (1.25, 3.83) 
BMI/HDL3        
BMI <28 /Nl HDL 690 10791 38 3.52 1.00 1.00 1.00 
BMI <28 /Low HDL   345 5242 19 3.62 1.12 (0.64, 1.96) 1.14 (0.65, 1.98) 1.14 (0.65, 1.99) 
BMI ≥28 /Nl HDL                   391 5942 31 5.22 1.57 (0.97, 2.53) 1.70 (0.95, 3.04) 1.86 (1.07, 3.25) 
BMI ≥28 /Low HDL                       390 5793 28 4.83 1.60 (0.98, 2.61) 1.74 (0.95, 3.18) 1.92 (1.07, 3.43) 
BMI/TG4        
BMI <28 /Nl TG 719 11176 42 3.76 1.00 1.00 1.00 
BMI <28 /High TG   316 4857 15 3.09 0.77 (0.42, 1.38) 0.77 (0.43, 1.39) 0.77 (0.43, 1.39) 
BMI ≥28 /Nl TG                   409 6338 29 4.58 1.29 (0.80, 2.07) 1.38 (0.77, 2.46) 1.52 (0.87, 2.65) 
BMI ≥28 /High TG                     372 5397 30 5.56 1.56 (0.97, 2.49) 1.67 (0.93, 3.01) 1.85 (1.06, 3.22) 
BMI/Dyslipidemia5        
BMI <28 /No dyslip. 567 8850 31 3.50 1.00 1.00 1.00 
BMI <28 /Dyslipid. 468 7183 26 3.62 1.04 (0.61, 1.75) 1.05 (0.62, 1.77) 1.05 (0.62, 1.76) 
BMI ≥28 /No dyslip. 289 4461 22 4.93 1.48 (0.85, 2.56) 1.60 (0.84, 3.07) 1.76 (0.94, 3.28) 
BMI ≥28 /Dyslip. 492 7274 37 5.09 1.59 (0.99, 2.58) 1.73 (0.96, 3.12) 1.90 (1.08, 3.33) 
BMI/HBP6        
BMI <28 /No HBP 698 10851 34 3.13 1.00 1.00 1.00 
BMI <28 /HBP 337 5182 23 4.44 1.05 (0.61, 1.81) 1.06 (0.62, 1.84) 1.05 (0.61, 1.81) 
BMI ≥28 /No HBP             386 5963 28 4.70 1.59 (0.96, 2.62) 1.70 (0.94, 3.08) 1.84 (1.05, 3.25) 
BMI ≥28 /HBP                  395 5772 31 5.37 1.53 (0.94, 2.50) 1.67 (0.90, 3.08) 1.84 (1.03, 3.29) 
BMI/MetDys7        
BMI <28 /0,1 MetDys 708 11131 40 3.59 1.00 1.00 1.00 
BMI <28 /2,3 MetDys 327 4902 17 3.47 0.80 (0.45, 1.42) 0.81 (0.46, 1.45) 0.81 (0.45, 1.43) 
BMI ≥28 /0,1 MetDys 368 5857 25 4.27 1.25 (0.76, 2.06) 1.34 (0.74, 2.44) 1.47 (0.84, 2.60) 
BMI ≥28 /2,3 MetDys            413 5878 34 5.78 1.58 (1.00, 2.51) 1.73 (0.96, 3.12) 1.93 (1.11, 3.38) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
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2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table A.9.  Effect of BMI ≥30 kg/m2 and BMI <30 kg/m2 modified by metabolic 
indicators and dysfunction in women 
     Adjusted Adj. plus WC Adj. plus HC 
BMI/ Metabolic 
Indicator N PY Cases 
I/1000 
py HR1 (95% CI) HR (95%CI) HR (95% CI) 
BMI/IFG or T2DM2            
BMI <30 /No IFG-DM 1341 20708 113 5.46 1.00 1.00 1.00 
BMI <30 /IFG-DM 259 3781 23 6.08 1.05 (0.67, 1.65) 1.04 (0.66,1.66) 1.03 (0.65, 1.62) 
BMI ≥30 /No IFG-DM 227 3330 27 8.11 1.49 (0.97, 2.27) 1.47 (0.85,2.55) 1.32 (0.76, 2.31) 
BMI ≥30 /IFG-DM 175 2480 20 8.07 1.37 (0.85, 2.23) 1.36 (0.72,2.57) 1.22 (0.66, 2.25) 
BMI/HDL3        
BMI <30 /Nl HDL 1133 17322 95 5.48 1.00 1.00 1.00 
BMI <30 /Low HDL 467 7166 41 5.72 1.02 (0.70, 1.48) 1.02 (0.69,1.49) 1.01 (0.69, 1.47) 
BMI ≥30 /Nl HDL  163 2322 15 6.46 1.19 (0.69, 2.05) 1.18 (0.61,2.30) 1.04 (0.54, 2.03) 
BMI ≥30 /Low HDL     239 3488 32 9.17 1.60 (1.06, 2.42) 1.59 (0.90,2.82) 1.41 (0.82, 2.45) 
BMI/TG4        
BMI <30 /Nl TG 1318 20335 108 5.31 1.00 1.00 1.00 
BMI <30 /High TG 282 4153 28 6.74 1.18 (0.78, 1.80) 1.18 (0.77,1.82) 1.17 (0.77, 1.78) 
BMI ≥30 /Nl TG     235 3410 30 8.80 1.67 (1.11, 2.51) 1.68 (0.97,2.89) 1.50 (0.86, 2.60) 
BMI ≥30 /High TG  167 2400 17 7.08 1.22 (0.72, 2.06) 1.23 (0.64,2.39) 1.10 (0.59, 2.08) 
BMI/Dyslipidemia5        
BMI <30 /No dyslip. 1036 15955 84 5.26 1.00 1.00 1.00 
BMI <30 /Dyslip. 564 8533 52 6.09 1.12 (0.79, 1.59) 1.13 (0.79,1.62) 1.11 (0.78, 1.58) 
BMI ≥30 /No dyslip. 131 1893 13 6.87 1.32 (0.73, 2.37) 1.35 (0.68,2.70) 1.18 (0.59, 2.36) 
BMI ≥30 /Dyslip. 271 3917 34 8.68 1.57 (1.04, 2.37) 1.62 (0.91,2.90) 1.41 (0.81, 2.45) 
BMI/HBP6        
BMI <30 /No HBP 1229 18519 96 5.18 1.00 1.00 1.00 
BMI <30 /HBP 371 5969 40 6.70 1.12 (0.76, 1.65) 1.12 (0.76,1.65) 1.11 (0.76, 1.63) 
BMI ≥30 /No HBP  202 2850 23 8.07 1.56 (0.99, 2.46) 1.55 (0.88,2.76) 1.39 (0.79, 2.46) 
BMI ≥30 /HBP  200 2960 24 8.11 1.41 (0.88, 2.23) 1.40 (0.76,2.58) 1.23 (0.67, 2.27) 
BMI/MetDys7        
BMI <30 /0,1 MetDys 1319 20202 105 5.20 1.00 1.00 1.00 
BMI <30 /2,3 MetDys 281 4286 31 7.23 1.27 (0.84, 1.91) 1.28 (0.84,1.96) 1.25 (0.83, 1.89) 
BMI ≥30 /0,1 MetDys 195 2815 20 7.10 1.39 (0.86, 2.24) 1.45 (0.80,2.63) 1.27 (0.70, 2.30) 
BMI ≥30 /2,3 MetDys 207 2995 27 9.02 1.61 (1.04, 2.50) 1.70 (0.93,3.11) 1.46 (0.81, 2.63) 
1 Adjusted for all subjects adjusted for age, average adult height, education, cigarettes/day, 
alcohol intake and physical activity. 
2 IFG = fasting glucose 100–125 mg/dL. T2DM=random glucose > 200 mg/dL, fasting glucose ≥ 
126 mg/dL, or taking glucose-lowering medication. 
3 Low HDL = HDL <40 (m), 50 (w) mg/dL or lipid-lowering medication. 
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4 High TG = TG ≥150 mg/dL or lipid lowering medication. 
5 Dyslipidemia = use of lipid-lowering medication, TG ≥150, or HDL <40 (men), <50 (women). 
6 High blood pressure identified using modified JNC-7 criteria. 
7 The metabolic dysfunctions are IFG (diabetes, fasting glucose >125 mg/dL, or 100–125 mg/dL); 
dyslipidemia (lipid-lowering medication; or as TG ≥150 or HDL <40 (m), <50 (w) at baseline); and 
HBP identified using modified JNC-7 criteria. 
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Table A.10. Number of subjects, person-years, number of cases, and rates for 
BMI and metabolic variable categories in men and women combined 
Obese (m), Overweight (w) 
Status/ Metabolic Indicator N PY Cases I/1000 py 
BMI/IFG-DM2     
BMI <30(m), <25(w)/No IFG-DM 1772 27995 118 4.22 
BMI <30(m), <25(w)/ IFG-DM 566 8160 33 4.04 
BMI ≥ 30(m), ≥25(w)/No IFG-DM 925 14032 92 6.56 
BMI ≥ 30(m), ≥25(w)/IFG-DM 555 7879 56 7.11 
BMI/HDL-C3     
BMI <30(m), <25(w)/Nl HDL 1631 25277 108 4.27 
BMI <30(m), <25(w)/ Low HDL 707 10877 43 3.95 
BMI ≥30(m), ≥25(w)/Nl HDL  746 11100 71 6.40 
BMI ≥30(m), ≥25(w)/Low HDL     734 10811 77 7.12 
BMI/TG4     
BMI <30(m), <25(w)/Nl TG 1768 27530 115 4.18 
BMI <30(m), <25(w)/High TG 570 8624 36 4.17 
BMI ≥30(m), ≥25(w)/Nl TG    913 13728 94 6.85 
BMI ≥30(m), ≥25(w)/High TG  567 8183 54 6.60 
BMI/Dyslipidemia5     
BMI <30(m), <25(w)/No dyslip. 1412 21894 93 4.25 
BMI <30(m), <25(w)/Dyslipid. 926 14260 58 4.07 
BMI ≥30(m), ≥25(w)/No dyslip. 611 9265 57 6.15 
BMI ≥30(m), ≥25(w)/Dyslip. 869 12647 91 7.20 
BMI/HBP6     
BMI <30(m), <25(w)/No HBP 1681 25923 98 3.78 
BMI <30(m), <25(w)/HBP 657 10231 53 5.18 
BMI ≥ 30(m), ≥25(w)/No HBP  834 12260 83 6.77 
BMI ≥ 30(m), ≥25(w)/HBP  646 9652 65 6.73 
BMI/MetDys7     
BMI <30(m), <25(w)/0,1 MetDys 1761 27524 111 4.03 
BMI <30(m), <25(w)/2,3 MetDys 577 8631 40 4.63 
BMI ≥ 30(m), ≥25(w)/0,1 MetDys 829 12481 79 6.33 
BMI ≥ 30(m), ≥25(w)/2,3 MetDys 651 9431 69 7.32 
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Table A.11. Number of subjects, person-years, number of cases, and rates for 
BMI and metabolic variable categories in men and women combined 
 Men Women 
Obese (m), Overweight (w) Status/ 
Metabolic Indicator N PY Cases 
I/1000 
py N PY Cases 
I/1000 
py 
BMI/IFG-DM2           
BMI <30(m), <25(w)/No IFG-DM 909 14654 55 3.75 863 13341 63 4.72 
BMI <30(m), <25(w)/ IFG-DM 461 6604 24 3.63 105 1555 9 5.79 
BMI ≥ 30(m), ≥25(w)/No IFG-DM 220 3335 15 4.50 705 10697 77 7.20 
BMI ≥ 30(m), ≥25(w)/IFG-DM 226 3174 22 6.93 329 4705 34 7.23 
BMI/HDL-C3         
BMI <30(m), <25(w)/Nl HDL 874 13699 53 3.87 757 11578 55 4.75 
BMI <30(m), <25(w)/ Low HDL 496 7560 26 3.44 211 3318 17 5.12 
BMI ≥30(m), ≥25(w)/Nl HDL  207 3034 16 5.27 539 8066 55 6.82 
BMI ≥30(m), ≥25(w)/Low HDL     239 3475 21 6.04 495 7336 56 7.63 
BMI/TG4         
BMI <30(m), <25(w)/Nl TG 910 14216 55 3.87 858 13314 60 4.51 
BMI <30(m), <25(w)/High TG 460 7043 24 3.41 110 1582 12 7.59 
BMI ≥30(m), ≥25(w)/Nl TG    218 3298 16 4.85 695 10431 78 7.48 
BMI ≥30(m), ≥25(w)/High TG  228 3212 21 6.54 339 4972 33 6.64 
BMI/Dyslipidemia5         
BMI <30(m), <25(w)/No dyslip. 703 10970 44 4.01 709 10924 49 4.49 
BMI <30(m), <25(w)/Dyslipid. 667 10288 35 3.40 259 3972 23 5.79 
BMI ≥30(m), ≥25(w)/No dyslip. 153 2341 9 3.84 458 6924 48 6.93 
BMI ≥30(m), ≥25(w)/Dyslip. 293 4169 28 6.72 576 8478 63 7.43 
BMI/HBP6         
BMI <30(m), <25(w)/No HBP 895 13939 48 3.44 786 11985 50 4.17 
BMI <30(m), <25(w)/HBP 475 7320 31 4.23 182 2911 22 7.56 
BMI ≥ 30(m), ≥25(w)/No HBP  189 ` 14 4.87 645 9384 69 7.35 
BMI ≥ 30(m), ≥25(w)/HBP  257 3634 23 6.33 389 6018 42 6.98 
BMI/MetDys7         
BMI <30(m), <25(w)/0,1 MetDys 902 14278 54 3.78 859 13246 57 4.30 
BMI <30(m), <25(w)/2,3 MetDys 468 6981 25 3.58 109 1650 15 9.09 
BMI ≥ 30(m), ≥25(w)/0,1 MetDys 174 2710 11 4.06 655 9771 68 6.96 
BMI ≥ 30(m), ≥25(w)/2,3 MetDys 272 3799 26 6.84 379 5631 43 7.64 
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Table A.12. Number of subjects, person-years, number of cases, and rates for 
WHtR and metabolic variable categories in men and women combined 
WHtR/Metabolic Indicator N PY Cases I/1000 py 
WHtR/IGF-DM2      
     WHtR <0.58/ No IFG-DM 1914 26477 133 5.02 
     WHtR <0.58/ IFG-DM 686 9050 40 4.42 
     WHtR ≥0.58/ No IFG-DM 570 7487 42 5.61 
     WHtR ≥0.58/ IFG-DM 553 6831 52 7.61 
WHtR/HDL3     
     WHtR <0.58/ Nl HDL 1701 23142 126 5.44 
     WHtR <0.58/ Low HDL 899 12385 47 3.79 
     WHtR ≥0.58/ Nl HDL 470 5851 35 5.98 
WHtR ≥0.58/ Low HDL 653 8466 59 6.97 
WHtR/ TG4     
     WHtR <0.58/ Nl TG 1952 26927 133 4.94 
     WHtR <0.58/ High TG 648 8600 40 4.65 
     WHtR ≥0.58/ Nl TG 560 7121 50 7.02 
     WHtR ≥0.58/ High TG 563 7197 44 6.11 
WHtR/ Dyslipidemia5     
     WHtR <0.58/ No Dyslip. 1489 20375 106 5.20 
     WHtR <0.58/ Dyslip. 1111 15151 67 4.42 
     WHtR ≥0.58/ No Dyslip. 353 4431 28 6.32 
     WHtR ≥0.58/ Dyslip. 770 9887 66 6.68 
WHtR/ HBP6     
     WHtR <0.58/ Nl HBP  1782 24137 110 4.56 
     WHtR <0.58/ High HBP 818 11390 63 5.53 
     WHtR ≥0.58/ Nl HBP 498 6329 40 6.32 
     WHtR ≥0.58/ High HBP 625 7988 54 6.76 
WHtR/ MetDys7     
     WHtR <0.58/0,1 MetDys 1872 25704 123 4.79 
     WHtR <0.58/2+ MetDys 728 9823 50 5.09 
     WHtR ≥0.58/0,1 MetDys 461 6007 33 5.49 
     WHtR ≥0.58/2+ MetDys 662 8311 61 7.34 
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Table A.13. Number of subjects, person-years, number of cases, and rates for 
WHtR and metabolic variable categories in men and women  
 
Men Women 
WHtR/Metabolic Indicator N PY Cases I/1000 py N PY Cases I/1000 py 
WHtR/IGF-DM2           
     WHtR <0.58/ No IFG-DM 684 9626 37 3.84 1230 16852 96 5.70 
     WHtR <0.58/ IFG-DM 429 5577 19 3.41 257 3473 21 6.05 
     WHtR ≥0.58/ No IFG-DM 331 4504 21 4.66 239 2983 21 7.04 
     WHtR ≥0.58/ IFG-DM 328 4106 27 6.58 225 2725 25 9.18 
WHtR/HDL3         
     WHtR <0.58/ Nl HDL 679 9297 40 4.30 1022 13844 86 6.21 
     WHtR <0.58/ Low HDL 434 5906 16 2.71 465 6480 31 4.78 
     WHtR ≥0.58/ Nl HDL 293 3815 21 5.51 177 2037 14 6.87 
     WHtR ≥0.58/ Low HDL 366 4796 27 5.63 287 3671 32 8.72 
WHtR/ TG4         
     WHtR <0.58/ Nl TG 752 10440 42 4.02 1200 16487 91 5.52 
     WHtR <0.58/ High TG 361 4763 14 2.94 287 3837 26 6.78 
     WHtR ≥0.58/ Nl TG 315 4147 24 5.79 245 2974 26 8.74 
     WHtR ≥0.58/ High TG 344 4464 24 5.38 219 2733 20 7.32 
WHtR/ Dyslipidemia5         
     WHtR <0.58/ No Dyslip. 570 7833 33 4.21 919 12543 73 5.82 
     WHtR <0.58/ Dyslip. 543 7370 23 3.12 568 7782 44 5.65 
     WHtR ≥0.58/ No Dyslip. 215 2811 15 5.34 138 1620 13 8.02 
     WHtR ≥0.58/ Dyslip. 444 5800 33 5.69 326 4087 33 8.07 
WHtR/ HBP6         
     WHtR <0.58/ Nl HBP  689 9477 29 3.06 1093 14660 81 5.53 
     WHtR <0.58/ High HBP 424 5725 27 4.72 394 5664 36 6.36 
     WHtR ≥0.58/ Nl HBP 279 3705 21 5.67 219 2624 19 7.24 
     WHtR ≥0.58/ High HBP 380 4905 27 5.50 245 3083 27 8.76 
WHtR/ MetDys7         
     WHtR <0.58/0,1 MetDys 692 9646 33 3.42 1180 16057 90 5.60 
     WHtR <0.58/2+ MetDys 421 5556 23 4.14 307 4267 27 6.33 
     WHtR ≥0.58/0,1 MetDys 262 3593 18 5.01 199 2413 15 6.22 
     WHtR ≥0.58/2+ MetDys 397 5017 30 5.98 265 3294 31 9.41 
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Table A.14. Number of subjects, person-years, number of cases, and rates for 
WC and metabolic variable categories in men and women combined 
` N PY Cases I/1000 py 
WC/IGF -T2DM2      
     WC ≤40(m), 34(w))/ No IFG-DM 1748 24508 118 4.81 
     WC ≤40(m), 34(w))/ IFG-DM 628 8304 32 3.85 
     WC > 40 (m), 34 (w)/ No IFG-DM 736 9456 57 6.03 
     WC > 40 (m), 34 (w)/ IFG-DM 611 7576 60 7.92 
WC/HDL-C3     
     WC ≤ 40(m), 34(w)/ Nl HDL 1575 21680 109 5.03 
     WC ≤ 40(m), 34(w)/Low  HDL 801 11132 41 3.68 
     WC > 40(m), 34(w)/ Nl HDL 596 7313 52 7.11 
     WC > 40(m), 34(w)/ Low HDL 751 9720 65 6.69 
WC/ TG4     
     WC ≤ 40(m), 34(w)/ Nl TG  1789 24954 120 4.81 
     WC ≤ 40(m), 34(w)/ High TG 587 7858 30 3.82 
     WC > 40(m), 34(w)/ Nl TG 723 9094 63 6.93 
     WC > 40(m), 34(w)/ High TG 624 7938 54 6.80 
WC/ Dyslipidemia5     
     WC ≤ 40(m), 34(w)/ No Dyslip. 1383 19128 95 4.97 
     WC ≤ 40(m), 34(w)/ Dyslip. 993 13685 55 4.02 
     WC > 40(m), 34(w)/ No Dyslip. 459 5679 39 6.87 
     WC > 40(m), 34(w)/ Dyslip. 888 11353 78 6.87 
WHtR/ HBP6     
     WC ≤ 40(m), 34(w)/ Nl HBP  1616 22251 95 4.27 
     WC ≤ 40(m), 34(w)/ High HBP 760 10561 55 5.21 
     WC > 40(m), 34(w)/ Nl HBP 664 8215 55 6.70 
     WC > 40(m), 34(w)/ High HBP 683 8818 62 7.03 
WC/ MetDys7     
     WC ≤ 40(m), 34(w)/0,1 MetDys 1708 23797 109 4.58 
     WC ≤ 40(m), 34(w)/2+ MetDys 668 9015 41 4.55 
     WC > 40(m), 34(w)/0,1 MetDys  625 7913 47 5.94 
     WC > 40(m),34(w)/2+ MetDys  722 9119 70 7.68 
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Table A.15. Number of subjects, person-years, number of cases, and rates for 
WC and metabolic variable categories in men and women 
 Men Women 
WC/Metabolic Indicator N PY Cases I/1000 py N PY Cases I/1000 py 
WC/IGF -T2DM2          
   WC ≤ 40(m), 34(w))/ No IFG-DM 721 10220 36 3.52 1027 14288 82 5.74 
   WC ≤ 40(m), 34(w))/ IFG-DM 455 5906 19 3.22 173 2398 13 5.42 
   WC > 40(m), 34 (w)/ No IFG-DM 294 3910 22 5.63 442 5546 35 6.31 
   WC > 40(m), 34 (w)/ IFG-DM 302 3777 27 7.15 309 3799 33 8.69 
WC/HDL-C3         
   WC ≤ 40(m), 34(w)/ Nl HDL 707 9731 37 3.80 868 11949 72 6.03 
   WC ≤ 40(m), 34(w)/Low  HDL 469 6394 18 2.81 332 4738 23 4.85 
   WC > 40(m), 34(w)/ Nl HDL 265 3380 24 7.10 331 3933 28 7.12 
   WC > 40(m), 34(w)/ Low HDL 331 4307 25 5.80 420 5413 40 7.39 
WC/ TG4         
   WC ≤ 40(m), 34(w)/ Nl TG  779 10840 42 3.87 1010 14114 78 5.53 
   WC ≤ 40(m), 34(w)/ High TG 397 5286 13 2.46 190 2572 17 6.61 
   WC > 40(m), 34(w)/ Nl TG 288 3747 24 6.41 435 5347 39 7.29 
   WC > 40(m), 34(w)/ High TG 308 3940 25 6.34 316 3998 29 7.25 
WC/ Dyslipidemia5         
   WC ≤ 40(m), 34(w)/ No Dyslip. 587 8097 32 3.95 796 11031 63 5.71 
   WC ≤ 40(m), 34(w)/ Dyslip. 589 8029 23 2.86 404 5656 32 5.66 
   WC > 40(m), 34(w)/ No Dyslip. 198 2546 16 6.28 261 3132 23 7.34 
   WC > 40(m), 34(w)/ Dyslip. 398 5141 33 6.42 490 6213 45 7.24 
WHtR/ HBP6         
   WC ≤ 40(m), 34(w)/ Nl HBP  712 9883 29 2.93 904 12368 66 5.34 
   WC ≤ 40(m), 34(w)/ High HBP 464 6243 26 4.16 296 4318 29 6.72 
   WC > 40(m), 34(w)/ Nl HBP 256 3299 21 6.37 408 4916 34 6.92 
   WC > 40(m), 34(w)/ High HBP 340 4388 28 6.38 343 4430 34 7.68 
WC/ MetDys7         
   WC ≤ 40(m), 34(w)/0,1 MetDys 715 10033 33 3.29 993 13764 76 5.52 
   WC ≤ 40(m), 34(w)/2+ MetDys 461 6093 22 3.61 207 2922 19 6.50 
   WC > 40(m), 34(w)/0,1 MetDys  239 3206 18 5.61 386 4707 29 6.16 
   WC > 40(m), 34(w)/2+ MetDys  357 4481 31 6.92 365 4638 39 8.41 
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Table A.16. Means of BMI at baseline and at the beginning of follow-up in 
categories from Tables 5.8–5.10 
BMI at Baseline1/ BMI at Start of Follow-up 
Mean BMI at 
Baseline 
Mean BMI at 
the Beginning 
of Follow-up 
All subjects     
    Any BMI /BMI <30 (m), 25(w) 23.9 24.6 
    BMI <30(m), 25(w) /BMI ≥30(m), 25(w) 24.4 29.1 
    BMI ≥30(m), 25(w) /BMI ≥30(m), 25(w) 30.6 32.9 
Men   
    Any BMI/BMI <30 25.6 26.2 
    BMI <30/BMI ≥30 27.8 32.0 
    BMI  ≥30/BMI ≥30 32.9 34.4 
Women   
   Any BMI /BMI <25 21.5 22.4 
   BMI <25 /BMI ≥25 22.9 27.8 
   BMI ≥25 /BMI ≥25 29.6 32.2 
BMI at Baseline1/ BMI  at Follow-up/ IFG or T2DM2   
All subjects   
    Any BMI /BMI <30(m), 25(w) / No IFG-DM 23.5 24.2 
    Any BMI /BMI <30(m), 25(w) / IFG-DM 25.2 25.7 
    BMI <30(m), 25(w) /BMI ≥30(m), 25(w) / No IFG-DM 24.1 28.7 
    BMI <30(m),25(w)/BMI ≥30(m), 25(w) / IFG-DM 25.1 30.0 
    BMI ≥30(m), 25(w)/BMI ≥30(m), 25(w) / No IFG-DM 29.6 31.9 
    BMI ≥30(m), 25(w)/BMI ≥30(m), 25(w)/ IFG-DM 31.8 34.1 
BMI at Baseline1/ BMI  at Follow-up / MetDys Status3 
  
All subjects   
    Any BMI /BMI <30 (m), 25(w) / 0,1 MetDys  23.7 24.4 
    Any BMI /BMI <30 (m), 25(w) / 2+ MetDys 25.5 26.2 
    BMI <30(m), 25(w)/BMI ≥30(m), 25(w)/ 0,1 MetDys 24.3 28.8 
    BMI <30(m), 25(w)/BMI ≥30(m), 25(w)/ 2+ MetDys 25.0 30.3 
    BMI ≥30(m), 25(w)/BMI ≥30(m), 25(w)/ 0,1 MetDys 29.9 32.2 
    BMI ≥30(m), 25(w)/BMI ≥30(m), 25(w)/ 2+ MetDys 32.1 34.4 
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